WO2007008309A2 - Stem and progenitor cell expansion by evi, evi-like genes and setbp1 - Google Patents
Stem and progenitor cell expansion by evi, evi-like genes and setbp1 Download PDFInfo
- Publication number
- WO2007008309A2 WO2007008309A2 PCT/US2006/021413 US2006021413W WO2007008309A2 WO 2007008309 A2 WO2007008309 A2 WO 2007008309A2 US 2006021413 W US2006021413 W US 2006021413W WO 2007008309 A2 WO2007008309 A2 WO 2007008309A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- cells
- gene
- nucleic acid
- patient
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 148
- 210000000130 stem cell Anatomy 0.000 title claims description 24
- 230000010261 cell growth Effects 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 287
- 238000000034 method Methods 0.000 claims abstract description 95
- 102100039121 Histone-lysine N-methyltransferase MECOM Human genes 0.000 claims abstract description 88
- 101710140875 Histone-lysine N-methyltransferase MECOM Proteins 0.000 claims abstract description 65
- 101000654718 Homo sapiens SET-binding protein Proteins 0.000 claims abstract description 53
- 102100032741 SET-binding protein Human genes 0.000 claims abstract description 49
- 230000001177 retroviral effect Effects 0.000 claims abstract description 32
- 230000001965 increasing effect Effects 0.000 claims abstract description 28
- 230000035755 proliferation Effects 0.000 claims abstract description 23
- 230000004663 cell proliferation Effects 0.000 claims abstract description 22
- 238000001727 in vivo Methods 0.000 claims abstract description 21
- 102100024594 Histone-lysine N-methyltransferase PRDM16 Human genes 0.000 claims abstract 4
- 101000686942 Homo sapiens Histone-lysine N-methyltransferase PRDM16 Proteins 0.000 claims abstract 4
- -1 PRDM 16 Proteins 0.000 claims description 144
- 238000003780 insertion Methods 0.000 claims description 82
- 230000037431 insertion Effects 0.000 claims description 82
- 239000013598 vector Substances 0.000 claims description 80
- 150000007523 nucleic acids Chemical group 0.000 claims description 69
- 102000039446 nucleic acids Human genes 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 48
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 47
- 230000010354 integration Effects 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 45
- 101001033728 Homo sapiens Histone-lysine N-methyltransferase MECOM Proteins 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 238000012937 correction Methods 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 238000004113 cell culture Methods 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 14
- 230000008901 benefit Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 102100024049 A-kinase anchor protein 13 Human genes 0.000 claims description 6
- 102100040141 Aminopeptidase O Human genes 0.000 claims description 6
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 claims description 6
- 102100022480 Cadherin-20 Human genes 0.000 claims description 6
- 102100024001 Hepatic leukemia factor Human genes 0.000 claims description 6
- 101000833679 Homo sapiens A-kinase anchor protein 13 Proteins 0.000 claims description 6
- 101000889627 Homo sapiens Aminopeptidase O Proteins 0.000 claims description 6
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 claims description 6
- 101000899410 Homo sapiens Cadherin-19 Proteins 0.000 claims description 6
- 101000899459 Homo sapiens Cadherin-20 Proteins 0.000 claims description 6
- 101000935111 Homo sapiens Cadherin-7 Proteins 0.000 claims description 6
- 101001005667 Homo sapiens Mastermind-like protein 2 Proteins 0.000 claims description 6
- 101001132733 Homo sapiens Rab GTPase-activating protein 1 Proteins 0.000 claims description 6
- 101100149321 Homo sapiens SETBP1 gene Proteins 0.000 claims description 6
- 101000838596 Homo sapiens Serine/threonine-protein kinase TAO3 Proteins 0.000 claims description 6
- 101000735431 Homo sapiens Terminal nucleotidyltransferase 4A Proteins 0.000 claims description 6
- 101000904499 Homo sapiens Transcription regulator protein BACH2 Proteins 0.000 claims description 6
- 101001051166 Homo sapiens Transcriptional activator MN1 Proteins 0.000 claims description 6
- 102100025130 Mastermind-like protein 2 Human genes 0.000 claims description 6
- 108010018525 NFATC Transcription Factors Proteins 0.000 claims description 6
- 102000002673 NFATC Transcription Factors Human genes 0.000 claims description 6
- 102100033883 Rab GTPase-activating protein 1 Human genes 0.000 claims description 6
- 102100025234 Receptor of activated protein C kinase 1 Human genes 0.000 claims description 6
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 claims description 6
- 102100028954 Serine/threonine-protein kinase TAO3 Human genes 0.000 claims description 6
- 102100034939 Terminal nucleotidyltransferase 4A Human genes 0.000 claims description 6
- 102100023998 Transcription regulator protein BACH2 Human genes 0.000 claims description 6
- 102100024592 Transcriptional activator MN1 Human genes 0.000 claims description 6
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 6
- 230000002349 favourable effect Effects 0.000 claims description 6
- 230000003394 haemopoietic effect Effects 0.000 claims description 6
- 230000002688 persistence Effects 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 101001125123 Homo sapiens Interferon-inducible double-stranded RNA-dependent protein kinase activator A Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 101001063514 Homo sapiens Telomerase-binding protein EST1A Proteins 0.000 claims description 4
- 101000655171 Homo sapiens Transmembrane protein 230 Proteins 0.000 claims description 4
- 102100029408 Interferon-inducible double-stranded RNA-dependent protein kinase activator A Human genes 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 102100031022 Telomerase-binding protein EST1A Human genes 0.000 claims description 4
- 102100033033 Transmembrane protein 230 Human genes 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000013611 chromosomal DNA Substances 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 claims description 3
- XOYCLJDJUKHHHS-LHBOOPKSSA-N (2s,3s,4s,5r,6r)-6-[[(2s,3s,5r)-3-amino-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@H](O2)C(O)=O)O)[C@@H](N)C1 XOYCLJDJUKHHHS-LHBOOPKSSA-N 0.000 claims description 3
- 102100035906 (Lyso)-N-acylphosphatidylethanolamine lipase Human genes 0.000 claims description 3
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims description 3
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims description 3
- 102100033828 26S proteasome regulatory subunit 10B Human genes 0.000 claims description 3
- 102100031928 40S ribosomal protein S29 Human genes 0.000 claims description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 102000034257 ADP-Ribosylation Factor 6 Human genes 0.000 claims description 3
- 108090000067 ADP-Ribosylation Factor 6 Proteins 0.000 claims description 3
- 102100039645 ADP-ribosylation factor-like protein 4A Human genes 0.000 claims description 3
- 102100024379 AF4/FMR2 family member 1 Human genes 0.000 claims description 3
- 101150059521 AHRR gene Proteins 0.000 claims description 3
- 102100040058 AP-4 complex subunit sigma-1 Human genes 0.000 claims description 3
- 102100023157 AT-rich interactive domain-containing protein 2 Human genes 0.000 claims description 3
- 102100027787 ATP synthase subunit g, mitochondrial Human genes 0.000 claims description 3
- 102100036622 ATP-binding cassette sub-family A member 10 Human genes 0.000 claims description 3
- 102100036618 ATP-binding cassette sub-family A member 13 Human genes 0.000 claims description 3
- 102100023388 ATP-dependent RNA helicase DHX15 Human genes 0.000 claims description 3
- 102100028100 Activating signal cointegrator 1 Human genes 0.000 claims description 3
- 102100035919 Acyl-CoA-binding domain-containing protein 5 Human genes 0.000 claims description 3
- 102100036664 Adenosine deaminase Human genes 0.000 claims description 3
- 102100026441 Adhesion G-protein coupled receptor D1 Human genes 0.000 claims description 3
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 claims description 3
- 102100034594 Angiopoietin-1 Human genes 0.000 claims description 3
- 102100039148 Ankyrin repeat domain-containing protein 49 Human genes 0.000 claims description 3
- 102100033652 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims description 3
- 102100026789 Aryl hydrocarbon receptor repressor Human genes 0.000 claims description 3
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 claims description 3
- 102100035958 Atypical kinase COQ8A, mitochondrial Human genes 0.000 claims description 3
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 102100023046 Band 4.1-like protein 3 Human genes 0.000 claims description 3
- 102100039887 Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4 Human genes 0.000 claims description 3
- 102100031500 Beta-1,4-glucuronyltransferase 1 Human genes 0.000 claims description 3
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 3
- 102100032487 Beta-mannosidase Human genes 0.000 claims description 3
- 102100035752 Biliverdin reductase A Human genes 0.000 claims description 3
- 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 claims description 3
- 102100031184 C-Maf-inducing protein Human genes 0.000 claims description 3
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 claims description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 3
- 102100028742 CAP-Gly domain-containing linker protein 4 Human genes 0.000 claims description 3
- 102100029871 CDKN2A-interacting protein Human genes 0.000 claims description 3
- 102000017926 CHRM2 Human genes 0.000 claims description 3
- 102100031973 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Human genes 0.000 claims description 3
- 102100021786 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Human genes 0.000 claims description 3
- 102100029400 CMRF35-like molecule 7 Human genes 0.000 claims description 3
- 102000015367 CRBN Human genes 0.000 claims description 3
- 102100029930 CST complex subunit STN1 Human genes 0.000 claims description 3
- 102100021287 CUE domain-containing protein 2 Human genes 0.000 claims description 3
- 102100033210 CUGBP Elav-like family member 2 Human genes 0.000 claims description 3
- 102100026860 CYFIP-related Rac1 interactor A Human genes 0.000 claims description 3
- 102100025332 Cadherin-9 Human genes 0.000 claims description 3
- 102100030044 Calcium-binding protein 8 Human genes 0.000 claims description 3
- 102100029968 Calreticulin Human genes 0.000 claims description 3
- 102100035249 Carbonyl reductase [NADPH] 3 Human genes 0.000 claims description 3
- 102100021633 Cathepsin B Human genes 0.000 claims description 3
- 102100022006 Cell division cycle protein 123 homolog Human genes 0.000 claims description 3
- 102100037633 Centrin-3 Human genes 0.000 claims description 3
- 102100031456 Centriolin Human genes 0.000 claims description 3
- 102100023309 Centrosomal protein of 152 kDa Human genes 0.000 claims description 3
- 101710181192 Centrosomal protein of 152 kDa Proteins 0.000 claims description 3
- 102100032401 Charged multivesicular body protein 2a Human genes 0.000 claims description 3
- 102100031011 Chemerin-like receptor 1 Human genes 0.000 claims description 3
- 102100036650 Chemokine-like protein TAFA-2 Human genes 0.000 claims description 3
- 102100038214 Chromodomain-helicase-DNA-binding protein 4 Human genes 0.000 claims description 3
- 102100031046 Coiled-coil domain-containing protein 12 Human genes 0.000 claims description 3
- 102100036571 Coiled-coil domain-containing protein 171 Human genes 0.000 claims description 3
- 102100030136 Complement C1q tumor necrosis factor-related protein 4 Human genes 0.000 claims description 3
- 102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 claims description 3
- 102100026891 Cystatin-B Human genes 0.000 claims description 3
- 102100026846 Cytidine deaminase Human genes 0.000 claims description 3
- 108010031325 Cytidine deaminase Proteins 0.000 claims description 3
- 102100037186 Cytochrome b-245 chaperone 1 Human genes 0.000 claims description 3
- 102100034025 Cytohesin-1 Human genes 0.000 claims description 3
- 102100025843 Cytohesin-4 Human genes 0.000 claims description 3
- 102100034478 Cytokine-dependent hematopoietic cell linker Human genes 0.000 claims description 3
- 102100033488 DENN domain-containing protein 10 Human genes 0.000 claims description 3
- 102100029816 DEP domain-containing mTOR-interacting protein Human genes 0.000 claims description 3
- 102000012677 DET1 Human genes 0.000 claims description 3
- 101150113651 DET1 gene Proteins 0.000 claims description 3
- 102100038017 DIS3-like exonuclease 2 Human genes 0.000 claims description 3
- 102100035925 DNA methyltransferase 1-associated protein 1 Human genes 0.000 claims description 3
- 102100036727 Deformed epidermal autoregulatory factor 1 homolog Human genes 0.000 claims description 3
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 claims description 3
- 102100037101 Deoxycytidylate deaminase Human genes 0.000 claims description 3
- 102100030220 Diacylglycerol kinase zeta Human genes 0.000 claims description 3
- 102100022825 Disintegrin and metalloproteinase domain-containing protein 22 Human genes 0.000 claims description 3
- 102100022820 Disintegrin and metalloproteinase domain-containing protein 28 Human genes 0.000 claims description 3
- 102100037849 Divergent protein kinase domain 1B Human genes 0.000 claims description 3
- 102100037567 Dual specificity protein phosphatase 14 Human genes 0.000 claims description 3
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 claims description 3
- 102100021242 Dymeclin Human genes 0.000 claims description 3
- 102100040633 Dynein regulatory complex subunit 7 Human genes 0.000 claims description 3
- 102100032710 E3 ubiquitin-protein ligase Jade-2 Human genes 0.000 claims description 3
- 102100023147 E3 ubiquitin-protein ligase MARCHF7 Human genes 0.000 claims description 3
- 102100026246 E3 ubiquitin-protein ligase NRDP1 Human genes 0.000 claims description 3
- 102100034121 E3 ubiquitin-protein ligase RNF125 Human genes 0.000 claims description 3
- 102100031534 E3 ubiquitin-protein ligase RNF144A Human genes 0.000 claims description 3
- 102100034830 E3 ubiquitin-protein ligase RNF216 Human genes 0.000 claims description 3
- 102100024816 E3 ubiquitin-protein ligase TRAF7 Human genes 0.000 claims description 3
- 102100028591 E3 ubiquitin-protein ligase ZNRF1 Human genes 0.000 claims description 3
- 102100029065 EF-hand domain-containing family member C2 Human genes 0.000 claims description 3
- 102100032449 EGF-like repeat and discoidin I-like domain-containing protein 3 Human genes 0.000 claims description 3
- 102100038415 ELKS/Rab6-interacting/CAST family member 1 Human genes 0.000 claims description 3
- 108091016436 EPS8 Proteins 0.000 claims description 3
- 102000020045 EPS8 Human genes 0.000 claims description 3
- 102100030323 Epigen Human genes 0.000 claims description 3
- 101000809594 Escherichia coli (strain K12) Shikimate kinase 1 Proteins 0.000 claims description 3
- 102100026979 Exocyst complex component 4 Human genes 0.000 claims description 3
- 102100038195 Exonuclease mut-7 homolog Human genes 0.000 claims description 3
- 102100029595 Fatty acyl-CoA reductase 2 Human genes 0.000 claims description 3
- 102100026542 Fibronectin type-III domain-containing protein 3A Human genes 0.000 claims description 3
- 102100028122 Forkhead box protein P1 Human genes 0.000 claims description 3
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 claims description 3
- 102100034600 GDNF-inducible zinc finger protein 1 Human genes 0.000 claims description 3
- 102100037755 GRB2-associated-binding protein 3 Human genes 0.000 claims description 3
- 102100028953 Gelsolin Human genes 0.000 claims description 3
- 102100022967 General transcription factor II-I repeat domain-containing protein 1 Human genes 0.000 claims description 3
- 102100041007 Glia maturation factor gamma Human genes 0.000 claims description 3
- 102100023518 Glutamine-dependent NAD(+) synthetase Human genes 0.000 claims description 3
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 claims description 3
- 102100040579 Guanidinoacetate N-methyltransferase Human genes 0.000 claims description 3
- 102100035910 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 Human genes 0.000 claims description 3
- 102100035786 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 Human genes 0.000 claims description 3
- 102100034058 Gypsy retrotransposon integrase-like protein 1 Human genes 0.000 claims description 3
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 3
- 102100028673 HORMA domain-containing protein 1 Human genes 0.000 claims description 3
- 102100028670 HORMA domain-containing protein 2 Human genes 0.000 claims description 3
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims description 3
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 claims description 3
- 102100033070 Histone acetyltransferase KAT6B Human genes 0.000 claims description 3
- 102100038720 Histone deacetylase 9 Human genes 0.000 claims description 3
- 102100038586 Histone demethylase UTY Human genes 0.000 claims description 3
- 102100027704 Histone-lysine N-methyltransferase SETD7 Human genes 0.000 claims description 3
- 102100028411 Homeobox protein Hox-B3 Human genes 0.000 claims description 3
- 101000929842 Homo sapiens (Lyso)-N-acylphosphatidylethanolamine lipase Proteins 0.000 claims description 3
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims description 3
- 101001069718 Homo sapiens 26S proteasome regulatory subunit 10B Proteins 0.000 claims description 3
- 101000704060 Homo sapiens 40S ribosomal protein S29 Proteins 0.000 claims description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 101000886015 Homo sapiens ADP-ribosylation factor-like protein 4A Proteins 0.000 claims description 3
- 101000833180 Homo sapiens AF4/FMR2 family member 1 Proteins 0.000 claims description 3
- 101000890244 Homo sapiens AP-4 complex subunit sigma-1 Proteins 0.000 claims description 3
- 101000685261 Homo sapiens AT-rich interactive domain-containing protein 2 Proteins 0.000 claims description 3
- 101000936950 Homo sapiens ATP synthase subunit g, mitochondrial Proteins 0.000 claims description 3
- 101000929654 Homo sapiens ATP-binding cassette sub-family A member 10 Proteins 0.000 claims description 3
- 101000929660 Homo sapiens ATP-binding cassette sub-family A member 13 Proteins 0.000 claims description 3
- 101000907886 Homo sapiens ATP-dependent RNA helicase DHX15 Proteins 0.000 claims description 3
- 101000874516 Homo sapiens Acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase Proteins 0.000 claims description 3
- 101000649017 Homo sapiens Activating signal cointegrator 1 Proteins 0.000 claims description 3
- 101000782705 Homo sapiens Acyl-CoA-binding domain-containing protein 5 Proteins 0.000 claims description 3
- 101000718219 Homo sapiens Adhesion G-protein coupled receptor D1 Proteins 0.000 claims description 3
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 claims description 3
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 claims description 3
- 101000889457 Homo sapiens Ankyrin repeat domain-containing protein 49 Proteins 0.000 claims description 3
- 101000733555 Homo sapiens Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 Proteins 0.000 claims description 3
- 101000961040 Homo sapiens Atrial natriuretic peptide receptor 2 Proteins 0.000 claims description 3
- 101000875771 Homo sapiens Atypical kinase COQ8A, mitochondrial Proteins 0.000 claims description 3
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims description 3
- 101001049975 Homo sapiens Band 4.1-like protein 3 Proteins 0.000 claims description 3
- 101000729794 Homo sapiens Beta-1,4-glucuronyltransferase 1 Proteins 0.000 claims description 3
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 3
- 101001016707 Homo sapiens Beta-mannosidase Proteins 0.000 claims description 3
- 101000802825 Homo sapiens Biliverdin reductase A Proteins 0.000 claims description 3
- 101000993081 Homo sapiens C-Maf-inducing protein Proteins 0.000 claims description 3
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 claims description 3
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 3
- 101000767061 Homo sapiens CAP-Gly domain-containing linker protein 4 Proteins 0.000 claims description 3
- 101000793819 Homo sapiens CDKN2A-interacting protein Proteins 0.000 claims description 3
- 101000703758 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Proteins 0.000 claims description 3
- 101000616698 Homo sapiens CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Proteins 0.000 claims description 3
- 101000990007 Homo sapiens CMRF35-like molecule 7 Proteins 0.000 claims description 3
- 101000585157 Homo sapiens CST complex subunit STN1 Proteins 0.000 claims description 3
- 101000894806 Homo sapiens CUE domain-containing protein 2 Proteins 0.000 claims description 3
- 101000944442 Homo sapiens CUGBP Elav-like family member 2 Proteins 0.000 claims description 3
- 101000912003 Homo sapiens CYFIP-related Rac1 interactor A Proteins 0.000 claims description 3
- 101000935098 Homo sapiens Cadherin-9 Proteins 0.000 claims description 3
- 101000794470 Homo sapiens Calcium-binding protein 8 Proteins 0.000 claims description 3
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 claims description 3
- 101000737274 Homo sapiens Carbonyl reductase [NADPH] 3 Proteins 0.000 claims description 3
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 claims description 3
- 101000762448 Homo sapiens Cdc42 effector protein 1 Proteins 0.000 claims description 3
- 101000897353 Homo sapiens Cell division cycle protein 123 homolog Proteins 0.000 claims description 3
- 101000880522 Homo sapiens Centrin-3 Proteins 0.000 claims description 3
- 101000941711 Homo sapiens Centriolin Proteins 0.000 claims description 3
- 101000943253 Homo sapiens Charged multivesicular body protein 2a Proteins 0.000 claims description 3
- 101000919756 Homo sapiens Chemerin-like receptor 1 Proteins 0.000 claims description 3
- 101000715173 Homo sapiens Chemokine-like protein TAFA-2 Proteins 0.000 claims description 3
- 101000883749 Homo sapiens Chromodomain-helicase-DNA-binding protein 4 Proteins 0.000 claims description 3
- 101000776612 Homo sapiens Cilia- and flagella-associated protein 73 Proteins 0.000 claims description 3
- 101000777336 Homo sapiens Coiled-coil domain-containing protein 12 Proteins 0.000 claims description 3
- 101000715241 Homo sapiens Coiled-coil domain-containing protein 171 Proteins 0.000 claims description 3
- 101000794263 Homo sapiens Complement C1q tumor necrosis factor-related protein 4 Proteins 0.000 claims description 3
- 101000737813 Homo sapiens Cyclin-dependent kinase 2-associated protein 1 Proteins 0.000 claims description 3
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 claims description 3
- 101000954166 Homo sapiens Cytochrome b-245 chaperone 1 Proteins 0.000 claims description 3
- 101000870136 Homo sapiens Cytohesin-1 Proteins 0.000 claims description 3
- 101000855828 Homo sapiens Cytohesin-4 Proteins 0.000 claims description 3
- 101000710210 Homo sapiens Cytokine-dependent hematopoietic cell linker Proteins 0.000 claims description 3
- 101000870988 Homo sapiens DENN domain-containing protein 10 Proteins 0.000 claims description 3
- 101000865183 Homo sapiens DEP domain-containing mTOR-interacting protein Proteins 0.000 claims description 3
- 101000951062 Homo sapiens DIS3-like exonuclease 2 Proteins 0.000 claims description 3
- 101000930289 Homo sapiens DNA methyltransferase 1-associated protein 1 Proteins 0.000 claims description 3
- 101000929421 Homo sapiens Deformed epidermal autoregulatory factor 1 homolog Proteins 0.000 claims description 3
- 101000928746 Homo sapiens Dehydrogenase/reductase SDR family member 9 Proteins 0.000 claims description 3
- 101000955042 Homo sapiens Deoxycytidylate deaminase Proteins 0.000 claims description 3
- 101000864576 Homo sapiens Diacylglycerol kinase zeta Proteins 0.000 claims description 3
- 101000756722 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 22 Proteins 0.000 claims description 3
- 101000756756 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 28 Proteins 0.000 claims description 3
- 101000806069 Homo sapiens Divergent protein kinase domain 1B Proteins 0.000 claims description 3
- 101000881116 Homo sapiens Dual specificity protein phosphatase 14 Proteins 0.000 claims description 3
- 101001057587 Homo sapiens Dual specificity protein phosphatase 6 Proteins 0.000 claims description 3
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 claims description 3
- 101000816903 Homo sapiens Dynein regulatory complex subunit 7 Proteins 0.000 claims description 3
- 101000994468 Homo sapiens E3 ubiquitin-protein ligase Jade-2 Proteins 0.000 claims description 3
- 101000978673 Homo sapiens E3 ubiquitin-protein ligase MARCHF7 Proteins 0.000 claims description 3
- 101000692706 Homo sapiens E3 ubiquitin-protein ligase NRDP1 Proteins 0.000 claims description 3
- 101000711567 Homo sapiens E3 ubiquitin-protein ligase RNF125 Proteins 0.000 claims description 3
- 101001130270 Homo sapiens E3 ubiquitin-protein ligase RNF144A Proteins 0.000 claims description 3
- 101000734278 Homo sapiens E3 ubiquitin-protein ligase RNF216 Proteins 0.000 claims description 3
- 101000830899 Homo sapiens E3 ubiquitin-protein ligase TRAF7 Proteins 0.000 claims description 3
- 101000915580 Homo sapiens E3 ubiquitin-protein ligase ZNRF1 Proteins 0.000 claims description 3
- 101000840931 Homo sapiens EF-hand domain-containing family member C2 Proteins 0.000 claims description 3
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 claims description 3
- 101001100208 Homo sapiens ELKS/Rab6-interacting/CAST family member 1 Proteins 0.000 claims description 3
- 101000966913 Homo sapiens ELL-associated factor 2 Proteins 0.000 claims description 3
- 101000938352 Homo sapiens Epigen Proteins 0.000 claims description 3
- 101000911699 Homo sapiens Exocyst complex component 4 Proteins 0.000 claims description 3
- 101000958030 Homo sapiens Exonuclease mut-7 homolog Proteins 0.000 claims description 3
- 101000917301 Homo sapiens Fatty acyl-CoA reductase 2 Proteins 0.000 claims description 3
- 101000913670 Homo sapiens Fibronectin type-III domain-containing protein 3A Proteins 0.000 claims description 3
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 claims description 3
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 claims description 3
- 101001067667 Homo sapiens GDNF-inducible zinc finger protein 1 Proteins 0.000 claims description 3
- 101001024905 Homo sapiens GRB2-associated-binding protein 3 Proteins 0.000 claims description 3
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 claims description 3
- 101000903798 Homo sapiens General transcription factor II-I repeat domain-containing protein 1 Proteins 0.000 claims description 3
- 101001039458 Homo sapiens Glia maturation factor gamma Proteins 0.000 claims description 3
- 101001112831 Homo sapiens Glutamine-dependent NAD(+) synthetase Proteins 0.000 claims description 3
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 claims description 3
- 101000893897 Homo sapiens Guanidinoacetate N-methyltransferase Proteins 0.000 claims description 3
- 101001073272 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 Proteins 0.000 claims description 3
- 101001073247 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 Proteins 0.000 claims description 3
- 101000926251 Homo sapiens Gypsy retrotransposon integrase-like protein 1 Proteins 0.000 claims description 3
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 3
- 101000985263 Homo sapiens HORMA domain-containing protein 2 Proteins 0.000 claims description 3
- 101100395441 Homo sapiens HORMAD1 gene Proteins 0.000 claims description 3
- 101000843842 Homo sapiens Heme-binding protein 1 Proteins 0.000 claims description 3
- 101001045758 Homo sapiens Hepatocyte nuclear factor 1-beta Proteins 0.000 claims description 3
- 101000944174 Homo sapiens Histone acetyltransferase KAT6B Proteins 0.000 claims description 3
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 claims description 3
- 101000808558 Homo sapiens Histone demethylase UTY Proteins 0.000 claims description 3
- 101000650682 Homo sapiens Histone-lysine N-methyltransferase SETD7 Proteins 0.000 claims description 3
- 101000839775 Homo sapiens Homeobox protein Hox-B3 Proteins 0.000 claims description 3
- 101000599449 Homo sapiens Importin-8 Proteins 0.000 claims description 3
- 101001008896 Homo sapiens Inactive histone-lysine N-methyltransferase 2E Proteins 0.000 claims description 3
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 claims description 3
- 101000852486 Homo sapiens Inositol 1,4,5-triphosphate receptor associated 2 Proteins 0.000 claims description 3
- 101000975428 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 1 Proteins 0.000 claims description 3
- 101001011393 Homo sapiens Interferon regulatory factor 2 Proteins 0.000 claims description 3
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims description 3
- 101000999373 Homo sapiens Interferon-related developmental regulator 2 Proteins 0.000 claims description 3
- 101001044420 Homo sapiens Intraflagellar transport protein 56 Proteins 0.000 claims description 3
- 101000997838 Homo sapiens Janus kinase and microtubule-interacting protein 2 Proteins 0.000 claims description 3
- 101000975000 Homo sapiens KAT8 regulatory NSL complex subunit 1-like protein Proteins 0.000 claims description 3
- 101001047009 Homo sapiens Kelch repeat and BTB domain-containing protein 4 Proteins 0.000 claims description 3
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 claims description 3
- 101001139117 Homo sapiens Krueppel-like factor 7 Proteins 0.000 claims description 3
- 101001004313 Homo sapiens LHFPL tetraspan subfamily member 2 protein Proteins 0.000 claims description 3
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 3
- 101001017764 Homo sapiens Lipopolysaccharide-responsive and beige-like anchor protein Proteins 0.000 claims description 3
- 101000826600 Homo sapiens Lysine-specific demethylase RSBN1L Proteins 0.000 claims description 3
- 101001098256 Homo sapiens Lysophospholipase Proteins 0.000 claims description 3
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 claims description 3
- 101000576156 Homo sapiens MOB kinase activator 3A Proteins 0.000 claims description 3
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 claims description 3
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 claims description 3
- 101001055354 Homo sapiens Mediator of RNA polymerase II transcription subunit 6 Proteins 0.000 claims description 3
- 101001059535 Homo sapiens Megakaryocyte-associated tyrosine-protein kinase Proteins 0.000 claims description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 3
- 101001012669 Homo sapiens Melanoma inhibitory activity protein 2 Proteins 0.000 claims description 3
- 101001014566 Homo sapiens Membrane-spanning 4-domains subfamily A member 3 Proteins 0.000 claims description 3
- 101000936433 Homo sapiens Methylglutaconyl-CoA hydratase, mitochondrial Proteins 0.000 claims description 3
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 claims description 3
- 101000960626 Homo sapiens Mitochondrial inner membrane protease subunit 2 Proteins 0.000 claims description 3
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 claims description 3
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 claims description 3
- 101000980497 Homo sapiens Mitotic deacetylase-associated SANT domain protein Proteins 0.000 claims description 3
- 101001074975 Homo sapiens Molybdopterin molybdenumtransferase Proteins 0.000 claims description 3
- 101001012646 Homo sapiens Monoglyceride lipase Proteins 0.000 claims description 3
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 claims description 3
- 101000928929 Homo sapiens Muscarinic acetylcholine receptor M2 Proteins 0.000 claims description 3
- 101001030232 Homo sapiens Myosin-9 Proteins 0.000 claims description 3
- 101001024511 Homo sapiens N-acetyl-D-glucosamine kinase Proteins 0.000 claims description 3
- 101001072470 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Proteins 0.000 claims description 3
- 101000973461 Homo sapiens NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 Proteins 0.000 claims description 3
- 101001111187 Homo sapiens NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial Proteins 0.000 claims description 3
- 101000743795 Homo sapiens NFX1-type zinc finger-containing protein 1 Proteins 0.000 claims description 3
- 101000775053 Homo sapiens Neuroblast differentiation-associated protein AHNAK Proteins 0.000 claims description 3
- 101001112229 Homo sapiens Neutrophil cytosol factor 1 Proteins 0.000 claims description 3
- 101000864039 Homo sapiens Nonsense-mediated mRNA decay factor SMG5 Proteins 0.000 claims description 3
- 101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 claims description 3
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 3
- 101001137535 Homo sapiens Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Proteins 0.000 claims description 3
- 101000594463 Homo sapiens Olfactory receptor 2AG2 Proteins 0.000 claims description 3
- 101000945735 Homo sapiens Parafibromin Proteins 0.000 claims description 3
- 101000891031 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP10 Proteins 0.000 claims description 3
- 101000701363 Homo sapiens Phospholipid-transporting ATPase IC Proteins 0.000 claims description 3
- 101001094872 Homo sapiens Plexin-C1 Proteins 0.000 claims description 3
- 101001094868 Homo sapiens Plexin-D1 Proteins 0.000 claims description 3
- 101001094809 Homo sapiens Polynucleotide 5'-hydroxyl-kinase Proteins 0.000 claims description 3
- 101000605345 Homo sapiens Prefoldin subunit 1 Proteins 0.000 claims description 3
- 101000599816 Homo sapiens Probable E3 ubiquitin-protein ligase IRF2BPL Proteins 0.000 claims description 3
- 101000640325 Homo sapiens Probable asparagine-tRNA ligase, mitochondrial Proteins 0.000 claims description 3
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims description 3
- 101001083769 Homo sapiens Probable helicase with zinc finger domain Proteins 0.000 claims description 3
- 101000701518 Homo sapiens Probable phospholipid-transporting ATPase IM Proteins 0.000 claims description 3
- 101001090551 Homo sapiens Proline-rich protein 5-like Proteins 0.000 claims description 3
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims description 3
- 101001117509 Homo sapiens Prostaglandin E2 receptor EP4 subtype Proteins 0.000 claims description 3
- 101000892360 Homo sapiens Protein AF-17 Proteins 0.000 claims description 3
- 101000959489 Homo sapiens Protein AF-9 Proteins 0.000 claims description 3
- 101000728208 Homo sapiens Protein Aster-A Proteins 0.000 claims description 3
- 101000881752 Homo sapiens Protein ELYS Proteins 0.000 claims description 3
- 101001056567 Homo sapiens Protein Jumonji Proteins 0.000 claims description 3
- 101000624382 Homo sapiens Protein MON2 homolog Proteins 0.000 claims description 3
- 101000734678 Homo sapiens Protein PEAK3 Proteins 0.000 claims description 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 3
- 101000878687 Homo sapiens Protein cramped-like Proteins 0.000 claims description 3
- 101001026852 Homo sapiens Protein kinase C epsilon type Proteins 0.000 claims description 3
- 101000981715 Homo sapiens Protein lifeguard 4 Proteins 0.000 claims description 3
- 101000643431 Homo sapiens Protein phosphatase Slingshot homolog 2 Proteins 0.000 claims description 3
- 101000735368 Homo sapiens Protocadherin-9 Proteins 0.000 claims description 3
- 101000848490 Homo sapiens Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2 Proteins 0.000 claims description 3
- 101000922030 Homo sapiens Putative uncharacterized protein encoded by LINC00158 Proteins 0.000 claims description 3
- 101000793150 Homo sapiens Putative uncharacterized protein encoded by LINC00173 Proteins 0.000 claims description 3
- 101000851655 Homo sapiens Putative uncharacterized protein encoded by LINC00311 Proteins 0.000 claims description 3
- 101000665452 Homo sapiens RNA binding protein fox-1 homolog 2 Proteins 0.000 claims description 3
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 claims description 3
- 101000629813 Homo sapiens RNA-binding protein MEX3B Proteins 0.000 claims description 3
- 101001095989 Homo sapiens RalBP1-associated Eps domain-containing protein 1 Proteins 0.000 claims description 3
- 101000712964 Homo sapiens Ras association domain-containing protein 3 Proteins 0.000 claims description 3
- 101000620593 Homo sapiens Ras-related protein Rab-37 Proteins 0.000 claims description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 3
- 101000668416 Homo sapiens Regulator of chromosome condensation Proteins 0.000 claims description 3
- 101000823237 Homo sapiens Reticulon-1 Proteins 0.000 claims description 3
- 101001094537 Homo sapiens Retrotransposon Gag-like protein 3 Proteins 0.000 claims description 3
- 101001091996 Homo sapiens Rho GTPase-activating protein 22 Proteins 0.000 claims description 3
- 101001091991 Homo sapiens Rho GTPase-activating protein 25 Proteins 0.000 claims description 3
- 101001106395 Homo sapiens Rho GTPase-activating protein 5 Proteins 0.000 claims description 3
- 101000704874 Homo sapiens Rho family-interacting cell polarization regulator 2 Proteins 0.000 claims description 3
- 101000752249 Homo sapiens Rho guanine nucleotide exchange factor 3 Proteins 0.000 claims description 3
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 claims description 3
- 101001088129 Homo sapiens Ropporin-1-like protein Proteins 0.000 claims description 3
- 101000836397 Homo sapiens SEC14 domain and spectrin repeat-containing protein 1 Proteins 0.000 claims description 3
- 101000706551 Homo sapiens SUN domain-containing protein 2 Proteins 0.000 claims description 3
- 101000706563 Homo sapiens SUN domain-containing protein 3 Proteins 0.000 claims description 3
- 101000643849 Homo sapiens SUN domain-containing protein 5 Proteins 0.000 claims description 3
- 101000687634 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Proteins 0.000 claims description 3
- 101000821521 Homo sapiens Saccharopine dehydrogenase-like oxidoreductase Proteins 0.000 claims description 3
- 101000684514 Homo sapiens Sentrin-specific protease 6 Proteins 0.000 claims description 3
- 101000632056 Homo sapiens Septin-9 Proteins 0.000 claims description 3
- 101000700735 Homo sapiens Serine/arginine-rich splicing factor 7 Proteins 0.000 claims description 3
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 claims description 3
- 101000576904 Homo sapiens Serine/threonine-protein kinase MRCK beta Proteins 0.000 claims description 3
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 claims description 3
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 claims description 3
- 101000783373 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Proteins 0.000 claims description 3
- 101000826125 Homo sapiens Single-stranded DNA-binding protein 2 Proteins 0.000 claims description 3
- 101000863692 Homo sapiens Ski oncogene Proteins 0.000 claims description 3
- 101000616767 Homo sapiens Small integral membrane protein 29 Proteins 0.000 claims description 3
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 claims description 3
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 claims description 3
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 claims description 3
- 101000687654 Homo sapiens Sorting nexin-20 Proteins 0.000 claims description 3
- 101000665020 Homo sapiens Sorting nexin-5 Proteins 0.000 claims description 3
- 101000868440 Homo sapiens Sorting nexin-8 Proteins 0.000 claims description 3
- 101000881252 Homo sapiens Spectrin beta chain, non-erythrocytic 1 Proteins 0.000 claims description 3
- 101000658075 Homo sapiens Splicing factor U2AF 26 kDa subunit Proteins 0.000 claims description 3
- 101000820460 Homo sapiens Stomatin Proteins 0.000 claims description 3
- 101000820457 Homo sapiens Stonin-2 Proteins 0.000 claims description 3
- 101000600912 Homo sapiens Substance-K receptor Proteins 0.000 claims description 3
- 101000584515 Homo sapiens Synaptic vesicle glycoprotein 2B Proteins 0.000 claims description 3
- 101000820476 Homo sapiens Syntaxin-binding protein 4 Proteins 0.000 claims description 3
- 101000788541 Homo sapiens TBC1 domain family member 26 Proteins 0.000 claims description 3
- 101000891623 Homo sapiens TBC1 domain family member 5 Proteins 0.000 claims description 3
- 101000802053 Homo sapiens THUMP domain-containing protein 1 Proteins 0.000 claims description 3
- 101000800493 Homo sapiens Talin rod domain-containing protein 1 Proteins 0.000 claims description 3
- 101000626125 Homo sapiens Tetranectin Proteins 0.000 claims description 3
- 101000658614 Homo sapiens Tetraspanin-33 Proteins 0.000 claims description 3
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 claims description 3
- 101000801891 Homo sapiens Thioredoxin, mitochondrial Proteins 0.000 claims description 3
- 101000712600 Homo sapiens Thyroid hormone receptor beta Proteins 0.000 claims description 3
- 101000597047 Homo sapiens Transcription elongation factor A N-terminal and central domain-containing protein 2 Proteins 0.000 claims description 3
- 101000723923 Homo sapiens Transcription factor HIVEP2 Proteins 0.000 claims description 3
- 101000825082 Homo sapiens Transcription factor SOX-12 Proteins 0.000 claims description 3
- 101000801209 Homo sapiens Transducin-like enhancer protein 4 Proteins 0.000 claims description 3
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 claims description 3
- 101000597750 Homo sapiens Transmembrane protein 17 Proteins 0.000 claims description 3
- 101000798689 Homo sapiens Transmembrane protein 33 Proteins 0.000 claims description 3
- 101000899433 Homo sapiens Transmembrane protein C1orf162 Proteins 0.000 claims description 3
- 101000763003 Homo sapiens Two pore channel protein 1 Proteins 0.000 claims description 3
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 claims description 3
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 claims description 3
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 claims description 3
- 101001087412 Homo sapiens Tyrosine-protein phosphatase non-receptor type 18 Proteins 0.000 claims description 3
- 101000805909 Homo sapiens U3 small nucleolar RNA-associated protein 6 homolog Proteins 0.000 claims description 3
- 101000841471 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 15 Proteins 0.000 claims description 3
- 101000761725 Homo sapiens Ubiquitin-conjugating enzyme E2 J1 Proteins 0.000 claims description 3
- 101000662020 Homo sapiens Ubiquitin-like modifier-activating enzyme 6 Proteins 0.000 claims description 3
- 101000912683 Homo sapiens Uncharacterized protein C12orf76 Proteins 0.000 claims description 3
- 101000957921 Homo sapiens Uncharacterized protein C18orf25 Proteins 0.000 claims description 3
- 101000983556 Homo sapiens Uncharacterized protein C2orf42 Proteins 0.000 claims description 3
- 101000884236 Homo sapiens Uncharacterized protein C4orf45 Proteins 0.000 claims description 3
- 101000667337 Homo sapiens V-set and transmembrane domain-containing protein 4 Proteins 0.000 claims description 3
- 101000805441 Homo sapiens V-type proton ATPase subunit G 3 Proteins 0.000 claims description 3
- 101000805613 Homo sapiens Vacuole membrane protein 1 Proteins 0.000 claims description 3
- 101000871912 Homo sapiens Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 Proteins 0.000 claims description 3
- 101000653426 Homo sapiens Very-long-chain enoyl-CoA reductase Proteins 0.000 claims description 3
- 101000740765 Homo sapiens Voltage-dependent calcium channel subunit alpha-2/delta-4 Proteins 0.000 claims description 3
- 101000743189 Homo sapiens WD repeat-containing protein 31 Proteins 0.000 claims description 3
- 101000665937 Homo sapiens Wnt inhibitory factor 1 Proteins 0.000 claims description 3
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims description 3
- 101000744718 Homo sapiens YTH domain-containing family protein 3 Proteins 0.000 claims description 3
- 101000818532 Homo sapiens Zinc finger and BTB domain-containing protein 20 Proteins 0.000 claims description 3
- 101000916535 Homo sapiens Zinc finger and BTB domain-containing protein 44 Proteins 0.000 claims description 3
- 101000759564 Homo sapiens Zinc finger and BTB domain-containing protein 8A Proteins 0.000 claims description 3
- 101000744900 Homo sapiens Zinc finger homeobox protein 3 Proteins 0.000 claims description 3
- 101000759226 Homo sapiens Zinc finger protein 143 Proteins 0.000 claims description 3
- 101000744929 Homo sapiens Zinc finger protein 205 Proteins 0.000 claims description 3
- 101000818786 Homo sapiens Zinc finger protein 253 Proteins 0.000 claims description 3
- 101000788753 Homo sapiens Zinc finger protein 358 Proteins 0.000 claims description 3
- 101000802338 Homo sapiens Zinc finger protein 382 Proteins 0.000 claims description 3
- 101000818829 Homo sapiens Zinc finger protein 429 Proteins 0.000 claims description 3
- 101000785690 Homo sapiens Zinc finger protein 521 Proteins 0.000 claims description 3
- 101000760250 Homo sapiens Zinc finger protein 579 Proteins 0.000 claims description 3
- 101000785613 Homo sapiens Zinc finger protein 652 Proteins 0.000 claims description 3
- 101000964749 Homo sapiens Zinc finger protein 710 Proteins 0.000 claims description 3
- 101000760293 Homo sapiens Zinc finger protein 747 Proteins 0.000 claims description 3
- 101000964730 Homo sapiens Zinc finger protein 79 Proteins 0.000 claims description 3
- 101000857270 Homo sapiens Zinc finger protein GLIS1 Proteins 0.000 claims description 3
- 101000785641 Homo sapiens Zinc finger protein with KRAB and SCAN domains 1 Proteins 0.000 claims description 3
- 101001046427 Homo sapiens cGMP-dependent protein kinase 2 Proteins 0.000 claims description 3
- 102100037966 Importin-8 Human genes 0.000 claims description 3
- 102100027767 Inactive histone-lysine N-methyltransferase 2E Human genes 0.000 claims description 3
- 102100036343 Inositol 1,4,5-triphosphate receptor associated 2 Human genes 0.000 claims description 3
- 102100024039 Inositol 1,4,5-trisphosphate receptor type 1 Human genes 0.000 claims description 3
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 claims description 3
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims description 3
- 102100036480 Interferon-related developmental regulator 2 Human genes 0.000 claims description 3
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims description 3
- 102100030699 Interleukin-21 receptor Human genes 0.000 claims description 3
- 102100022488 Intraflagellar transport protein 56 Human genes 0.000 claims description 3
- 102100033439 Janus kinase and microtubule-interacting protein 2 Human genes 0.000 claims description 3
- 102100023009 KAT8 regulatory NSL complex subunit 1-like protein Human genes 0.000 claims description 3
- 102100022838 Kelch repeat and BTB domain-containing protein 4 Human genes 0.000 claims description 3
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims description 3
- 102100020692 Krueppel-like factor 7 Human genes 0.000 claims description 3
- 102100025687 LHFPL tetraspan subfamily member 2 protein Human genes 0.000 claims description 3
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 3
- 102100033353 Lipopolysaccharide-responsive and beige-like anchor protein Human genes 0.000 claims description 3
- 102100024030 Lysine-specific demethylase RSBN1L Human genes 0.000 claims description 3
- 102100037611 Lysophospholipase Human genes 0.000 claims description 3
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 3
- 102100025930 MOB kinase activator 3A Human genes 0.000 claims description 3
- 102100024573 Macrophage-capping protein Human genes 0.000 claims description 3
- 102100025134 Mastermind-like protein 3 Human genes 0.000 claims description 3
- 102100026174 Mediator of RNA polymerase II transcription subunit 6 Human genes 0.000 claims description 3
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 claims description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
- 102100029778 Melanoma inhibitory activity protein 2 Human genes 0.000 claims description 3
- 102100032517 Membrane-spanning 4-domains subfamily A member 3 Human genes 0.000 claims description 3
- 102100027392 Methylglutaconyl-CoA hydratase, mitochondrial Human genes 0.000 claims description 3
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 claims description 3
- 102100039840 Mitochondrial inner membrane protease subunit 2 Human genes 0.000 claims description 3
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 claims description 3
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 claims description 3
- 102100024249 Mitotic deacetylase-associated SANT domain protein Human genes 0.000 claims description 3
- 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 claims description 3
- 102100029814 Monoglyceride lipase Human genes 0.000 claims description 3
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims description 3
- 102100038938 Myosin-9 Human genes 0.000 claims description 3
- 102100035286 N-acetyl-D-glucosamine kinase Human genes 0.000 claims description 3
- 102100036710 N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Human genes 0.000 claims description 3
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 claims description 3
- 102100022198 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 Human genes 0.000 claims description 3
- 102100023964 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial Human genes 0.000 claims description 3
- 102100038552 NEDD4-binding protein 1 Human genes 0.000 claims description 3
- 101710081124 NEDD4-binding protein 1 Proteins 0.000 claims description 3
- 102100039043 NFX1-type zinc finger-containing protein 1 Human genes 0.000 claims description 3
- 102100031837 Neuroblast differentiation-associated protein AHNAK Human genes 0.000 claims description 3
- 102100023620 Neutrophil cytosol factor 1 Human genes 0.000 claims description 3
- 102100029940 Nonsense-mediated mRNA decay factor SMG5 Human genes 0.000 claims description 3
- 102000001756 Notch2 Receptor Human genes 0.000 claims description 3
- 108010029751 Notch2 Receptor Proteins 0.000 claims description 3
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 claims description 3
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 3
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims description 3
- 102100021007 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 Human genes 0.000 claims description 3
- 102100035517 Olfactory receptor 2AG2 Human genes 0.000 claims description 3
- 102100034743 Parafibromin Human genes 0.000 claims description 3
- 102100037499 Parkinson disease protein 7 Human genes 0.000 claims description 3
- 102100040349 Peptidyl-prolyl cis-trans isomerase FKBP10 Human genes 0.000 claims description 3
- 102100030448 Phospholipid-transporting ATPase IC Human genes 0.000 claims description 3
- 102100035381 Plexin-C1 Human genes 0.000 claims description 3
- 102100035380 Plexin-D1 Human genes 0.000 claims description 3
- 102100035460 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 claims description 3
- 102100038255 Prefoldin subunit 1 Human genes 0.000 claims description 3
- 102100037864 Probable E3 ubiquitin-protein ligase IRF2BPL Human genes 0.000 claims description 3
- 102100033917 Probable asparagine-tRNA ligase, mitochondrial Human genes 0.000 claims description 3
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims description 3
- 102100031018 Probable helicase with zinc finger domain Human genes 0.000 claims description 3
- 102100030468 Probable phospholipid-transporting ATPase IM Human genes 0.000 claims description 3
- 102100034734 Proline-rich protein 5-like Human genes 0.000 claims description 3
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims description 3
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 claims description 3
- 101710145576 Prostaglandin-H2 D-isomerase Proteins 0.000 claims description 3
- 102000004885 Protease-activated receptor 4 Human genes 0.000 claims description 3
- 108090001010 Protease-activated receptor 4 Proteins 0.000 claims description 3
- 102100040638 Protein AF-17 Human genes 0.000 claims description 3
- 102100039686 Protein AF-9 Human genes 0.000 claims description 3
- 102100029800 Protein Aster-A Human genes 0.000 claims description 3
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 claims description 3
- 102100037113 Protein ELYS Human genes 0.000 claims description 3
- 102100025733 Protein Jumonji Human genes 0.000 claims description 3
- 102100023396 Protein MON2 homolog Human genes 0.000 claims description 3
- 102100034688 Protein PEAK3 Human genes 0.000 claims description 3
- 102100030244 Protein SOX-15 Human genes 0.000 claims description 3
- 102100038012 Protein cramped-like Human genes 0.000 claims description 3
- 102100037339 Protein kinase C epsilon type Human genes 0.000 claims description 3
- 102100024094 Protein lifeguard 4 Human genes 0.000 claims description 3
- 102100035698 Protein phosphatase Slingshot homolog 2 Human genes 0.000 claims description 3
- 108091000520 Protein-Arginine Deiminase Type 4 Proteins 0.000 claims description 3
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 claims description 3
- 102100034957 Protocadherin-9 Human genes 0.000 claims description 3
- 102100034621 Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2 Human genes 0.000 claims description 3
- 102100031094 Putative uncharacterized protein encoded by LINC00158 Human genes 0.000 claims description 3
- 102100030974 Putative uncharacterized protein encoded by LINC00173 Human genes 0.000 claims description 3
- 102100036797 Putative uncharacterized protein encoded by LINC00311 Human genes 0.000 claims description 3
- 102100038187 RNA binding protein fox-1 homolog 2 Human genes 0.000 claims description 3
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 claims description 3
- 102100026869 RNA-binding protein MEX3B Human genes 0.000 claims description 3
- 102100028208 Raftlin Human genes 0.000 claims description 3
- 101710159571 Raftlin Proteins 0.000 claims description 3
- 102100037881 RalBP1-associated Eps domain-containing protein 1 Human genes 0.000 claims description 3
- 102100033244 Ras association domain-containing protein 3 Human genes 0.000 claims description 3
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 claims description 3
- 102100022294 Ras-related protein Rab-37 Human genes 0.000 claims description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 3
- 102100039977 Regulator of chromosome condensation Human genes 0.000 claims description 3
- 102100022647 Reticulon-1 Human genes 0.000 claims description 3
- 102100035122 Retrotransposon Gag-like protein 3 Human genes 0.000 claims description 3
- 102100035757 Rho GTPase-activating protein 22 Human genes 0.000 claims description 3
- 102100035759 Rho GTPase-activating protein 25 Human genes 0.000 claims description 3
- 102100021428 Rho GTPase-activating protein 5 Human genes 0.000 claims description 3
- 102100032023 Rho family-interacting cell polarization regulator 2 Human genes 0.000 claims description 3
- 102100021689 Rho guanine nucleotide exchange factor 3 Human genes 0.000 claims description 3
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 claims description 3
- 102100032261 Ropporin-1-like protein Human genes 0.000 claims description 3
- 102100027289 SEC14 domain and spectrin repeat-containing protein 1 Human genes 0.000 claims description 3
- 101150046762 SELENOT gene Proteins 0.000 claims description 3
- 108091006161 SLC17A5 Proteins 0.000 claims description 3
- 108091006524 SLC27A3 Proteins 0.000 claims description 3
- 108091006660 SLC9A9 Proteins 0.000 claims description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 3
- 101150058731 STAT5A gene Proteins 0.000 claims description 3
- 102100031131 SUN domain-containing protein 2 Human genes 0.000 claims description 3
- 102100031129 SUN domain-containing protein 3 Human genes 0.000 claims description 3
- 102100020975 SUN domain-containing protein 5 Human genes 0.000 claims description 3
- 102100024837 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Human genes 0.000 claims description 3
- 102100021591 Saccharopine dehydrogenase-like oxidoreductase Human genes 0.000 claims description 3
- 102100023713 Sentrin-specific protease 6 Human genes 0.000 claims description 3
- 102100028024 Septin-9 Human genes 0.000 claims description 3
- 102100029287 Serine/arginine-rich splicing factor 7 Human genes 0.000 claims description 3
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 claims description 3
- 102100025347 Serine/threonine-protein kinase MRCK beta Human genes 0.000 claims description 3
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 claims description 3
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 claims description 3
- 102100036140 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Human genes 0.000 claims description 3
- 102100023105 Sialin Human genes 0.000 claims description 3
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 3
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims description 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 3
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 3
- 102100023007 Single-stranded DNA-binding protein 2 Human genes 0.000 claims description 3
- 102100029969 Ski oncogene Human genes 0.000 claims description 3
- 102100021829 Small integral membrane protein 29 Human genes 0.000 claims description 3
- 102100027195 Sodium channel protein type 4 subunit alpha Human genes 0.000 claims description 3
- 102100036916 Sodium-coupled neutral amino acid transporter 1 Human genes 0.000 claims description 3
- 102100033774 Sodium-coupled neutral amino acid transporter 2 Human genes 0.000 claims description 3
- 102100029967 Sodium/hydrogen exchanger 9 Human genes 0.000 claims description 3
- 102100023047 Solute carrier family 27 member 3 Human genes 0.000 claims description 3
- 102100024801 Sorting nexin-20 Human genes 0.000 claims description 3
- 102100038624 Sorting nexin-5 Human genes 0.000 claims description 3
- 102100032848 Sorting nexin-8 Human genes 0.000 claims description 3
- 102100037612 Spectrin beta chain, non-erythrocytic 1 Human genes 0.000 claims description 3
- 102100035034 Splicing factor U2AF 26 kDa subunit Human genes 0.000 claims description 3
- 108010048349 Steroidogenic Factor 1 Proteins 0.000 claims description 3
- 102100029856 Steroidogenic factor 1 Human genes 0.000 claims description 3
- 102100021685 Stomatin Human genes 0.000 claims description 3
- 102100021684 Stonin-2 Human genes 0.000 claims description 3
- 102100037342 Substance-K receptor Human genes 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 102100030700 Synaptic vesicle glycoprotein 2B Human genes 0.000 claims description 3
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 claims description 3
- 102100021678 Syntaxin-binding protein 4 Human genes 0.000 claims description 3
- 108700012457 TACSTD2 Proteins 0.000 claims description 3
- 102100025224 TBC1 domain family member 26 Human genes 0.000 claims description 3
- 102100040256 TBC1 domain family member 5 Human genes 0.000 claims description 3
- 102100034704 THUMP domain-containing protein 1 Human genes 0.000 claims description 3
- 108090000008 TNF receptor-associated factor 4 Proteins 0.000 claims description 3
- 102000003715 TNF receptor-associated factor 4 Human genes 0.000 claims description 3
- 102000003565 TRPV2 Human genes 0.000 claims description 3
- 102100033112 Talin rod domain-containing protein 1 Human genes 0.000 claims description 3
- 102100024554 Tetranectin Human genes 0.000 claims description 3
- 102100034916 Tetraspanin-33 Human genes 0.000 claims description 3
- 102100037549 Thioredoxin reductase-like selenoprotein T Human genes 0.000 claims description 3
- 102100034795 Thioredoxin, mitochondrial Human genes 0.000 claims description 3
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 claims description 3
- 102100023476 Transcription cofactor vestigial-like protein 3 Human genes 0.000 claims description 3
- 101710176204 Transcription cofactor vestigial-like protein 3 Proteins 0.000 claims description 3
- 102100035145 Transcription elongation factor A N-terminal and central domain-containing protein 2 Human genes 0.000 claims description 3
- 102100028438 Transcription factor HIVEP2 Human genes 0.000 claims description 3
- 102100033763 Transducin-like enhancer protein 4 Human genes 0.000 claims description 3
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 claims description 3
- 102100035317 Transmembrane protein 17 Human genes 0.000 claims description 3
- 102100032461 Transmembrane protein 33 Human genes 0.000 claims description 3
- 102100022518 Transmembrane protein C1orf162 Human genes 0.000 claims description 3
- 101150077905 Trpv2 gene Proteins 0.000 claims description 3
- 102100040255 Tubulin-specific chaperone C Human genes 0.000 claims description 3
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims description 3
- 102100026736 Two pore channel protein 1 Human genes 0.000 claims description 3
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims description 3
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 claims description 3
- 102100033018 Tyrosine-protein phosphatase non-receptor type 18 Human genes 0.000 claims description 3
- 102100037934 U3 small nucleolar RNA-associated protein 6 homolog Human genes 0.000 claims description 3
- 102100029164 Ubiquitin carboxyl-terminal hydrolase 15 Human genes 0.000 claims description 3
- 102100024860 Ubiquitin-conjugating enzyme E2 J1 Human genes 0.000 claims description 3
- 102100037939 Ubiquitin-like modifier-activating enzyme 6 Human genes 0.000 claims description 3
- 102100026138 Uncharacterized protein C12orf76 Human genes 0.000 claims description 3
- 102100038728 Uncharacterized protein C18orf25 Human genes 0.000 claims description 3
- 102100026538 Uncharacterized protein C2orf42 Human genes 0.000 claims description 3
- 102100038068 Uncharacterized protein C4orf45 Human genes 0.000 claims description 3
- 101000803348 Ustilago maydis (strain 521 / FGSC 9021) Virulence-associated membrane protein 1 Proteins 0.000 claims description 3
- 102100039764 V-set and transmembrane domain-containing protein 4 Human genes 0.000 claims description 3
- 102100037818 V-type proton ATPase subunit G 3 Human genes 0.000 claims description 3
- 102100038001 Vacuole membrane protein 1 Human genes 0.000 claims description 3
- 102100033637 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 Human genes 0.000 claims description 3
- 102100030747 Very-long-chain enoyl-CoA reductase Human genes 0.000 claims description 3
- 102100037053 Voltage-dependent calcium channel subunit alpha-2/delta-4 Human genes 0.000 claims description 3
- 102100038156 WD repeat-containing protein 31 Human genes 0.000 claims description 3
- 102100038258 Wnt inhibitory factor 1 Human genes 0.000 claims description 3
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims description 3
- 102100039674 YTH domain-containing family protein 3 Human genes 0.000 claims description 3
- 102100021146 Zinc finger and BTB domain-containing protein 20 Human genes 0.000 claims description 3
- 102100028132 Zinc finger and BTB domain-containing protein 44 Human genes 0.000 claims description 3
- 102100023251 Zinc finger and BTB domain-containing protein 8A Human genes 0.000 claims description 3
- 102100039966 Zinc finger homeobox protein 3 Human genes 0.000 claims description 3
- 102100023389 Zinc finger protein 143 Human genes 0.000 claims description 3
- 102100039959 Zinc finger protein 205 Human genes 0.000 claims description 3
- 102100021361 Zinc finger protein 253 Human genes 0.000 claims description 3
- 102100025431 Zinc finger protein 358 Human genes 0.000 claims description 3
- 102100034659 Zinc finger protein 382 Human genes 0.000 claims description 3
- 102100021352 Zinc finger protein 429 Human genes 0.000 claims description 3
- 102100026302 Zinc finger protein 521 Human genes 0.000 claims description 3
- 102100024724 Zinc finger protein 579 Human genes 0.000 claims description 3
- 102100026453 Zinc finger protein 652 Human genes 0.000 claims description 3
- 102100040663 Zinc finger protein 710 Human genes 0.000 claims description 3
- 102100024685 Zinc finger protein 747 Human genes 0.000 claims description 3
- 102100040706 Zinc finger protein 79 Human genes 0.000 claims description 3
- 102100025883 Zinc finger protein GLIS1 Human genes 0.000 claims description 3
- 102100026463 Zinc finger protein with KRAB and SCAN domains 1 Human genes 0.000 claims description 3
- 210000004504 adult stem cell Anatomy 0.000 claims description 3
- 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 claims description 3
- 102100022421 cGMP-dependent protein kinase 2 Human genes 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 102000004311 liver X receptors Human genes 0.000 claims description 3
- 108090000865 liver X receptors Proteins 0.000 claims description 3
- 239000003595 mist Substances 0.000 claims description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 3
- 230000003525 myelopoietic effect Effects 0.000 claims description 3
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 claims description 3
- 108010093459 tubulin-specific chaperone C Proteins 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 102100035984 Adenosine receptor A2b Human genes 0.000 claims description 2
- 102100026329 Ciliogenesis and planar polarity effector 2 Human genes 0.000 claims description 2
- 102100030796 E3 ubiquitin-protein ligase rififylin Human genes 0.000 claims description 2
- 101000783756 Homo sapiens Adenosine receptor A2b Proteins 0.000 claims description 2
- 101000855378 Homo sapiens Ciliogenesis and planar polarity effector 2 Proteins 0.000 claims description 2
- 101000703348 Homo sapiens E3 ubiquitin-protein ligase rififylin Proteins 0.000 claims description 2
- 101001021527 Homo sapiens Huntingtin-interacting protein 1 Proteins 0.000 claims description 2
- 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 claims description 2
- 101000603420 Homo sapiens Nuclear pore complex-interacting protein family member A1 Proteins 0.000 claims description 2
- 101001121964 Homo sapiens OCIA domain-containing protein 1 Proteins 0.000 claims description 2
- 101000982889 Homo sapiens Ornithine decarboxylase antizyme 2 Proteins 0.000 claims description 2
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 claims description 2
- 101000591128 Homo sapiens RNA-binding protein Musashi homolog 2 Proteins 0.000 claims description 2
- 101001093937 Homo sapiens SEC14-like protein 1 Proteins 0.000 claims description 2
- 101000697502 Homo sapiens Stathmin-3 Proteins 0.000 claims description 2
- 102100035957 Huntingtin-interacting protein 1 Human genes 0.000 claims description 2
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 2
- UWSDONTXWQOZFN-UHFFFAOYSA-N N-nitrosopiperidine Chemical compound O=NN1CCCCC1 UWSDONTXWQOZFN-UHFFFAOYSA-N 0.000 claims description 2
- 101150012484 NEUROD4 gene Proteins 0.000 claims description 2
- 102000007530 Neurofibromin 1 Human genes 0.000 claims description 2
- 108010085793 Neurofibromin 1 Proteins 0.000 claims description 2
- 102100032061 Neurogenic differentiation factor 4 Human genes 0.000 claims description 2
- 102100038845 Nuclear pore complex-interacting protein family member A1 Human genes 0.000 claims description 2
- 102100027183 OCIA domain-containing protein 1 Human genes 0.000 claims description 2
- 102100027035 Ornithine decarboxylase antizyme 2 Human genes 0.000 claims description 2
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 claims description 2
- 102100034027 RNA-binding protein Musashi homolog 2 Human genes 0.000 claims description 2
- 102100035214 SEC14-like protein 1 Human genes 0.000 claims description 2
- 102100028052 Stathmin-3 Human genes 0.000 claims description 2
- 230000002939 deleterious effect Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 102100030390 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Human genes 0.000 claims 2
- 102100029318 Chondroitin sulfate synthase 1 Human genes 0.000 claims 2
- 101000583063 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Proteins 0.000 claims 2
- 101000989500 Homo sapiens Chondroitin sulfate synthase 1 Proteins 0.000 claims 2
- 101000610107 Homo sapiens Pre-B-cell leukemia transcription factor 1 Proteins 0.000 claims 2
- 102100040171 Pre-B-cell leukemia transcription factor 1 Human genes 0.000 claims 2
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 claims 1
- 102100020963 Actin-binding LIM protein 1 Human genes 0.000 claims 1
- 102100026025 Acyl-coenzyme A synthetase ACSM6, mitochondrial Human genes 0.000 claims 1
- 102100040069 Aldehyde dehydrogenase 1A1 Human genes 0.000 claims 1
- 102100031818 Androgen-dependent TFPI-regulating protein Human genes 0.000 claims 1
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 claims 1
- 102100029649 Beta-arrestin-1 Human genes 0.000 claims 1
- 102100024265 Beta-ureidopropionase Human genes 0.000 claims 1
- 102000014814 CACNA1C Human genes 0.000 claims 1
- 102100035432 Complement factor H Human genes 0.000 claims 1
- 102100039195 Cullin-1 Human genes 0.000 claims 1
- 102100020800 DNA damage-regulated autophagy modulator protein 1 Human genes 0.000 claims 1
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 claims 1
- 102100030442 Derlin-3 Human genes 0.000 claims 1
- 102100027118 Engulfment and cell motility protein 1 Human genes 0.000 claims 1
- 102100036443 Epiplakin Human genes 0.000 claims 1
- 102100023938 G patch domain-containing protein 2-like Human genes 0.000 claims 1
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims 1
- 102100022650 Homeobox protein Hox-A7 Human genes 0.000 claims 1
- 101000783802 Homo sapiens Actin-binding LIM protein 1 Proteins 0.000 claims 1
- 101000720143 Homo sapiens Acyl-coenzyme A synthetase ACSM6, mitochondrial Proteins 0.000 claims 1
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 claims 1
- 101000890570 Homo sapiens Aldehyde dehydrogenase 1A1 Proteins 0.000 claims 1
- 101000775248 Homo sapiens Androgen-dependent TFPI-regulating protein Proteins 0.000 claims 1
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 claims 1
- 101000761934 Homo sapiens Beta-ureidopropionase Proteins 0.000 claims 1
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 claims 1
- 101000746063 Homo sapiens Cullin-1 Proteins 0.000 claims 1
- 101000716088 Homo sapiens Cyclin-L1 Proteins 0.000 claims 1
- 101000931929 Homo sapiens DNA damage-regulated autophagy modulator protein 1 Proteins 0.000 claims 1
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 claims 1
- 101000842622 Homo sapiens Derlin-3 Proteins 0.000 claims 1
- 101001057862 Homo sapiens Engulfment and cell motility protein 1 Proteins 0.000 claims 1
- 101000851943 Homo sapiens Epiplakin Proteins 0.000 claims 1
- 101001031607 Homo sapiens Four and a half LIM domains protein 1 Proteins 0.000 claims 1
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 claims 1
- 101000904740 Homo sapiens G patch domain-containing protein 2-like Proteins 0.000 claims 1
- 101001045116 Homo sapiens Homeobox protein Hox-A7 Proteins 0.000 claims 1
- 101000852613 Homo sapiens Importin-11 Proteins 0.000 claims 1
- 101001139112 Homo sapiens Krueppel-like factor 9 Proteins 0.000 claims 1
- 101000941877 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 1 Proteins 0.000 claims 1
- 101000969792 Homo sapiens Metallophosphoesterase MPPED2 Proteins 0.000 claims 1
- 101000969786 Homo sapiens Metallophosphoesterase domain-containing protein 1 Proteins 0.000 claims 1
- 101001038567 Homo sapiens Nucleolar protein 4-like Proteins 0.000 claims 1
- 101000990746 Homo sapiens Olfactory receptor 52N1 Proteins 0.000 claims 1
- 101100521059 Homo sapiens PRDM16 gene Proteins 0.000 claims 1
- 101000741974 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein Proteins 0.000 claims 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 claims 1
- 101000958299 Homo sapiens Protein lyl-1 Proteins 0.000 claims 1
- 101000643424 Homo sapiens Protein phosphatase Slingshot homolog 1 Proteins 0.000 claims 1
- 101000864990 Homo sapiens Serine incorporator 5 Proteins 0.000 claims 1
- 101000852225 Homo sapiens THO complex subunit 5 homolog Proteins 0.000 claims 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 1
- 101000621459 Homo sapiens Vesicle transport through interaction with t-SNAREs homolog 1A Proteins 0.000 claims 1
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims 1
- 101000804811 Homo sapiens WD repeat and SOCS box-containing protein 1 Proteins 0.000 claims 1
- 101000788678 Homo sapiens Zinc finger MYM-type protein 1 Proteins 0.000 claims 1
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 claims 1
- 102100036399 Importin-11 Human genes 0.000 claims 1
- 102100020684 Krueppel-like factor 9 Human genes 0.000 claims 1
- 102100032656 Leucine-rich repeat serine/threonine-protein kinase 1 Human genes 0.000 claims 1
- 102100022187 Leucine-rich repeat-containing protein 4C Human genes 0.000 claims 1
- 101710084185 Leucine-rich repeat-containing protein 4C Proteins 0.000 claims 1
- 101700049202 MYO1C Proteins 0.000 claims 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102100021276 Metallophosphoesterase MPPED2 Human genes 0.000 claims 1
- 102100021275 Metallophosphoesterase domain-containing protein 1 Human genes 0.000 claims 1
- 102100040313 Nucleolar protein 4-like Human genes 0.000 claims 1
- 102100030605 Olfactory receptor 52N1 Human genes 0.000 claims 1
- 101150063753 PRDM16 gene Proteins 0.000 claims 1
- 102100038634 Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein Human genes 0.000 claims 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims 1
- 102100040923 Protein flightless-1 homolog Human genes 0.000 claims 1
- 102100038231 Protein lyl-1 Human genes 0.000 claims 1
- 102100035704 Protein phosphatase Slingshot homolog 1 Human genes 0.000 claims 1
- 101100400073 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SRY1 gene Proteins 0.000 claims 1
- 102100029726 Serine incorporator 5 Human genes 0.000 claims 1
- 108010030731 Stromal Interaction Molecule 2 Proteins 0.000 claims 1
- 102100035562 Stromal interaction molecule 2 Human genes 0.000 claims 1
- 102100036436 THO complex subunit 5 homolog Human genes 0.000 claims 1
- 102100026785 Unconventional myosin-Ic Human genes 0.000 claims 1
- 102100023019 Vesicle transport through interaction with t-SNAREs homolog 1A Human genes 0.000 claims 1
- 102100035334 WD repeat and SOCS box-containing protein 1 Human genes 0.000 claims 1
- 102100025100 Zinc finger MYM-type protein 1 Human genes 0.000 claims 1
- 108010032969 beta-Arrestin 1 Proteins 0.000 claims 1
- 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 24
- 238000000338 in vitro Methods 0.000 abstract description 14
- 230000004913 activation Effects 0.000 abstract description 10
- 238000010367 cloning Methods 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 210000005260 human cell Anatomy 0.000 abstract description 2
- 210000003714 granulocyte Anatomy 0.000 description 48
- 238000001415 gene therapy Methods 0.000 description 47
- 238000004458 analytical method Methods 0.000 description 39
- 210000001185 bone marrow Anatomy 0.000 description 38
- 208000016532 chronic granulomatous disease Diseases 0.000 description 36
- 210000000440 neutrophil Anatomy 0.000 description 31
- 210000005259 peripheral blood Anatomy 0.000 description 31
- 239000011886 peripheral blood Substances 0.000 description 31
- 210000000265 leukocyte Anatomy 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 22
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 20
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 208000027024 X-linked chronic granulomatous disease Diseases 0.000 description 16
- 208000036733 chronic X-linked granulomatous disease Diseases 0.000 description 16
- 238000002054 transplantation Methods 0.000 description 16
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 230000002147 killing effect Effects 0.000 description 12
- 241001430294 unidentified retrovirus Species 0.000 description 12
- 241001225321 Aspergillus fumigatus Species 0.000 description 11
- 230000007774 longterm Effects 0.000 description 11
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 230000026683 transduction Effects 0.000 description 11
- 210000002798 bone marrow cell Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 238000002591 computed tomography Methods 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 238000007857 nested PCR Methods 0.000 description 8
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108010002998 NADPH Oxidases Proteins 0.000 description 6
- 102000004722 NADPH Oxidases Human genes 0.000 description 6
- 108700009124 Transcription Initiation Site Proteins 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 229940091771 aspergillus fumigatus Drugs 0.000 description 6
- 229960002092 busulfan Drugs 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 206010024652 Liver abscess Diseases 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 230000002629 repopulating effect Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 101000852145 Homo sapiens Erythropoietin receptor Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 108020003468 cytochrome b558 Proteins 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 230000031864 metaphase Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 4
- 229960004740 voriconazole Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 206010015535 Euphoric mood Diseases 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 101710185494 Zinc finger protein Proteins 0.000 description 3
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000019254 respiratory burst Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101150076401 16 gene Proteins 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- 101710197633 Actin-1 Proteins 0.000 description 2
- 108090000104 Actin-related protein 3 Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100025287 Cytochrome b Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010075028 Cytochromes b Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 description 2
- 101000992396 Homo sapiens Oxysterol-binding protein-related protein 3 Proteins 0.000 description 2
- 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 2
- 101000665894 Homo sapiens Replication initiator 1 Proteins 0.000 description 2
- 101000962366 Homo sapiens Type II inositol 1,4,5-trisphosphate 5-phosphatase Proteins 0.000 description 2
- 206010050167 Lymph node abscess Diseases 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100032154 Oxysterol-binding protein-related protein 3 Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102100022036 Presenilin-2 Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 102100038242 Replication initiator 1 Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000713880 Spleen focus-forming virus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100039257 Type II inositol 1,4,5-trisphosphate 5-phosphatase Human genes 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008953 bacterial degradation Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000701 chemical imaging Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- QFXKXRXFBRLLPQ-UHFFFAOYSA-N diphenyleneiodonium Chemical compound C1=CC=C2[I+]C3=CC=CC=C3C2=C1 QFXKXRXFBRLLPQ-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001237 metamyelocyte Anatomy 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003887 myelocyte Anatomy 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000004765 promyelocyte Anatomy 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011536 re-plating Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- TZJAEGCLMLTGRJ-UHFFFAOYSA-N 2-(2-aminoethyl)benzenesulfonyl fluoride Chemical compound NCCC1=CC=CC=C1S(F)(=O)=O TZJAEGCLMLTGRJ-UHFFFAOYSA-N 0.000 description 1
- SASSOMDKBRXDKV-UHFFFAOYSA-N 2-phenylethanamine;sulfuryl difluoride Chemical compound FS(F)(=O)=O.NCCC1=CC=CC=C1 SASSOMDKBRXDKV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 101710171434 Aftiphilin Proteins 0.000 description 1
- 102100031815 Aftiphilin Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100035388 Beta-enolase Human genes 0.000 description 1
- 101710161338 Beta-enolase Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 101100069853 Caenorhabditis elegans hil-3 gene Proteins 0.000 description 1
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 101710103147 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150071534 EDS gene Proteins 0.000 description 1
- 101710102442 Erythropoietin receptor Proteins 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 101000992392 Homo sapiens Oxysterol-binding protein-related protein 6 Proteins 0.000 description 1
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 101800002690 NPP Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 102100032149 Oxysterol-binding protein-related protein 6 Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 1
- 241001573961 Parotis Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010058878 Salmonella sepsis Diseases 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 206010041917 Staphylococcal abscess Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 101001057161 Xenopus laevis MDS1 and EVI1 complex locus protein EVI1-A Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 102000056667 human SETBP1 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 108010060845 lactose permease Proteins 0.000 description 1
- 208000013104 leukocyte disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003343 megakaryocytopoietic effect Effects 0.000 description 1
- 230000014690 mesenchyme development Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000009800 pulmonary aspergilloma Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000035921 thrombopoiesis Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Definitions
- the invention relates to the field of cell biology and gene therapy.
- the invention relates to methods of increasing cell proliferation in vivo or in culture by modulating expression of certain regulatory genes.
- Retroviral vectors for example, have been successfully used in clinical gene therapy trials to treat severe combined immunodeficiencies (SCID), where gene correction conferred a selective advantage to lymphocytes (Cavazzana-Calvo, et al. (2000) Science 288:669-672; Aiuti, et al. (2002) Science 296:2410-2413; Gaspar, et al. (2004) Lancet 364:2181-2187, each of the foregoing which is hereby incorporated by reference in its entirety).
- SCID severe combined immunodeficiencies
- human gene therapy has been less effective (Kohn, et al. (1998) Nature Med. 4:775-780; Malech, et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:12133-12138, each of the foregoing which is hereby incorporated by reference in its entirety).
- a method of increasing cell proliferation by modulating levels of EVI and related genes is provided.
- Activation of EVI-1, PRDMl 6, or SETBP1 can increase the proliferation rate, self renewal and/or in vitro and/or in vivo survival and/or engraftment of human cells, either in vitro or in vivo.
- the gene modulation can be performed by various means, including traditional cloning methods and retroviral-based gene activation methods.
- the method can also be used to more efficiently deliver gene-corrected cells to a patient in need of treatment.
- a method of expanding cells is provided, by obtaining at least one cell from a patient, transfecting, infecting or transducing said cell with a retroviral or nonintegrating vector, such that cell entry and/ or integration of the vector promotes proliferation, persistence, or selective advantage of the cell, allowing the transfected cell to proliferate, reinfusing a plurality of proliferated transfected cells into said patient, and allowing said proliferated cells to expand further in the patient.
- the transfected cell can have characteristics of a cell such as, for example, a hematopoietic progenitor cell, a hematopoietic stem cell, or a stem cell.
- the method can be used to treat a patient with a hematopoietic or other treatable disease.
- the vector can also have a sequence for correction or modification of a defective or deleterious gene.
- a method of increasing cell proliferation in a mammalian cell by obtaining a cell, contacting the cell with a nucleic acid sequence encoding a protein selected from the group consisting of EVI-1, PRDMl 6, SETBP1, and a fragment thereof, allowing said nucleic acid to enter the cell, and allowing said cell to proliferate, where the cell having the nucleic acid proliferates at an increased rate compared to a cell that has not been contacted with the nucleic acid sequence.
- the proliferation can occur, for example, in a cell culture, ex vivo, or in vivo.
- the nucleic acid can integrate, for example, into the chromosomal DNA.
- the nucleic acid can be present, for example, in the cytoplasm of the cell.
- the nucleic acid can be operably linked to a promoter.
- the nucleic acid can be constitutively expressed.
- the expression of the nucleic acid can be inducible, for example, by an exogenously added agent.
- the nucleic acid can be present in a vector, such as, for example, a viral vector.
- the nucleic acid can be expressed for a number of division cycles such as, for example, about 1, 3, 5, 8, 10, 13, 17, or 20 division cycles, then expression can decrease or stop thereafter.
- the cell can have characteristics of a cell selected from the group consisting of a hematopoietic stem cell, hematopoietic progenitor cell, a stem cell, an embryonic stem cell, an adult stem cell, a multipotent stem cell, and a myelopoietic stem cell.
- a method of expansion of a gene-corrected cell by obtaining a cell in need of gene correction, transfecting the cell with a functional copy of a the gene in need of correction, transfecting the cell with a copy of a nucleic acid encoding a polypeptide sequence selected from the group consisting of EVI-1, PRDM 16, SETBP1, and a fragment thereof; and allowing the cell to proliferate in culture.
- a method of forming a bodily tissue having gene corrected cells is provided, by obtaining a cell in need of gene correction, transfecting the cell with a functional copy of a the gene in need of correction, transfecting the cell with a copy of a nucleic acid encoding a polypeptide sequence selected from the group consisting of EVI-1, PRDMl 6, SETBP1, and a fragment thereof, allowing the cell to proliferate in culture, and treating the cell culture to allow formation of a bodily tissue.
- a method of identifying a gene is provided, the modulation of which increases the proliferation rate of a cell, by obtaining a sample of cells from a patient having previously received a therapeutic transfection with a nucleic acid sequence, identifying positions of nucleic acid insertion in the cells from the sample, identifying a favorable insertion site based upon disproportional representation of the site in the population of transfected cells, and identifying a gene associated with the insertion site.
- a nucleic acid integration region is provided, that, when insertionally modulated, results in increased hematopoietic cell proliferation, as is selected from the EVI-1 gene, the PRDM 16 gene, and the SETBP1 gene.
- a nucleic acid sequence whose modulation of expression is associated with the increased proliferation of hematopoietic cells is provided, selected from the following group: MGC 10731, PADI4, CDA, CDW52, ZBTB8, AK2, FLJ32112, TACSTD2, FLJ13150, MGC24133, NOTCH2, NOHMA, EST1B, PBXl, PLA2G4A, HRPT2, ATP6V1G3, PTPRC, NUCKS, CABC1, LOC339789, PRKCE, AFTIPHILIN, NAGK, MARCH7, DHRS9, PRKRA, SESTD1, MGC42174, CMKOR1, TBC1D5, THRB, MAP4, IFRD2, ARHGEF3, FOXP1, ZBTB20, EAF2, MGLL, PLXND1, SLC9A9, SELT, CCNLl, MDS1, BCL6, MIST, STM2, TEC,
- a method of identifying a favorable insertion site of a nucleic acid sequence in a proliferating cell culture by transfecting a cell sample with a nucleic acid sequence, allowing cell proliferation to occur, determining at least one main insertion site of the nucleic acid using linear amplification mediated PCR (LAM-PCR) over time, using the at least one main insertion site to predict the location of at least one main insertion site of another cell sample transfected with a substantially similar nucleic acid sequence over a similar time period, obtaining a sample of cells from a patient having previously received a therapeutic transfection with a nucleic acid sequence, identifying positions of nucleic acid insertion in the cells from the sample, and identifying a favorable insertion site based upon disproportional representation of the site in the population of transfected cells.
- LAM-PCR linear amplification mediated PCR
- a method of expansion of a cell comprising contacting the cell with a polypeptide selected from the group consisting of: an EVI-1 polypeptide, a PRDMl 6 polypeptide, a SETBP1 polypeptide, a fragment thereof, or a synthetic peptide derivative thereof.
- a method of treating an individual having a disease caused by a mutated gene or an inappropriately expressed gene is provided, by administered cells that have been corrected for the gene of interest, where the cells also have an increased level of at least one of an EVI-1 polypeptide, a PRDM 16 polypeptide, or a SETBP1 polypeptide.
- the disease is chronic granulomatous disease (CGD).
- a method of improving gene therapy is provided, by treating an individual with gene-corrected cells that have also been altered to have increased levels of at least one of the following polypeptides: an EVI-1 polypeptide, a PRDMl 6 polypeptide, or a SETBP1 polypeptide.
- Figure 1 shows hematopoietic reconstitution and gene marking in patient P1 after gene therapy.
- Cell counts are shown both before and after gene therapy. Absolute neutrophil counts are measured against the right y-axis, while counts of helper T cells (CD4+CD3+), cytotoxic T cells (CD8+CD3+) and B cells (CD 19+) are measured against the left y-axis.
- helper T cells CD4+CD3+
- cytotoxic T cells CD8+CD3+
- B cells CD 19+
- Figure 2 shows hematopoietic reconstitution and gene marking in patient P2 after gene therapy.
- Cell counts are shown both before and after gene therapy. Absolute neutrophil counts are measured against the right y-axis, while counts of helper T cells (CD4+CD3+), cytotoxic T cells (CD8+CD3+) and B cells (CD19+) are measured against the left y-axis.
- helper T cells CD4+CD3+
- cytotoxic T cells CD8+CD3+
- B cells CD19+
- Figure 3 illustrates quantification of gene-modified cells in peripheral blood leukocytes (PBL), granulocytes (CD 15+), T-cells (CD3+) and B cells (CD 19+) for patient P1 by quantitative PCR (QPCR).
- PBL peripheral blood leukocytes
- CD 15+ granulocytes
- CD3+ T-cells
- B cells CD 19+
- Figure 4 illustrates quantification of gene-modified cells in peripheral blood leukocytes (PBL), granulocytes (CD 15+), T-cells (CD3+) and B cells (CD 19+) for patient P2 by quantitative PCR (QPCR).
- PBL peripheral blood leukocytes
- CD 15+ granulocytes
- CD3+ T-cells
- B cells CD 19+
- Figure 5 shows gene marking in CFCs derived from bone marrow aspirates of patient P1 (days +122 and +381).
- Vector-containing CFCs were detected by PCR using primers specific for cDNA encoding gp91 phox .
- Input DNA was controlled by amplification of sequences derived from the human erythropoietin receptor (hEPO-R).
- Figure 6 shows gene marking in CFCs derived from bone marrow aspirates of patient P2 (days +119 and +245).
- Vector-containing CFCs were detected by PCR using primers specific for cDNA encoding gp91 phox .
- Input DNA was controlled by amplification of sequences derived from the human erythropoietin receptor (hEPO-R).
- Figure 7 illustrates the RIS distribution of retroviral vector insertions from 30 kb upstream to 5 kb downstream of RefSeq genes in patient P1.
- Absolute numbers of integrations into the 3 common integration site (CIS) related RefSeq genes MDS1/EVI-1, PRDM 16 and SETBP1 are shown as black bars, while integrations into non CIS-related genes are shown in grey.
- the insertions are listed according to their location within the affected gene expressed as the percentage of the overall length of the gene.
- the last column summarizes all integrations up to 5 kb downstream of a gene. Up, upstream of the start of transcription; down, downstream of the RefSeq gene. TSS, transcription start site.
- Figure 8 illustrates the RIS distribution of retroviral vector insertions from 30 kb up- to 5 kb downstream of RefSeq genes in patient P2. Absolute numbers of integrations into the 3 CIS related RefSeq genes MDS1/EVI-1, PRDM16 and SETBP1 are shown as black bars, while integrations into non CIS-related genes are shown in grey. The insertions are listed according to their location within the affected gene expressed as the percentage of the overall length of the gene. The last column summarizes all integrations up to 5 kb downstream of a gene. Up, upstream of the start of transcription; down, downstream of the RefSeq gene. TSS, transcription start site.
- Figure 9 shows a LAM-PCR band pattern analysis of peripheral blood leukocytes and sorted CD14+, CD15+, CD3+ and CD19+ cells (purity CD3+/CD19+, >98%) derived from patient P1 from 21 to 542 days post-transplantation after undergoing CGD gene therapy as described in Example 1.
- M 100 bp ladder; -C, 100 ng non-transduced human genomic DNA; 3' IC, 3'-LTR internal control.
- Figure 10 shows a LAM-PCR band pattern analysis of peripheral blood leukocytes and sorted CD14+, CD15+, CD3+ and CD19+ cells (purity CD3+/CD19+, >98%) derived from patient P2 from 24 to 343 days post-transplantation after undergoing CGD gene therapy as described in Example 1.
- M 100 bp ladder; -C, 100 ng non-transduced human genomic DNA; 3' IC, 3'-LTR internal control.
- Figure 11 is a DNA map showing retroviral insertion site (RIS) clusters in highly active clones with integrants in the MDS1/EVI-1 gene. The insertions are tightly clustered within relevant regulatory upstream portions of the gene locus. Grey dots indicate RIS derived from P1, while white squares indicate RIS from P2.
- RIS retroviral insertion site
- Figure 12 is a DNA map showing RIS clusters in highly active clones with integrants in the PRDM 16 gene. The insertions are tightly clustered within relevant regulatory upstream portions of the gene locus. Grey dots indicate RIS derived from P1, while white squares indicate RIS from P2.
- Figure 13 is a DNA map showing RIS clusters in highly active clones with integrants in the SETBP1 gene. The insertions are tightly clustered within relevant regulatory upstream portions of the gene locus. Grey dots indicate RIS derived from P1, while white squares indicate RIS from P2.
- Figure 14 shows the long term follow up of individual clones contributing to hematopoiesis at different time points after transplantation in patient P1.
- Each individual CIS related clone detected is represented by one line, with each column representing an individual sampling time point.
- Grey boxes represent the detection of a specific clone at a time point via LAM-PCR, tracking PCR, and/or quantitative-competitive (QC-) PCR.
- the white boxes indicate the lack of detection at that time point, indicating that the clone contributes no or few cells to the peripheral circulation.
- * no LAM-PCR performed
- ⁇ no tracking PCR performed
- # no QC-PCR performed.
- Figure 15 shows the long term follow up of individual clones contributing to hematopoiesis at different time points after transplantation in patient P2.
- Each individual CIS related clone detected is represented by one line, with each column representing an individual sampling time point.
- Grey boxes represent the detection of a specific clone at a time point via LAM-PCR, tracking PCR, and/or quantitative-competitive (QC-) PCR.
- the white boxes indicate the lack of detection at that time point, indicating that the clone contributes no or few cells to the peripheral circulation.
- * no LAM-PCR performed
- ⁇ no tracking PCR performed
- # no QC-PCR performed.
- Figure 16 is a graph showing the overall contribution of clones with insertions in or near the three CIS-related RefSeq genes compared to all RIS locations at different time points detected in patient P1 during long-term myelopoiesis after gene modification.
- the insertion frequencies at MDS1-EVI-1 (light gray), PRDM 16 (dark gray) and SETBP1 (black) in relation to non-CIS-related insertion frequencies (white) is illustrated as a percentage of all integration site junction sequences (entire column) detected at each specific time point.
- the black line denotes the approximate percentage of gene marked cells containing vector gp91 phox among peripheral blood granulocytes.
- BM bone marrow
- G granulocytes
- MC monocytes
- PB peripheral blood.
- Figure 17 is a graph showing the overall contribution of clones with insertions in or near the three CIS-related RefSeq genes compared to all RIS locations at different time points detected in patient P2 during long-term myelopoiesis after gene modification.
- the insertion frequencies at MDS1-EVI-1 (light gray), PRDM 16 (dark gray) and SETBP1 (black) in relation to non-CIS-related insertion frequencies (white) is illustrated as a percentage of all integration site junction sequences (entire column) detected at each specific time point.
- the black line denotes the approximate percentage of gene marked cells containing vector gp91 phox among peripheral blood granulocytes.
- BM bone marrow
- G granulocytes
- MC monocytes
- PB peripheral blood.
- Figure 18 illustrates a series of electrophoretic separations of nucleic acid on agarose gels showing the quantitative-competitive analysis of predominant clones from patient P1.
- the coamplification of 50 ng wild-type (WT) DNA from PB in competition with 500 copies of a 26-bp deleted internal standard (IS) allows semi-quantitative estimation of single clones.
- Time-course analysis revealed the sustained presence of all clones after their first detection (> 3 months post-transplant). Numbers indicate days after transplantation.
- -C 50 ng non-transduced genomic DNA.
- Figure 19 illustrates a series of electrophoretic separations of nucleic acid on agarose gels showing the quantitative-competitive analysis of predominant clones from patient P2.
- the coamplification of 50 ng wild-type (WT) DNA from PB in competition with 500 copies of a 26-bp deleted internal standard (IS) allows semi-quantitative estimation of single clones.
- Time-course analysis revealed the sustained presence of all clones after their first detection (> 3 months post-transplant). Numbers indicate days after transplantation.
- -C 50 ng non-transduced genomic DNA.
- Figure 20 shows LAM-PCR analysis of bone-marrow derived colonies from patient P1 at days +192 and +381 after transplantation.
- Colony numbers 1-3, 5, 7, 9-11, and 13 are colony-forming units — granulocyte-macrophage (CFU-GM)-derived colonies, whereas colonies 4, 6, 8, and 12 represent burst-forming units — erythrocyte (BFU-E) colonies.
- Figure 21 shows LAM-PCR analysis of bone-marrow derived colonies from patient P2 at day +245 after transplantation.
- Colony numbers 1-3 and 5 are CFU-GM- derived colonies, whereas colonies 4 and 6 represent BFU-E colonies.
- M, 100 bp ladder; -C 100 ng nontransduced human genomic DNA.
- FIG. 22 illustrates transcriptional activation of CIS genes by retroviral insertion.
- RT-PCR analysis of MDS1/EVI-1 (a), PRDM16 (b) and SETBP1 (c) was performed on bone marrow from patient P1 at day +381 and on peripheral blood leukocytes from patient P2 at days +287 and +343.
- Panel (a) shows analysis of MDS1/EVI-1 plus EVI-1 transcripts in the upper panel (PR+/PR-) and analysis of MDS1/EVI-1 only transcripts in the lower panel (PR+).
- the primer pairs used to detected EVI-1 transcripts are located within EVI-1 (exon 5 to exon 6) and therefore also detect MDS1/EVI-1 transcripts.
- MDS/EVI-1 transcripts were detected with primer pairs located in the second exon of MDS1 and EVI-1 (Example 6).
- Panel (b) shows analysis of PR+/PR- in the upper panel and analysis of PR+ in the lower panel for PRDMl 6 transcripts.
- Panel (c) illustrates analysis of SETBP1 expression level.
- Panel (d) shows results from the ⁇ -actin RT-PCR.
- -C H 2 O control
- PR PR-domain
- BM bone marrow cells
- PB peripheral blood leukocytes
- ND healthy donor.
- Figure 23 illustrates expression of gp91 phox protein on transduced cells in the days after transplantation of the gene-modified cells.
- Granulocytes (CD 15+) and T cells (CD3+) of patients P1 (a) and P2 (b) were labeled with the monoclonal antibody 7D5 and a lineage specific marker.
- FIG. 24 show results that demonstrate continued expression of gp91 phox protein and functional reconstitution of NADPH oxidase activity in transduced cells.
- the top panel illustrates gp91 phox expression in CD34+ bone marrow cells of patient P1 at day +381.
- the bottom panel exhibits dithionite reduced minus oxidized differential spectra of flavocytochrome in protein extracts obtained from granulocytes.
- the granulocytes were isolated from the peripheral blood of a healthy donor ("control"), patient P1 at day +242 (“P1") and patient P2 at day +120 (“P2”) after reinfusion of gene transduced cells.
- Granulocytes were also obtained from an X-CGD patient ("X-CGD”) for comparison.
- the two major absorption peaks at 426 nm ( ⁇ -peak) and 559 nm ( ⁇ -peak) correspond to the reduced heme groups within gp91 phox and are visible in granulocyte extracts from a healthy donor and P1, while these bands are completely absent in extracts obtained from cells of an untreated X-CGD patient.
- Figure 25 illustrates functional reconstitution of NADPH oxidase activity in peripheral blood leukocytes (PBLs) and isolated granulocytes of patient P1 as revealed by oxidation of dihydrorhodamine (DHR) 123 and NBT reduction.
- DHR dihydrorhodamine
- Superoxide production in PBLs was measured by DHR 123 oxidation in opsonised E. coli, as indicated by black dots.
- Superoxide production in isolated granulocytes was measured by stimulation with PMA (open dots) or by reduction of NBT to formazan (open squares).
- Figure 26 shows an example of DHR 123 oxidation by neutrophils of patient P1 at day +473 after gene therapy both before (left panel) and after (right panel) PMA stimulation.
- Figure 27 shows NBT reduction in single granulocytes obtained from patient P1 at day +381 after gene therapy both before (left panel) and after (right panel) stimulation with opsonised zymosan (OPZ).
- OPOZ opsonised zymosan
- Figure 28 illustrates functional reconstitution of NADPH oxidase activity in peripheral blood leukocytes (PBLs) and isolated granulocytes of patient P2 as revealed by oxidation of dihydrorhodamine (DHR) 123 and NBT reduction.
- PBLs peripheral blood leukocytes
- DHR dihydrorhodamine
- Superoxide production in PBLs was measured by DHR 123 oxidation in opsonised E. coli, as indicated by black dots.
- Superoxide production in isolated granulocytes was measured by stimulation with PMA (open dots) or by reduction of NBT to formazan (open squares).
- Figure 29 shows an example of DHR 123 oxidation by neutrophils of patient P2 at day +344 after gene therapy both before (left panel) and after (right panel) PMA stimulation.
- Figure 30 shows NBT reduction in single granulocytes obtained from patient P2 at day +245 after gene therapy both before (left panel) and after (right panel) stimulation with opsonised zymosan (OPZ).
- OPOZ opsonised zymosan
- Figure 31 illustrates superoxide anion production by granulocytes obtained from a healthy control (a), patient P1 at day +193 (b) and patient P2 at day +50 (c) as revealed by cytochrome c reduction after stimulation with 0.1 ⁇ g/ml PMA plus 1 ⁇ M fMLP.
- the reaction was inhibited by superoxide dismutase (SOD) or specific inhibitors of the phagocytic NADPH oxidase activity, such as 4-2- Aminoethylbenzene sulfonylfluoride (AEBSF) or diphenylene iodonium (DPI).
- SOD superoxide dismutase
- AEBSF 4-2- Aminoethylbenzene sulfonylfluoride
- DPI diphenylene iodonium
- Figure 32 shows the kinetics of E. coli killing by neutrophils obtained from a healthy donor ("pos. control”), patient P1 ("P1"), patient P2 ("P2”) and an individual with X-CGD ("X-CGD”) compared to incubation of E. coli in the absence of granulocytes as a negative control (“E. coli control").
- Figure 33 illustrates transmission electron microscopy images of opsonised E. coli strain ML-35 at 2.5 hours after phagocytosis by granulocytes from the healthy donor (d, h), the X-CGD patient (b, e), and patient P1 at day +242 (c, f, g) at a ratio of 10:1 (E. c ⁇ /z:granulocytes).
- Black arrows in (e) and (f) denote undigested E. coli inside the phagocytic vacuole.
- White arrows in (g) and (h) indicate E. coli degradation.
- Inserts on the upper right hand corner show magnifications of undigested (e, f) and digested (g, h) bacteria.
- Encircled areas in panels (b-d) indicate enlarged cells shown in panels (e-h).
- Scale bars in panels (b-d) represent 5 ⁇ m; in panels (e-h), 2 ⁇ m.
- Figure 34 illustrates killing of A. fumigatus hyphae by gene-modified granulocytes as revealed by mitochondrial MTT reduction (a) and transmission electron microscopy (b - d).
- panel (a) the time course of fungus killing is shown at a ratio of 1 seeded Aspergillus spore to 20 granulocytes obtained from either a healthy donor or patient P1 at day +381 after reinfusion of gene transduced cells. MTT reduction of Aspergillus hyphae alone was normalized to 100%.
- panels (b-d) the fate of A.
- Figure 35 shows fused PET scans of patient P1 (b) and fused PET-CT scans of patient P2 (c,d) both before (a,c) and either 50 (b) or 53 (d) daus after gene therapy.
- the circle in (a) denotes two active abscesses due to Staphylococcus aureus infection in the liver of patient P1
- the circle in (c) shows 18 F-FDG uptake in the wall of a lung cavity of patient P2 due to A. fumigatus infection.
- Figure 36 shows that immortalized bone marrow cells (SF-I cells) containing a Setbpl integration can engraft and induce myeloid leukemia with minimal to mild maturation in irradiated transplanted mice.
- SF-I cells immortalized bone marrow cells
- Immortalized clones usually appeared after 1 month of culturing.
- the figure shows gates for Ly5.1 + cells from bone marrow (a, left), spleen (b, left), and thymus (c, left) from a mouse (Ly5.2) 2 months after transplantation with the immortalized clone SF-I. Staining was done with Gr-I (RB6-8C5)(a, right), CD 19 (lD3)(b, right), and Thy-1.2 (53-2. l)(c, right) antibodies and corresponding isotype control antibodies (a-c, middle lane) in combination with Ly5.2 antibody. Numbers represent the percent of gated events. Details of this protocol are described in Du et al., Blood 106:3932- 3939 (2005), herein incorporated by reference in its entirety.
- Table 1 provides a list of proviral integration site sequences detected by LAM-PCR.
- LAM-PCR amplicons derived from patient P1 are shown in Table l(a) while those from patient P2 are listed in Table l(b).
- the RefSeq gene nearest to an identified integration site within a 100kb window is listed.
- the two integrations in the most productive clone in patient P1 are defined by the "Sequence Identity” 77110 A09 (MDS1) and 75916 A08 (OSBPL6 and PRKRA).
- MDS1 Meth A09
- OSBPL6 and PRKRA 75916 A08
- “Genomic Length” denotes the size of the LAM-PCR amplicon without linker- and LTR-sequences.
- Sequnce Orientation denotes vector integration within the human genome.
- TSS transcription start site
- PB peripheral blood
- BM bone marrow
- CD15 purified granulocytes
- Table 2 provides a list of vector integrants detected in the CIS genes MDS1/EVI-1, PRDM16 and SETBPL Data for patient P1 is listed in Table 2(a) while data for patient P2 is listed in Table 2(b).
- Vector integration was detected by LAM-PCR (L), tracking PCR (T), and/or quantitative competitive PCR (Q).
- LAM-PCR LAM-PCR
- T tracking PCR
- Q quantitative competitive PCR
- CIS clones chosen for a specific tracking over time are marked (T and/or Q) in the column "Track.”
- the most productive clone in P1 which was tracked using the sequence information obtained from 75916 A08 is annotated in this table by the second integration 77110 A09 (MDS 1), which is also present in this particular clone. Empty spaces define no detection.
- CIS clones without "Integration Number” were additionally detected by tracking PCR due to their close location to other clones for which tracking PCR was performed.
- Vector integration indicates whether vector integration took place in the same orientation or in the reverse orientation of CIS gene expression. *, no LAM-PCR performed; ⁇ , no tracking PCR performed; #, no QC-PCR performed.
- Table 3 provides a list of primers used for specific tracking of individual CIS clones and generation of clone specific internal standard.
- F1anking primers 1 and 2 (FP1 and FP2), in combination with vector specific primers, were used to track an individual CIS clone in patients P1 (Table 3a) and P2 (Table 3b) over time and to generate a clone specific internal standard.
- For quantitative competitive PCR vector specific primers and flanking primers 3 and 4 were used to coamplify a particular integration site and the appropriate internal standard (as described in Example 4).
- Table 4 provides the accompanying SEQ ID NO for each primer listed in Table 3.
- Table 5 is a summary of clinical data showing the colony formation of bone marrow total BM mononuclear cells obtained from bone marrow aspirates of patient P1.
- Table 6 is a summary of clinical data showing the incorporation of 3H- Thymidine into mitogen- or antigen-stimulated mononuclear cells vs. non-stimulated mononuclear cells obtained from patients P1 and P2 at different time points.
- Table 7 is a summary of clinical data showing examples of plasma protein levels at days +546 for patient P1 and day +489 for patient P2.
- LAM-PCR analysis is a highly sensitive method for identifying an unknown nucleic acid sequence that flanks a known sequence present in a sample.
- the method is a powerful way to determine the insertion position of a transferred nucleic acid, such as a retroviral vector sequence, after an integration event.
- the method can also be used to determine how the integration sites change over time in a dividing cell culture.
- the method is particularly useful for clonal analysis of transfected hematopoietic cells or other transfected cells.
- LAM-PCR analysis was used to examine blood samples from two patients that were successfully receiving gene therapy by retroviral-based gene correction to treat chronic granulomatous disease (CGD) in an ongoing trial as described in Example 1.
- CGD chronic granulomatous disease
- high efficiency transduction of autologous CD34+ bone marrow cells and busulfan conditioning were used to successfully correct the cytochrome b g ⁇ 91 p ox gene defect in two patients for more than a year.
- a main goal of the analysis was to examine whether the retrovirus vector integration insertion site is less inert with respect to its genomic context than previously thought (Wu, et al. (2003) Science 300:1749-1751; Laufs, et al. (2003) Blood 101:2191-2198; Hematti, et al. (2004) PLoS Biol. 2:e423, each of which is hereby incorporated by reference in its entirety).
- the repopulating cell clones contained activating insertions in three genes. These three genes are the "positive regulatory (PR) domain" zinc finger genes MDS1/EVI-1 and PRDM 16 and a SET binding protein SETBP1.
- the activating insertions were found to drive a 3 to 5 fold expansion of gene corrected cells, and selectively proliferated and dominated (>80%) gene-corrected long term myelopoiesis in both patients.
- Two of the three genes that were found to contain the activating insertions encode zinc finger proteins that are related PR domain proteins.
- proteins including certain transcriptional regulatory proteins, have regions that fold around a central zinc ion, producing a compact domain termed a "zinc finger.”
- zinc-finger motifs have been identified.
- One group of zinc finger proteins is the "PR domain family" of transcription factor proteins, which includes, for example, the related genes EVI-1, PRDM16, and others. These PR domain family genes have been implicated, in some cases, to play a role in the development of cancer.
- the EVI-1 protein (“ecotropic viral integration site 1”) is a zinc finger DNA-binding protein that is characterized by two domains of seven and three repeats of the Cys2-His2-type zinc finger motif (Morishita et al. (1988) Cell 54: 831-840; for a review, see Chi et al. (2003) J Biol Chem. 278:49806-49811, each of the foregoing which is hereby incorporated by reference in its entirety).
- EVI-1 is not generally detected in normal hematopoietic organs including bone marrow, the inappropriate expression of EVI-1 is often triggered by chromosomal rearrangements that disrupt the 3q26 chromosomal region where the EVI-1 gene is located (Fichelson, et al. (1992) Leukemia 6:93-99, which is hereby incorporated by reference in its entirety). Further, EVI-1 up-regulation can occur in chronic myelogenous leukemia patients, even though chromosomes appear normal by conventional cytogenetics, indicating that the inappropriate activation of EVI-1 can occur.
- High EVI-1 expression has been shown to predict poor survival in acute myeloid leukemia (Barjesteh van Waalwijk van Doom-Khosrovani, et al. (2003) Blood 101: 837-845, which is hereby incorporated by reference in its entirety).
- the related zinc finger protein PRDM16 (“positive regulatory domain containing 16") has also been found to be a DNA binding protein.
- the PR domain is characteristic for a sub-class of zinc finger genes that function as negative regulators of tumorigenesis [Fears, S. et al., 1996, Proc. Natl. Acad. ScL 93:1642-1647, herein incorporated by reference in its entirety].
- the PR domain of MDS1/EVI-1 (alias PRDM3) is a common target for wild-type retrovirus and vector insertion induced tumorigenesis, where the disruption of the PR domain activates PR domain negative oncogene EVI-1.
- Constitutive expression of the PR negative oncogene EVI-1 induces self- limiting myeloproliferation followed by a myelodysplastic syndrome in mice.
- PRDM16 alias MDS1 -EVI-1 -like gene 1
- MDS1/EVI-1 The biology of PRDM16 (alias MDS1 -EVI-1 -like gene 1) is very similar to MDS1/EVI-1.
- translocation of MDS1/EVI-1 or PRDM16 next to Ribophorin 1 gene on chromosome 3q21 leads to overexpression of the alternatively spliced PR domain negative transcript.
- SET is a translocation breakpoint-encoded protein in acute undifferentiated leukaemia and SET binding protein 1 (SETBP1) is assumed to play a key role in SET associated leukemogenesis.
- the LAM-PCR analysis showed a stable highly polyclonal hematopoietic repopulation of gene-corrected cells up to 381 days in patient 1 (P1) and up to 343 days in patient 2 (P2), although the band pattern indicated the appearance of individual pre-dominant clones 5 months after therapy ( Figures 9, 10).
- a total of 948 unique RIS patient P1: 551; patient P2: 397) were retrieved by shotgun cloning and sequencing of LAM products, of which 765 (P1: 435; P2: 330) could be mapped unequivocally to the human genome using the UCSC BLAT alignment tools. Integration preferentially occurred in gene coding regions (P1: 47%; P2: 52%) and was highly skewed to the ⁇ 5kb transcriptional start site region (P1: 20%; P2: 21%) ( Figures 7, 8).
- RIS distribution in both patients was not stable over time and became increasingly non-random but still polyclonal in both patients.
- the distribution also clustered to a much higher degree around particular common insertion sites (CIS) than shown by previous in vitro and in vivo integration site studies (Wu, et al. (2003) Science 300:1749- 1751; Laufs, et al. (2003) Blood 101:2191-2198; and Hematti, et al. (2004) PLoS Biol. 2:e423, each of which is hereby incorporated by reference in its entirety).
- This clustering around common insertion sites allowed the prediction of the distribution and location of P2 insertions from the results in P1, whose gene modification procedure had been conducted 4 months earlier.
- AU 134 detectable integrations at these three CISs occurred either in or near PR domain-containing zinc finger genes MDS1/EVI-1 or PRDM16 or in or near the SETBP1 gene. AU insertions were located in or near the upstream region of these genes, preferentially close to the transcriptional start site or internal ATG sites ( Figures 7, 8, and 11-13), exhibiting an unprecedented degree of non-random clustering.
- Granulocytes have a life-span of 2-3 days. Therefore, the repeated detection over time of individual cell clones by retrovirus insertional marking is indicative of a repopulating progenitor cell or stem cell with long-term activity.
- the expansion of repopulating clones with these insertions occurred in both patients P1 and P2 with significant intensity.
- PR domain and SETBP1 related insertions comprised > 90% of all clones detected at more than three time points after treatment. The in vivo selection advantage of these clones was further underlined by the observation that of 134 hits into gene loci affected by insertions more than three times, all of these CIS were related to these 3 genes.
- retrovirus gene activation can occur as a consequence of any retrovirus vector insertion event, and may be of influence on the biological fate of the target cell.
- the location of an insertion defines the likelihood of whether such events lead to side effects, ultimately depending on the biological relevance of a gene for the affected cell type, in this case hematopoiesis.
- This data is of very significant influence for the efficacy and biosafety assessment of gene therapy vectors in ongoing and future clinical trials.
- this insertional side effect very likely favored by reinfusion of high numbers of gene corrected CD34+ BM cells containing insertion events, may have facilitated the therapeutic success observed.
- RNA microarray analysis of the same sample using the Affymetrix HG U133_Plus_2.0 Array confirmed overexpression of MDS1/EVI-1 or EVI-1 (36-fold) and SETBP1 (32-fold). Abnormal expression of PRDM16 was not found.
- Transduced cells were strictly dependent on growth factors for proliferation and differentiation. No colony formation was observed when bone marrow mononuclear cells (patient P1: days +122, +192 and +241) were plated on methylcellulose and cultured for 14 days in the absence of cytokines (as described in Example 7). Colony forming cells (CFCs) derived from CD34+ cells of patient P1 at day +381 were replated in the presence of cytokines into secondary and tertiary methylcellulose cultures. Few cell clusters were visible after the second replating, while no growth was observed in further replatings, indicating the absence of self-renewal capacity. Similar results were obtained with cells from patient P2 at day +245.
- CFCs colony forming cells
- gp91 phox was detected by FACS using the monoclonal antibody 7D5 (as described in Example 8 and Yamauchi, A. et al. Location of the epitope for 7D5, a monoclonal antibody raised against human flavocytochrome b558, to the extracellular peptide portion of primate gp91 phox . Microbiol Immunol 45, 249-257 (2001), herein incorporated by reference in its entirety). G ⁇ 91 phox was present mainly in CD 15+ cells with as many as 60% (patient P1, day +304) and 14% (patient P2, day +287) of the cells expressing the transgene.
- total neutrophils from patient P2 at day +50 produced 2.12 nmol superoxide/ 10 6 gene-corrected cells/min.
- X-CGD cells showed minimal ⁇ -Gal activity due to impaired perforation capacity in the absence of superoxide production ( Figure 32).
- gene corrected granulocytes obtained from patients P1 (day +473) and P2 (day +344) showed a substantial increase in ⁇ -Gal activity, illustrating improvement in antibacterial activity in neutrophils of both patients after gene therapy.
- Neutrophils from patient P1 consisted of a mixture of cells with clear bacterial degradation (lower circle, Figures 33c,g), and others without signs of bacterial degradation that were indistinguishable from non-corrected controls (upper circle, Figures 33c,f).
- gene corrected granulocytes obtained from P1 at day + 381 were able to degrade Aspergillus fumigatus hyphae as demonstrated by an enzymatic assay [Rex, J.H., Bennett, J.E., Gallin, J.I., Malech, H.L. & Melnick, D.A. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 162, 523-528 (1990), herein incorporated by reference in its entirety] and transmission electron microscopy (Figure 34).
- a patient in need of hematopoietic cell proliferation can be treated by retroviral insertion methods.
- a patient cell sample can be transfected with a retroviral or other type of gene vector carrying these genes, or activating their cellular alleles, using methods known to those of skill in the art.
- the cells can then be reinfused into the patient.
- Cell counts can be performed periodically to determine the effectiveness of the blood cell proliferation treatment.
- the amount of cells to be transfected, the ratio of viral vector to cells, cell growth methods, and readministration methods can be varied as needed to treat the particular disorder.
- the progress can be followed, for example, by LAM-PCR to confirm the activation of EVI-related genes. ( Figures 9-10, 14-15)
- the retroviral vector or other gene vector can be administered to the patient directly, rather than to cells that have been isolated from the patient.
- the method can be used to expand any type of mammalian cell.
- types of cell that may be expanded include but are not limited to a stem cell, an embryonic stem cell, an adult stem cell, a multipotent stem cell, a pluripotent stem cell, a hematopoietic cell, a hematopoietic stem cell, a progenitor cell, a myelopoietic stem cell, a peripheral blood cell, non-hematopoietic stem cells or progenitor cells, and the like.
- the cells to be treated can be present in a cell culture, or can be present in the body.
- the retroviral vector insertion or other vector transfer can be used to treat many cell-based diseases, in addition to the CGD shown herein. Any disease where an increase in cell proliferation is helpful can be treated by the method of the invention. Examples of such diseases include but are not limited to inherited diseases (severe combined immunodeficiencies, anemias like Fanconi anemia), cancer, AIDS, and the like.
- the invention can, in some embodiments, be used to predict the insertion location of a retroviral vector insertion in one patient, by following previous insertion results of another patient or similar animal and in vivo models. For example, in the current CGD analysis, the earlier studied successfully treated patient had activating DNA insertions in similar positions as those of the later studied successful patient. This can be especially useful for early prediction of the likelihood of successful treatment. Further, a knowledge of where a successful insertion is likely to be located can make more simple assays, such as dipstick assays for EVI-1 (or related gene) gene or protein expression useful for a quick test to see if a patient is responding to treatment.
- a patient in need of gene- correction can be treated.
- the gene correction can be performed in an in vitro culture of cells isolated from the patient.
- activation of the EVI-related genes can be performed. This can be done, for example, by administering a retroviral vector to the culture of gene corrected cells, allowing the cells to proliferate in vitro, then reinfusing or readministering said cells to the patient.
- retroviral treated cells are then both gene corrected and fast growing, allowing the patient to receive the gene therapy more rapidly. Many types of gene corrections can be performed using this method.
- suitable genes for correction include but are not limited to single gene or multiple gene inherited disorders of the blood forming and immune system or other body tissues that can be complemented, treated or stabilized by gene transfer, and the like. Examples include but are not limited to X-SCID, ADA-SCID, CGD, alpha 1 antitrypsin deficiency, and the like. Methods of treatment involving transfection of cells with EVI-related genes and SETBPl
- a nucleic acid encoding EVI-1, PRDM 16, or SETBP1 is operably linked to a transcriptional regulatory sequence, and transfected to a cell.
- the exogenous nucleic acid can be, for example, integrated into the genome, or can be present in the cell, for example, in the cytoplasm on a cytoplasmic vector.
- the nucleic acid can be stably or transiently expressed, transferred in synthetic form, including nucleic acid equivalents or mRNAs.
- the transcriptional regulator sequence such as a promoter, can be chosen, for example, so as to allow for constitutive expression, conditional expression, or inducible expression.
- EVI-1, PRDM 16, or SETBP1 polypeptides, or fragments thereof can be administered to a cell, hi some embodiments, active synthetic peptide analogs derived from EVI-1, PRDM 16, or SETBP1 polypeptide sequences can be administered to a cell, either in culture or in a patient, to allow increased cell proliferation.
- EVI-related and / or SETBP1 genes may be desirable to grow cells that express the EVI-related and / or SETBP1 genes for a short period of time only, in order to increase the rate of cell proliferation. This can be achieved, for example, using specific inducible promoters or transient expression methods as known in the art. In such situations, when the high rate of cell proliferation is achieved, the expression of the EVI-related and SETBP1 genes can be turned off by, for example, removing the inducing agent from the cell environment.
- the method can be suitable for increasing the proliferation of cells that are gene-corrected, or non-corrected.
- the method can be used for increasing the proliferation of any type of mammalian cell.
- EVI-related and SETBP1 -related gene expressing cells can be allowed to proliferate for several cycles before being reinfused into the patient.
- the cells can proliferate for about 1, 3, 5, 8, 10, 13, 17, or 20 or division cycles, prior to reinfusion into the patient, if desired.
- Agents that upregulate EVI-related and SETBPl genes can be allowed to proliferate for several cycles before being reinfused into the patient.
- the cells can proliferate for about 1, 3, 5, 8, 10, 13, 17, or 20 or division cycles, prior to reinfusion into the patient, if desired.
- Agents that upregulate EVI-related and SETBPl genes can be allowed to proliferate for several cycles before being reinfused into the patient.
- the cells can proliferate for about 1, 3, 5, 8, 10, 13, 17, or 20 or division cycles, prior to reinfusion into the patient, if desired.
- cell proliferation can be increased, either in vitro or in vivo, by contacting the cells to be proliferated with agents that can upregulate or modulate endogenous EVI-related and SETBP1 genes.
- Cell culture assays can be performed to determine candidate agents from a library of potential compounds, if desired. Test compounds that modulate EVI-related and SETBP1 gene expression are then chosen for further testing. This method can be used to find pharmaceutically valuable agents that can increase cell proliferation in vitro or in vivo.
- EVI-related gene as described herein, such as EVI-1, PRDMl 6, or SETBP1, and the like, either constitutively or transiently, can increase the proliferation of the gene-corrected cells so that successful readministration and treatment is more likely to occur.
- This modulation of EVI-related gene expression can be done by several means, such as simply administering the retroviral vector to gene-corrected cells, or, for example, by traditional molecular cloning methods.
- a method of forming a bodily tissue by obtaining a desired cell type from a patient, if desired, treating the cell with a nucleic acid to accomplish a gene-correction, treating the cell to allow for increased expression of an EVI-related and/or SETBP1 gene to cause increased cell proliferation, and treating the cell so as to form a desired tissue.
- the tissue can then be readministered into the patient as a form of gene therapy.
- Additional embodiments of the invention provide for a method of identifying genes whose modulation (such as upregulation or downregulation) can increase the proliferation rate, selective advantage, or persistence of a stem or progenitor cell.
- the method can involve obtaining a transfected cell, allowing it to proliferate for several cycles, then testing using LAM-PCR to determine where the successfully repopulated cells have the nucleic acid insertions. The testing can be performed, if desired, over a period of time to determine how the insertion sites change over time.
- Candidate genes can then be chosen for further analysis. As an example of this method, Table 1 shows a list of exemplary genes found to contain retroviral insertions in at least one of the two successfully treated CGD patients.
- genes, identified to be downstream of these insertion sites are shown in Table 1. These genes include but are not limited to MGC10731, PADI4, CDA, CDW52, ZBTB8, AK2, FLJ32112, TACSTD2, FLJ13150, MGC24133, NOTCH2, NOHMA, EST1B, PBXl, PLA2G4A, HRPT2, ATP6V1G3, PTPRC, NUCKS, CABC1, LOC339789, PRKCE, AFTffHHIN, NAGK, MARCH7, DHRS9, PRKRA, SESTD1, MGC42174, CMKOR1, TBC1D5, THRB, MAP4, IFRD2, ARHGEF3, FOXP1, ZBTB20, EAF2, MGLL, PLXND1, SLC9A9, SELT, CCNLl, MDS1, BCL6, MIST, STM2, TEC, OCIAD1, FLJ10808, SEPTIl
- X-linked chronic granulomatous disease in patient P1 was done in 1981. He suffered from severe bacterial and fungal infections as well as granuloma of the ureter with stenosis, pyeloplastic operation (1978), liver abscesses (1980), pseudomonassepticemia (1985), candida-oesophagitis(1992), salmonellasepticemia (1993), severe osteomyelitis, spondylitis with epidural and paravertebral abscess and corporectomy (June 2002). Since 2003 severe therapy-resistant liver abscesses ⁇ Staph, aureus) were diagnosed.
- gp91 phox expression is driven by the Friend mink cell Spleen focus-forming virus (SFFV) LTR, which has been shown to be highly active in stem and myeloid progenitor cells [Baum, C. et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 69, 7541-7547 (1995), herein incorporated by reference in its entirety].
- Vector containing supernatants were obtained from a stable PG 13 packaging cell line in X-VIVO10 at a titer of 1 x 10 6 TU/ml.
- CD34+ cells were prestimulated for 36 hours at a density of 1 x 10 6 cells/ml in X-VIVO 10 medium + 2 mM L-glutamine, supplemented with EL-3 (60 ng/ml), SCF (300 ng/ml), Flt3-L (300 ng/ml), and TPO (100 ng/ml) (Strahtman Biotech, Dengelsberg, Germany) in Lifecell Bags (Baxter). Following prestimulation, cells were adjusted to a density of 1 x 10 6 cells/ml in cytokine containing medium as described above.
- Transduction was performed in tissue culture flasks coated with 5 ⁇ g/cm 2 of CH-296 (Retronectin, Takara, Otsu, Japan) and preloaded with retroviral vector containing supernatant as described previously [Kuhlcke, K. et al. Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels. MoI Ther 5, 473-478 (2002), herein incorporated by reference in its entirety]. After 24 hours cells were pelleted and cell density was again adjusted to 1 x 10 6 cells/ml in cytokine containing medium. Cells were incubated on freshly coated/preloaded flasks for another round of transduction. This procedure was repeated once more for a total of three transduction rounds. 24 hours after the final transduction, cells were harvested and analyzed for phenotype and gene transfer efficiency, transported to the transplantation unit and reinfused into the patients.
- End of production materials were also tested for the presence of replication competent retroviruses by the extended XC plaque assay [Cham, J.C. et al. Alteration of the syncytium-forming property of XC cells by productive Moloney leukemia virus infection. Cancer Res 35, 1854-1857 (1975), herein incorporated by reference in its entirety] and by a gag-specific PCR as follows: Primers 5'- AGAGGAGAACGGCCAGTATTG-S 1 (SEQ ID NO: 136) and 5 r - ACTCCACTACCTCGCAGGCATT-3' (SEQ ID NO: 137) were used to amplify a 69-bp fragment of the retroviral gag cDNA.
- Amplification was detected with a FAM-labelled gag- probe (5 I -TGTCCGTTTCCTCCTGCGCGG-3 I ) (SEQ ID NO: 138).
- the human EPO receptor gene was used as an internal amplification control. PCR reactions were carried out for 40 cycles in a single tube. Each reaction cycle consisted of 15 seconds at 94°C followed by 1 minute at 60°C.
- the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Rothstadt, Germany) was used to determine the presence of proviral sequences in genomic DNA isolated from the blood and bone marrow cells of patients P1 and P2.
- the exon 8 primer gp91-f (5'-GGTTTTGGCGATCTC AACAGAA-3') (SEQ ID NO: 1) and exon 9 primer gp91-r (5 I -TGTATTGTCCCACTTCCATTTTGAA-3 I ) (SEQ ID NO: 2) were used to amplify a 114-b ⁇ fragment of the gp91 phox cDNA.
- Amplification was detected with the FAM-labelled probe gp91-p (5'-TCATCACCAAGGTGGTC ACTCACCCTTTC-S 1 ) (SEQ ID NO: 3).
- the human EPO receptor gene was used as an internal control to quantify the gp91 phox reaction.
- Primers hepo-f (5'-CTGCTGCCAGC TTTGAGTACACTA-S 1 ) (SEQ ID NO: 4) and hepo-r (5'-GAGATGCCAGAGTCAGATACCACAA-S') (SEQ ID NO: 5) amplified a 138-bp fragment from exon 8 of the 2£P0-receptor-gene.
- Amplification was determined by the VIC-labelled probe hepo-p (5'-ACCCCAGCT CCCAGCTCTTGCGT-S') (SEQ ID NO: 6). Both reactions were carried out in a single tube. The amplification cycle was 15 s at 94 °C followed by 1 min at 60 °C. hi each experiment, the amplification of DNA generated from HT 1080 cells containing a single copy of a gp91 phox vector mixed with wild type HT1080 cells in defined ratios was used to quantify the percentage of SF71 gp91 phox integrations per human genome.
- the percentage of transduced cells was estimated from the values obtained from the quantitative PCR (Q-PCR), which represent vector copies per diploid genome, after dividing by two to account for the mean of two proviral copies per transduced cell.
- Q-PCR quantitative PCR
- genomic DNA was isolated from individual bone marrow colonies and analyzed for the presence of vector derived sequences by nested PCR using gp91 phox specific primers.
- the primers used for first PCR were gpforOl: (5'-TTGTACGTGGG C AGACCGC AG AGA-3') (SEQ ID NO: 7) and gprevO2: (5'- CCAAAGGGCCCATCAACCGCTATC-3') (SEQ ID NO: 8).
- Nested PCR was done under similar conditions using the primer combination P8: (5'- GGATAGTGGGTCCCATGTTTCTG-3') (SEQ ID NO: 9) and RI l: (5'- CCGCTATCTTAGGTAG TTTCCACG-3') (SEQ ID NO: 10).
- EPO-R gene was amplified in parallel with the primer combination hEpo-F1: (5'- GAGCCGGGGACAGATGATGAGG-S') (SEQ ID NO: 11) and hEpo-R1: (5'- GCGGCTGGGATAAGGCTGTTC-3') (SEQ ID NO: 12) for the first PCR reaction and primers hepo-f (SEQ ID NO: 4) and hepo-r (SEQ ID NO: 5) for the nested PCR primers.
- hEpo-F1 (5'- GAGCCGGGGACAGATGATGAGG-S')
- hEpo-R1 (5'- GCGGCTGGGATAAGGCTGTTC-3') (SEQ ID NO: 12) for the first PCR reaction and primers hepo-f (SEQ ID NO: 4) and hepo-r (SEQ ID NO: 5) for the nested PCR primers.
- hexa- nucleotide primed double strand synthesis with Klenow polymerase, restriction digest using Msel, HinP1I, or Tsp5091 and ligation of a restriction site complementary linker cassette allowed amplification of the vector genome junctions.
- vector specific primers LTR II (5'>GCC CTT GAT CTG AAC TTC TC ⁇ 3') (SEQ ID NO: 14) and LTR IH (5'>TTC CAT GCC TTG CAA AAT GGC ⁇ 3 ') (SEQ ID NO: 15) were used in combination with linker cassette specific primers LC I (5'>GAC CCG GGA GAT CTG AAT TC3') (SEQ ID NO: 16) and LC II (5>GAT CTG AAT TCA GTG GCA CAG ⁇ 3') (SEQ ID NO: 17), respectively.
- LAM-PCR amplicons were purified, shotgun cloned into the TOPO TA vector (Invitrogen, Carlsbad, CA) and sequenced (GATC, Konstanz, Germany). Sequences were aligned to the human genome (hgl7, release 35, May 2004) using the UCSC BLAT genome browser (available on the world wide web at ucsc.genome.edu). (See also Table 1.) Relation to annotated genome features were studied with the same tool. Sequences that could not be mapped were either too short ( ⁇ 20 bps, 136 sequences, 15.5% of all obtained sequences), or showed no definitive hit or multiple hits on the human genome (40 sequences, 4.5% of all obtained sequences).
- QC-PCR was performed with defined dilutions of IS (50 copies and 500 copies) added to 50ng of patient DNA.
- vector primer LTR I SEQ ID NO: 13
- genomic flanking primer FP2 SEQ ID NOs: See Table 4
- the templates were coamplif ⁇ ed with 35 PCR cycles (denaturation at 95°C for 45 s, annealing at 54-60°C for 45 s, extension at 72°C for 60 s) after initial denaturation for 2 min and before final extension for 5 min.
- a 35 cycle actin PCR was carried out as a loading control using primers actin-1 (5'- TCCTGTGGCATCCACGAAACT-3') (SEQ ID NO: 140) and actin-2 (5'- GAAGCATTTGCGGTGGAC GAT-3') (SEQ ID NO: 141) for 5 min at 95 °C, 1 min at 95 °C, 1 min at 58 °C, 1 min at 72 °C, and 10 min at 72 °C.
- EVI-1 and MDS1-EVI-1 transcripts were detected, by ICR with primers EVT1-ex5-F2 (5'-TGGAGAAACACATGCTGTCA-3') (SEQ ID NO: 142) and EVl1-ex6-R2 (5'-ATAAAGGGCTTCACA CTGCT-3') (SEQ ID NO: 143).
- cDNA was subjected to a 36 cycle PCR using primers MDS1-ex2-F1 (5'-GCCACATCCAGT GAAGCATT-3') (SEQ ID NO: 144) and EVl1-ex2- R1 (5 '-TGAGCCAGCTTCCAACATCT-3') (SEQ ID NO: 145).
- PRDM16 To define the expression of PRDM16, a fragment of this PR domain was amplified using primer MEL1PR-F1 (5'-CTGACGGACGTGGAAGTGTCG-3') (SEQ ID NO: 148) with MEL1PR-F1 (5'-CAGGQGGTAGACGCCTTCCTT-3') (SEQ ID NO: 149), which hybridised in exon 3 and exon 5, respectively. 2% of the PCR product was amplified to a second PCR with primers MEL1PR-F2 (5'-TCTCCGAAGACCTGGGCAGT-3') (SEQ ID NO: 150) and MEL1PR-R2 (5'-CACCTG GCTCAATGTCCTTA-3') (SEQ ID NO: 151).
- SETBP1 Expression level of SETBP1 was analyzed using primers SETBP-F1 (5'-TAAAAGTGGACCAGACAGCA-3') (SEQ ID NO: 156) and SETBP-R1 (5'-TCACGAAGTTG TTGCCTGTT-3') (SEQ ID NO: 157).
- the primer U5 IV (5'>TCC GAT AGA CTG CGT CGC ⁇ 3') (SEQ ID NO: 158) together with primer EVI-ex2-R1, MDS1-ex2-F1, or MEL1N-R1.
- Nested PCR was performed, with 2% PCR product and primer U5 VI (5 '>TCT TGC TGT TTG CAT CCG AA ⁇ 3') (SEQ ID NO: 159) was used together with primer EVI1-ex2-R2 (SEQ ID NO; 147), MDS1-ex2-F2 (SEQ ID NO: 146), or MEL1N-R2 (SEQ ID NO: 155). Additionally, nested PCR was carried out with LTR I (SEQ ID NO: 13) and MELl-PR-F1 (SEQ ID NO: 148). 2% of the product was amplified with primer LTR II (SEQ ID NO: 14) and MELlPR- F2 (SEQ ID NO: 150).
- 36 cycle PCRs were accomplished with 3.33% of whole cDNA from patient 1 and 0.33% of whole cDNA from the normal donor for 2 minutes at 95°C, 45 seconds at 95°C, 45 seconds at 54°C, 1 minute at 72°C, and 5 minutes at 72°C.
- a 35 cycle actin PCR was carried out as a loading control with 0.0002-0.008% of cDNA and primers actin-1 (5'TCC TGT GGC ATC CAC GAA ACT 3') (SEQ ID NO: 140) and actin-2 (5' GAA GCA TTT GCG GTG GAC GAT 3') (SEQ ID NO: 141) for 5 minutes at 95°C, 1 minute at 95°C, 1 minute at 58°C, 1 minute at 72°C, and 10 minutes at 72°C.
- actin-1 5'TCC TGT GGC ATC CAC GAA ACT 3'
- actin-2 5' GAA GCA TTT GCG GTG GAC GAT 3'
- Bone marrow mononuclear cells (l-5xl ⁇ 4 ) or CD34+ purified cells (1- 5x10 3 ) were plated on methylcellulose in the presence or absence of cytokines (50 ng/ml hSCF, 10 ng/ml GM-CSF, 10 ng/m hIL3 and 3 U/ml hEpo) (MethoCult, Stem Cell Technologies, Vancouver, Canada). Colony growth was evaluated after 14 days.
- cytokines 50 ng/ml hSCF, 10 ng/ml GM-CSF, 10 ng/m hIL3 and 3 U/ml hEpo
- coli/ml were opsonized with 20% (v/v) Octaplas® (Octapharma AG, Lachen, Switzerland) for 5 min at 37°C.
- Opsonized E. coli final concentration 0.9x10 8 /ml
- granulocytes obtained from healthy donors or X-CGD patients after gene therapy.
- saponin Calbiochem, Darmstadt, Germany
- samples were incubated with ImM ortho- nitrophenyl- ⁇ D-galactopyranoside (Sigma-Aldrich, Seelze, Germany) at 37 °C for 30 min.
- ⁇ -galactosidase activity was followed by standard procedures at 420 nm.
- Aspergillus fumigatus killing assay was conducted as described by Rex et al. [Rex, J.H. et al. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 162, 523-528 (1990), herein incorporated by reference in its entirety] with minor modifications. Briefly, Aspergillus spores were seeded in 12 well plates at a density of 5x10 4 spores per well in Yeast nitrogen with amino acids (Sigma-Aldrich, Seelze, Germany). Hyphae were opsonized with 8% Octaplas® (Octapharma AG, Lachen, Switzerland) for 5 min at room temperature.
- E. coli killing 5x10 7 opsonized E. coli were incubated with 5x10 6 granulocytes in HBSS+Ca/Mg containing 2% human albumin in a water bath shaker at 37 °C for 2.5 h. The cells were harvested by centrifugation and fixed in 2.5% glutaraldehyde in PBS at room temperature for 30 min.
- Aspergillus fumigatus killing 3x10 5 Aspergillus spores were seeded in a 4 cm petri dish in Yeast Nitrogen Base with amino acids (Sigma). Germination was induced by 6 h incubation at 37 °C followed by decelerated growth at room temperature over night.
- Hyphae were washed in HBSS+Ca/Mg and opsonized with 8% Octaplas® (Octapharma AG, Lachen, Switzerland) in HBSS+Ca/Mg containing 0.5% human albumin for 5 min at room temperature.
- the opsonized hyphae were incubated with 3 ⁇ 10 6 granulocytes in HBSS+Ca/Mg containing 0.5% human albumin for 2 h at 37 °C. Fixation was carried out by direct addition of glutaraldehyde to a final concentration of 2.5%.
- Glutaraldehyde fixed samples were washed three times in PBS, fixed in 2% osmium tetroxide in PBS for 30 minutes, and dehydrated in ethanol followed by embedding in Epon and polymerization at 60 °C for 2 days.
- Ultrathin sections of 60 nm were prepared using an Ultramicrotome (Ultracut E, Reichert). The sections were then post-stained with 5% aqueous uranyl acetate for 30 min and lead citrate for 4 min, and examined on a Philips CM 12 transmission electron microscope.
- Bone marrow aspirates of both patients were routinely examined at several time points (P1: days +122, +192, +241, +381; P2: days +84, +119, +245). The following analyses were done: morphology (Pappenheim staining) was normal at all time points and showed a completely normal hematopoiesis, normal cellularity, normal megakaryo-, erythro- and granulopoiesis and no signs of leukemia.
- P1 day +381 megakaropoiesis normal, X-cell 1%, promyelocytes 8%, myelocytes 16%, metamyelocytes and bands 14%, segmented 15%, eosinophils 6%, basophils 1%, monocyte 3%, erythroblasts 21%, plasma cells 2%, lymphoids 12%.
- P2 day +245 megakaryopoiesis normal, promyelocytes 10%, myelocytes 19%, metamyelocytes and bands 12%, segmented 11%, eosinophils 4%, basophils 1%, monocytes 3%, erythroblast 26%, plasma cells 4%, lymphoids 10%.
- Bone marrow aspirates were taken at days +122, +192, +241 and +381 for P1 and at days +84, +119 and +245 for P2.
- a bone marrow total BM mononuclear cells were plated on methylcellulose (Methocult, Stem Cells Technologies) and colony formation was assessed 14 days later. Table 5 shows a summary of these data.
- CD3 and CD20 was performed at day +381 (P1) and day +491 (P2). No infiltration of blast
- Cytogenetic analysis were performed at the Department of Molecular Pathology, University Medical School, Hannover, Germany under the direction of Prof. Dr. med. B. Schlegelberger. The following samples were analyzed: P1: day +241 (16 metaphases), day +381 (18 metaphases); P2 day +119 (15 metaphases), day +245 (21 metaphases). In all cases a normal karyotype was observed.
- T-CeIl Function Analysis Mononuclear cells obtained at different time points from P1 and P2 were stimulated with diverse mitogens and antigens. Proliferative responses were assayed by 3 H- Thymidine incorporation. The ratio of 3 H-Thymidine incorporation in mitogen- or antigen stimulated vs. non-stimulated cells is given in Table 6 as a quotient, hi all cases, robust incorporation of 3 H-Thymidine were observed, indicating that the mitogen and antigen responses of patient lymphocytes are within the range of age-matched healthy individuals. Also, immunoscope analysis of V ⁇ T lymphocytes at day +245 (P1) and day +491 (P2) showed normal T cell receptor repertoires in both patients. Table 6.
- IgG antibodies against Tetanus Toxoid (610 U/l), Diphteria Toxoid (270 U/l) and Hemophilus influenzae Type B (3.10 ⁇ g/ml) were detected at day 597 in serum samples of P1.
- bone marrow cells obtained from C57EL/6-Ly5.1 + mice were expanded for 2 days in the presence of DMEM plus 15% heat- inactivated FBS, 10ng/ml IL-6, 6ng/ml IL-3, and 100ng/ml SCF. Expanded cells were subsequently transduced by co-culture on top of GP+E86 cells stably expressing MSCVneo. After transduction, cells were cultured in IMDM with 20% heat-inactivated horse serum plus 100 ng/ml SCF and 10 ng/ml IL-3, or 100 ng/ml SCF and 30 ng/ml FLT3L.
- More than 80 immortal cell clones were generated after retroviral transduction of murine bone marrow cells in the presence of SCF and IL3, of which some have been maintained in culture for more than 1.5 years. The majority of these clones had a phenotype similar to committed immature myeloid progenitors and were still IL-3 dependent. All karyotypes were found to be normal. Spontaneous differentiation of the cultures yielded neutrophils (10-40%) and macrophages (1-5%). 95% of cells could be differentiated into neutrophils in response to G-CSF, whereas GM-CSF treatment induced differentiation into macrophages (30%) and neutrophils (70%). Addition of PMA induced 50-70% of cells to differentiate into macrophages.
- SF-I SF-I- revealed a very immature phenotype (Sca-1-, 50% c-kit+) with lymphomyeloid differentiation capacity and an integration in Setbpl.
- transplantation of 2.5-5.6x10 6 Ly5.1 + SF- 1 cells resulted in a leukemic phenotype.
- All eleven hosts died of leukemia 56-118 days post transplant.
- Secondary recipients of IxIO 6 leukemic cells developed leukemias 30 days after transplantation.
- This SF-I cell line revealed two integrants, one located at an unknown gene locus (without abnormal gene expression) and one in intron 1 of Setbpl.
- the leukemic potential of SF-I cells is very likely related to the immature phenotype of the clone (engraftment and self-renewal capacity).
- This knowledge can be used to develop assays that evaluate the therapeutic value of gene-modified cells against its potential risks in clinical use. For example, such assays can be used to screen gene-modified cells in order to eliminate those clones that exceed a specified risk threshold for clinical therapies.
- immortalized early hematopoietic progenitor cells induced leukemias in transplanted hosts whereas immortalized immature myeloid cells did not.
- G-CSF mobilized peripheral blood CD34+ cells were collected from two X-CGD patients aged 26 (patient P1) and 25 years (patient P2), transduced with a monocistronic gammaretroviral vector expressing gp91 phox (SF71gp91 phox ) and reinfused 5 days later (Example 1). Transduction efficiency was 45% for P1 and 39.5% for P2 as estimated by gp91 phox expression (Example 2). The proviral copy number was 2.6 (P1) and 1.5 (P2) per transduced cell. The number of reinfused CD34+/gp91+ cells per kg was 5.IxIO 6 for P1 and 3.6 x10 6 for P2.
- liposomal busulfan Prior to reinfusion, liposomal busulfan (L-Bu) was administered intravenously on days -3 and -2 every 12 hours at a dose of 4 mg/kg/day. Liposomal busulfan conditioning was well tolerated by both patients P1 and P2. With the exception of a grade I mucositis from day +11 to day +17 observed in P1, no other non-hematological toxicities were observed.
- CFU-GM colony-forming units- granulocyte-macrophage
- BFU-E burst-forming units-erythrocyte
- HSCs hematopoietic stem cells
- Cells are isolated from a cell sample taken from a patient in need of blood cells.
- a retroviral vector is prepared.
- a cell culture is prepared in the presence of permissive cytokines. The cells are allowed to proliferate.
- cells are kept in culture in the presence of the same or a different set of cytokines or growth factors, e.g. to induce proliferation only at the stem cell stage, or only at a lineage differentiated stage, e.g. myelopoiesis or thrombopoiesis.
- the cells are prepared for reinfusion to the patient by washing in PBS to remove cell culture components, followed by sorting of cells according to phenotype.
- the cells are reinfused to the patient.
- the patient's cell count is taken weekly. By this method, the patient's blood cell count improves.
- EXAMPLE 25 Expansion of Hematopoietic Cells in vitro by Upregulating
- the human EVI-1 nucleic acid sequence operably linked to a tetracycline- inducible promoter, is inserted into a plasmid vector sequence using known molecular techniques, and is then transfected to a hematopoietic cell culture.
- the cell culture is allowed to proliferate as described in Example 24 for a 2 week period in the presence of the inducer agent.
- the cells are then counted and characterized using cell-type specific markers.
- Cells are reinfused intravenously, directly into the bone marrow or delivered to specific target tissues by direct application or injection in appropriate media, e.g. PBS.
- a patient in need of expansion of hematopoietic cells is treated with an injection of purified nucleic acid vector containing a nucleic acid sequence encoding EVI-1, operably linked to an inducible promoter.
- the nucleic acid integrates into the chromosomal DNA of the patient and/or is transcribed after the inducing agent is provided to the patient orally for 1 year.
- the hematopoietic cells are capable of in vivo expansion by this method, and the patient health improves.
- EXAMPLE 28 Administration of an Agent that Upregulates EVI-related Genes in a Cell Culture
- Cells are isolated from a patient in need of treatment.
- An agent that upregulates endogenous EVI-1 expression is added to a cell culture, such as an upstream regulator of EVI-1 expression. Cell count is measured daily. After several days, the agent is removed from the culture, the expanded cells are washed and reinfused into the patient.
- the human SETBP1 nucleic acid sequence operably linked to a steroid hormone inducible promoter, is inserted into an integrating vector sequence using known molecular techniques, and is then transfected to a hematopoietic cell culture.
- the cell culture is allowed to proliferate as described in Example 6 for one week in the presence of a steroid inducer agent.
- the cells are then counted and characterized using cell-type specific markers.
- the desired cells are isolated from the culture described in Example 11, and are washed in PBS. The cells are then reinfused directly into the bone marrow of the patient. By use of this method, the patient hematopoietic cell count improves, and the patient health improves.
- a patient in need of expansion of hematopoietic cells is treated with an injection of purified nucleic acid vector containing a nucleic acid sequence encoding PRDM 16, operably linked to an inducible promoter.
- the nucleic acid integrates into the chromosomal DNA of the patient and/or gets transcribed after the inducing agent is provided to the patient orally for 1 year.
- the hematopoietic cells are capable of in vivo expansion by this method, and the patient health improves.
Abstract
A method of increasing cell proliferation by modulating levels of EVI and related genes. Activation of EVI-1, PRDM16, or SETBP1 can increase the proliferation rate, self renewal and/or in vitro and/or in vivo survival and/or engraftment of human cells, either in vitro or in vivo. The gene modulation can be performed by various means, including traditional cloning methods and retroviral-based gene activation methods. The method can also be used to more efficiently deliver gene-corrected cells to a patient in need of treatment.
Description
STEM AND PROGENITOR CELL EXPANSION BY EVI, EVI-LIKE GENES AND SETBPl
FIELD OF THE INVENTION
[0001] The invention relates to the field of cell biology and gene therapy. In particular, the invention relates to methods of increasing cell proliferation in vivo or in culture by modulating expression of certain regulatory genes.
BACKGROUND OF THE INVENTION
[0002] Gene therapy methods are currently being pursued for the treatment of a variety of human diseases. Retroviral vectors, for example, have been successfully used in clinical gene therapy trials to treat severe combined immunodeficiencies (SCID), where gene correction conferred a selective advantage to lymphocytes (Cavazzana-Calvo, et al. (2000) Science 288:669-672; Aiuti, et al. (2002) Science 296:2410-2413; Gaspar, et al. (2004) Lancet 364:2181-2187, each of the foregoing which is hereby incorporated by reference in its entirety). However, in inherited leukocyte disorders without a selective advantage by gene correction, human gene therapy has been less effective (Kohn, et al. (1998) Nature Med. 4:775-780; Malech, et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:12133-12138, each of the foregoing which is hereby incorporated by reference in its entirety).
[0003] While insertion induced oncogenesis has been reported for wild type retroviruses (Hayward, et al. (1981) Nature 290:475-480; Selten, et al. (1984) Embo J. 3:3215-22, each of the foregoing which is hereby incorporated by reference in its entirety) and related replication competent vectors (Dudley, J. P. (2003) Trends MoI Med 9:43-45, which is hereby incorporated by reference in its entirety), retrovirus vector based gene therapy with non-replicating vectors was thought to lead to random monoallelic integration without relevant biological consequences (Coffin, et al. (1997) Retroviruses. Plainview, New York: Cold Spring Harbor Laboratory Press; Moolten, et al. (1992) Hum Gene Ther 3:479- 486, each of the foregoing which is hereby incorporated by reference in its entirety).
[0004] Although gene therapy methods, in theory, should provide useful methods for the treatment of many types of human diseases, several problems currently exist. One problem with current gene therapy methods is that gene-corrected cells growing in culture or in vivo, often do not expand rapidly. If these cultures could be treated so as to expand more rapidly, the gene therapy process could become more efficient and more likely to succeed. Thus, methods that are capable of increasing the rate of expansion of cells, such as mammalian hematopoietic cells, either in vitro or in vivo, would be useful to improve the effectiveness of a variety of gene therapy methods. Likewise, increasing the rate of expansion, and/or favoring the persistence of mammalian hematopoietic stem cells or progenitor cells, in vitro or in vivo, would be of great value independently of gene therapy methods and indications, including, but not restricted to, stem cell transplantation with and without ex vivo modification.
SUMMARY OF THE INVENTION
[0005] In some embodiments of the present invention, a method of increasing cell proliferation by modulating levels of EVI and related genes is provided. Activation of EVI-1, PRDMl 6, or SETBP1 can increase the proliferation rate, self renewal and/or in vitro and/or in vivo survival and/or engraftment of human cells, either in vitro or in vivo. The gene modulation can be performed by various means, including traditional cloning methods and retroviral-based gene activation methods. The method can also be used to more efficiently deliver gene-corrected cells to a patient in need of treatment.
[0006] In some embodiments of the present invention, a method of expanding cells is provided, by obtaining at least one cell from a patient, transfecting, infecting or transducing said cell with a retroviral or nonintegrating vector, such that cell entry and/ or integration of the vector promotes proliferation, persistence, or selective advantage of the cell, allowing the transfected cell to proliferate, reinfusing a plurality of proliferated transfected cells into said patient, and allowing said proliferated cells to expand further in the patient. The transfected cell can have characteristics of a cell such as, for example, a hematopoietic progenitor cell, a hematopoietic stem cell, or a stem cell. The method can be
used to treat a patient with a hematopoietic or other treatable disease. The vector can also have a sequence for correction or modification of a defective or deleterious gene.
[0007] In additional embodiments of the present invention, a method of increasing cell proliferation in a mammalian cell is provided, by obtaining a cell, contacting the cell with a nucleic acid sequence encoding a protein selected from the group consisting of EVI-1, PRDMl 6, SETBP1, and a fragment thereof, allowing said nucleic acid to enter the cell, and allowing said cell to proliferate, where the cell having the nucleic acid proliferates at an increased rate compared to a cell that has not been contacted with the nucleic acid sequence. The proliferation can occur, for example, in a cell culture, ex vivo, or in vivo. The nucleic acid can integrate, for example, into the chromosomal DNA. The nucleic acid can be present, for example, in the cytoplasm of the cell. The nucleic acid can be operably linked to a promoter. The nucleic acid can be constitutively expressed. The expression of the nucleic acid can be inducible, for example, by an exogenously added agent. The nucleic acid can be present in a vector, such as, for example, a viral vector. The nucleic acid can be expressed for a number of division cycles such as, for example, about 1, 3, 5, 8, 10, 13, 17, or 20 division cycles, then expression can decrease or stop thereafter. The cell can have characteristics of a cell selected from the group consisting of a hematopoietic stem cell, hematopoietic progenitor cell, a stem cell, an embryonic stem cell, an adult stem cell, a multipotent stem cell, and a myelopoietic stem cell.
[0008] m a further embodiment of the present invention, a method of expansion of a gene-corrected cell is provided, by obtaining a cell in need of gene correction, transfecting the cell with a functional copy of a the gene in need of correction, transfecting the cell with a copy of a nucleic acid encoding a polypeptide sequence selected from the group consisting of EVI-1, PRDM 16, SETBP1, and a fragment thereof; and allowing the cell to proliferate in culture.
[0009] In a further embodiment of the present invention, a method of forming a bodily tissue having gene corrected cells is provided, by obtaining a cell in need of gene correction, transfecting the cell with a functional copy of a the gene in need of correction, transfecting the cell with a copy of a nucleic acid encoding a polypeptide sequence selected
from the group consisting of EVI-1, PRDMl 6, SETBP1, and a fragment thereof, allowing the cell to proliferate in culture, and treating the cell culture to allow formation of a bodily tissue.
[0010] In a further embodiment of the present invention, a method of identifying a gene is provided, the modulation of which increases the proliferation rate of a cell, by obtaining a sample of cells from a patient having previously received a therapeutic transfection with a nucleic acid sequence, identifying positions of nucleic acid insertion in the cells from the sample, identifying a favorable insertion site based upon disproportional representation of the site in the population of transfected cells, and identifying a gene associated with the insertion site.
[0011] In a yet further embodiment of the present invention, a nucleic acid integration region is provided, that, when insertionally modulated, results in increased hematopoietic cell proliferation, as is selected from the EVI-1 gene, the PRDM 16 gene, and the SETBP1 gene.
[0012] In a further embodiment of the present invention, a nucleic acid sequence whose modulation of expression is associated with the increased proliferation of hematopoietic cells is provided, selected from the following group: MGC 10731, PADI4, CDA, CDW52, ZBTB8, AK2, FLJ32112, TACSTD2, FLJ13150, MGC24133, NOTCH2, NOHMA, EST1B, PBXl, PLA2G4A, HRPT2, ATP6V1G3, PTPRC, NUCKS, CABC1, LOC339789, PRKCE, AFTIPHILIN, NAGK, MARCH7, DHRS9, PRKRA, SESTD1, MGC42174, CMKOR1, TBC1D5, THRB, MAP4, IFRD2, ARHGEF3, FOXP1, ZBTB20, EAF2, MGLL, PLXND1, SLC9A9, SELT, CCNLl, MDS1, BCL6, MIST, STM2, TEC, OC1AD1, FLJ10808, SEPTIl, PRKG2, MLLT2, PGDS, MANBA, SRYl, SET7, MAML3, DCTD, CARF, IRF2, AHRR, POLS, ROPN1L, FLJ10246, IPOIl, C2GNT3, SSBP2, EDIL3, SIAT8D, FLJ20125, GNB2L1, C6orfl05, JARID2, C6orf32, HCG9, MGC57858, TBCC, SENP6, BACH2, REPS1, HDAC9, OSBPL3, H0XA7, CALN1, FKBP6, NCF1, HEPl, GNAI7, ZKSCAN1, MGC50844, LOC346673, CHRM2, ZH3HAV1, REPIN1, SMARCD3, CTSB, ADAM28, LYN, YTHDF3, SMARCA2, C9orf93, NPR2, BTEBl, ALDHlAl, AUH, C9orf3, WDR31, CEP1, GSN, RABGAP1, ZNF79, CUGBP2, C10orf7, PTPLA, PLXD2, ACBD5, PRKGl, MYST4, IFIT1, C10orfl29, CUEDC2, FAM45A, GRK5, OR52NI, OR2AG2, ZNF143, C1 lorffi, LM02, NGL-I, DGKZ, NR1H3, KBTBD4, C1QTNF4,
MGC5395, ARRBl, FLJ23441, FGIF, MAML2, LOC196264, HSPC063, ELKS, CACNA2D4, CHD4, EPS8, LRMP, NEUROD4, RNF41, FAM19A2, RASSF3, PAMC1, PLXNC1, DAP13, MGC4170, FLJ40142, JIK, CDK2AP1, GPR133, PCDH9, C13or£25, ABHD4, AP4S1, MIA2, RPS29, PSMC6, RTN1, MED6, C14orf43, C14orfll8, RPS6KA5, GNG2, PAK6, B2M, ATP8B4, TRIP4, CSK, MESDC1, RKHD3, AKAP13, DET1, DKFZp547K1113, SV2B, LRRKl, CHSYl, TRAF7, ZNF205, ABCC1, THUMPD1, IL21R, MGC2474, N4BP1, SLIC1, CDH9, GPR56, ATBF1, ZNRF1, CMIP, MGC22001, C17orf31, SAT2, ADORA2B, TRPV2, NF1, LOC117584, MLLT6, STAT5A, STAT3, HOXB3, HLF, MAP3K3, SCN4A, ABCA10, EPB41L3, ZNF521, RNF125, SETBP1, FLJ20071, CDH7, MBP, MBP, NFATC1, GAMT, MOBKL2A, NFIC, CALR, GPSN2, ZNF382, EGLN2, PNKP, LAIR1, ZNF579, SOX12, C20orD0, PLCBl, SNX5, LOC200261, ZNF336, BAKl, SPAG4L, EPB411L1, NCOA3, KIAA1404, STIMN3, CBR3, DYRKlA, CSTB, C22orfl4, UPBl, MN1, XBP1, C22orfl9, RBM9, MYH9, TXN2, PSCD4, UNC84B, FLJ2544, ZCCHC5, MST4, IDS, UTY, SKI, PRDM16, PARK7, CHC1, ZMYMl, INPP5B, GLIS1, SLC27A3, ASHlL, SLAMF1, PBXl, CGI-49, ELYS, RNF144, FAM49A, FLJ21069, SFRS7, SPTBN1 , TMEM17, ARHGAP25, FLJ20558, CAPG, PTPN18, RBMS1, LOC91526, KLF7, FLJ23861, CMKOR1, CRBN, ITPR1, RAFTLIN, TNA, CCDC12, FHIT, VGL-3, PPMlL, EVI-1, MDS1, HDSH3TC1, DHX15, TMEM33, CXCL3, EPGN, LRBA, FLJ25371, CPE, POLS, PTGER4, LHFPL2, C5orfl2, CETN3, PHF15, PFDN1, KIAA0555, GNB2L1, HLA-E, SLC17A5, UBE2J1, BACH2, HIVEP2, SNX8, TRIAD3, RAC1, ARL4A, ELMOl, BLVRA, SUNC1, ABCA13, GTF2IRD1, RSBN1L, ADAM22, MLL5, IMMP2L, SEC8L1, FLJ12571, CULl, ANGPT1, DEPDC6, EPPKl, MLANA, MLLT3, SMUl, TLE4, C9orf3, ABCAl, STOM, RABGAP1, NEK6, NR5A1, MGC20262, FLJ20433, MAP3K8, ARHGAP22, C10orf72, TACR2, NKX2, OBFC1, VTIlA, ABLFMl, FLJ14213, MS4A3, B3GNT6, NADSYN1, CENTD2, MAML2, ATP5L, FLIl, CACNAlC, HEBP1, MLSTD1, IPO8, ARID2, SLC38A1, KRT7, USP15, KIAA1040, WIF1, CGI-119, DUSP6, FLJl 1259, CMKLR1, SSHl, TPCN1, FLJ42957, JIK, FLT3, TPT1, FNDC3, ARHGAP5, ARF6, GPHN, C14orf4, STN2, PPP2R5C, CDC42BPB, CEP152, 0AZ2, AKAP13, CHSYl, CRAMP1L, MHC2TA, NPP, SPN, MMP2, DKFZp434I099, SIAT4B, PLCG2, MYOlC, C17orBl, MGC51025, WSBl, TRAF4, SSH2, HCA66, RFFL, DUSP14, TCF2, ZNF652,
STXBP4, HLF, MSE, VMP1, HELZ, TREM5, RAB37, SEC 14Ll, SEPT9, BIRC5, PSCD1, MGC4368, NDUFV2, C18orf25, ATP8B1, CDH7, FLJ44881, NFATC1, C19orf35, GNG7, MATK, C3, ZNF358, LYLl, F2RL3, ZNF253, ZNF429, KIAA1533, U2AF1L3, GMFG, BC-2, C20orf30, PLCBl, LOC200261, C20orfll2, ADA, PREXl, C21orB4, C21orf42, ERG, ABCGl, MN1, HORMAD2, LOC113826, C22orfl, EFHC2, SYLT4, MGC27005, FHLl, GAB3, and CSF2RA.
[0013] In a further embodiment of the present invention, a method of identifying a favorable insertion site of a nucleic acid sequence in a proliferating cell culture is provided, by transfecting a cell sample with a nucleic acid sequence, allowing cell proliferation to occur, determining at least one main insertion site of the nucleic acid using linear amplification mediated PCR (LAM-PCR) over time, using the at least one main insertion site to predict the location of at least one main insertion site of another cell sample transfected with a substantially similar nucleic acid sequence over a similar time period, obtaining a sample of cells from a patient having previously received a therapeutic transfection with a nucleic acid sequence, identifying positions of nucleic acid insertion in the cells from the sample, and identifying a favorable insertion site based upon disproportional representation of the site in the population of transfected cells.
[0014] In a further embodiment of the present invention, a method of expansion of a cell is provided, comprising contacting the cell with a polypeptide selected from the group consisting of: an EVI-1 polypeptide, a PRDMl 6 polypeptide, a SETBP1 polypeptide, a fragment thereof, or a synthetic peptide derivative thereof.
[0015] In a further embodiment of the present invention, a method of treating an individual having a disease caused by a mutated gene or an inappropriately expressed gene is provided, by administered cells that have been corrected for the gene of interest, where the cells also have an increased level of at least one of an EVI-1 polypeptide, a PRDM 16 polypeptide, or a SETBP1 polypeptide. In additional embodiments of the present invention, the disease is chronic granulomatous disease (CGD).
[0016] In additional embodiments of the present invention, a method of improving gene therapy is provided, by treating an individual with gene-corrected cells that
have also been altered to have increased levels of at least one of the following polypeptides: an EVI-1 polypeptide, a PRDMl 6 polypeptide, or a SETBP1 polypeptide.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 shows hematopoietic reconstitution and gene marking in patient P1 after gene therapy. Cell counts are shown both before and after gene therapy. Absolute neutrophil counts are measured against the right y-axis, while counts of helper T cells (CD4+CD3+), cytotoxic T cells (CD8+CD3+) and B cells (CD 19+) are measured against the left y-axis.
[0018] Figure 2 shows hematopoietic reconstitution and gene marking in patient P2 after gene therapy. Cell counts are shown both before and after gene therapy. Absolute neutrophil counts are measured against the right y-axis, while counts of helper T cells (CD4+CD3+), cytotoxic T cells (CD8+CD3+) and B cells (CD19+) are measured against the left y-axis.
[0019] Figure 3 illustrates quantification of gene-modified cells in peripheral blood leukocytes (PBL), granulocytes (CD 15+), T-cells (CD3+) and B cells (CD 19+) for patient P1 by quantitative PCR (QPCR).
[0020] Figure 4 illustrates quantification of gene-modified cells in peripheral blood leukocytes (PBL), granulocytes (CD 15+), T-cells (CD3+) and B cells (CD 19+) for patient P2 by quantitative PCR (QPCR).
[0021] Figure 5 shows gene marking in CFCs derived from bone marrow aspirates of patient P1 (days +122 and +381). Vector-containing CFCs were detected by PCR using primers specific for cDNA encoding gp91phox. Input DNA was controlled by amplification of sequences derived from the human erythropoietin receptor (hEPO-R).
[0022] Figure 6 shows gene marking in CFCs derived from bone marrow aspirates of patient P2 (days +119 and +245). Vector-containing CFCs were detected by PCR using primers specific for cDNA encoding gp91phox. Input DNA was controlled by amplification of sequences derived from the human erythropoietin receptor (hEPO-R).
[0023] Figure 7 illustrates the RIS distribution of retroviral vector insertions from 30 kb upstream to 5 kb downstream of RefSeq genes in patient P1. Absolute numbers of
integrations into the 3 common integration site (CIS) related RefSeq genes MDS1/EVI-1, PRDM 16 and SETBP1 are shown as black bars, while integrations into non CIS-related genes are shown in grey. The insertions are listed according to their location within the affected gene expressed as the percentage of the overall length of the gene. The last column summarizes all integrations up to 5 kb downstream of a gene. Up, upstream of the start of transcription; down, downstream of the RefSeq gene. TSS, transcription start site.
[0024] Figure 8 illustrates the RIS distribution of retroviral vector insertions from 30 kb up- to 5 kb downstream of RefSeq genes in patient P2. Absolute numbers of integrations into the 3 CIS related RefSeq genes MDS1/EVI-1, PRDM16 and SETBP1 are shown as black bars, while integrations into non CIS-related genes are shown in grey. The insertions are listed according to their location within the affected gene expressed as the percentage of the overall length of the gene. The last column summarizes all integrations up to 5 kb downstream of a gene. Up, upstream of the start of transcription; down, downstream of the RefSeq gene. TSS, transcription start site.
[0025] Figure 9 shows a LAM-PCR band pattern analysis of peripheral blood leukocytes and sorted CD14+, CD15+, CD3+ and CD19+ cells (purity CD3+/CD19+, >98%) derived from patient P1 from 21 to 542 days post-transplantation after undergoing CGD gene therapy as described in Example 1. M, 100 bp ladder; -C, 100 ng non-transduced human genomic DNA; 3' IC, 3'-LTR internal control.
[0026] Figure 10 shows a LAM-PCR band pattern analysis of peripheral blood leukocytes and sorted CD14+, CD15+, CD3+ and CD19+ cells (purity CD3+/CD19+, >98%) derived from patient P2 from 24 to 343 days post-transplantation after undergoing CGD gene therapy as described in Example 1. M, 100 bp ladder; -C, 100 ng non-transduced human genomic DNA; 3' IC, 3'-LTR internal control.
[0027] Figure 11 is a DNA map showing retroviral insertion site (RIS) clusters in highly active clones with integrants in the MDS1/EVI-1 gene. The insertions are tightly clustered within relevant regulatory upstream portions of the gene locus. Grey dots indicate RIS derived from P1, while white squares indicate RIS from P2.
[0028] Figure 12 is a DNA map showing RIS clusters in highly active clones with integrants in the PRDM 16 gene. The insertions are tightly clustered within relevant
regulatory upstream portions of the gene locus. Grey dots indicate RIS derived from P1, while white squares indicate RIS from P2.
[0029] Figure 13 is a DNA map showing RIS clusters in highly active clones with integrants in the SETBP1 gene. The insertions are tightly clustered within relevant regulatory upstream portions of the gene locus. Grey dots indicate RIS derived from P1, while white squares indicate RIS from P2.
[0030] Figure 14 shows the long term follow up of individual clones contributing to hematopoiesis at different time points after transplantation in patient P1. Each individual CIS related clone detected is represented by one line, with each column representing an individual sampling time point. Grey boxes represent the detection of a specific clone at a time point via LAM-PCR, tracking PCR, and/or quantitative-competitive (QC-) PCR. The white boxes indicate the lack of detection at that time point, indicating that the clone contributes no or few cells to the peripheral circulation. *, no LAM-PCR performed; §, no tracking PCR performed; #, no QC-PCR performed.
[0031] Figure 15 shows the long term follow up of individual clones contributing to hematopoiesis at different time points after transplantation in patient P2. Each individual CIS related clone detected is represented by one line, with each column representing an individual sampling time point. Grey boxes represent the detection of a specific clone at a time point via LAM-PCR, tracking PCR, and/or quantitative-competitive (QC-) PCR. The white boxes indicate the lack of detection at that time point, indicating that the clone contributes no or few cells to the peripheral circulation. *, no LAM-PCR performed; §, no tracking PCR performed; #, no QC-PCR performed.
[0032] Figure 16 is a graph showing the overall contribution of clones with insertions in or near the three CIS-related RefSeq genes compared to all RIS locations at different time points detected in patient P1 during long-term myelopoiesis after gene modification. The insertion frequencies at MDS1-EVI-1 (light gray), PRDM 16 (dark gray) and SETBP1 (black) in relation to non-CIS-related insertion frequencies (white) is illustrated as a percentage of all integration site junction sequences (entire column) detected at each specific time point. The black line denotes the approximate percentage of gene marked cells
containing vector gp91phox among peripheral blood granulocytes. BM, bone marrow; G, granulocytes; MC, monocytes; PB, peripheral blood.
[0033] Figure 17 is a graph showing the overall contribution of clones with insertions in or near the three CIS-related RefSeq genes compared to all RIS locations at different time points detected in patient P2 during long-term myelopoiesis after gene modification. The insertion frequencies at MDS1-EVI-1 (light gray), PRDM 16 (dark gray) and SETBP1 (black) in relation to non-CIS-related insertion frequencies (white) is illustrated as a percentage of all integration site junction sequences (entire column) detected at each specific time point. The black line denotes the approximate percentage of gene marked cells containing vector gp91phox among peripheral blood granulocytes. BM, bone marrow; G, granulocytes; MC, monocytes; PB, peripheral blood.
[0034] Figure 18 illustrates a series of electrophoretic separations of nucleic acid on agarose gels showing the quantitative-competitive analysis of predominant clones from patient P1. The coamplification of 50 ng wild-type (WT) DNA from PB in competition with 500 copies of a 26-bp deleted internal standard (IS) allows semi-quantitative estimation of single clones. Time-course analysis revealed the sustained presence of all clones after their first detection (> 3 months post-transplant). Numbers indicate days after transplantation. -C, 50 ng non-transduced genomic DNA.
[0035] Figure 19 illustrates a series of electrophoretic separations of nucleic acid on agarose gels showing the quantitative-competitive analysis of predominant clones from patient P2. The coamplification of 50 ng wild-type (WT) DNA from PB in competition with 500 copies of a 26-bp deleted internal standard (IS) allows semi-quantitative estimation of single clones. Time-course analysis revealed the sustained presence of all clones after their first detection (> 3 months post-transplant). Numbers indicate days after transplantation. -C, 50 ng non-transduced genomic DNA.
[0036] Figure 20 shows LAM-PCR analysis of bone-marrow derived colonies from patient P1 at days +192 and +381 after transplantation. Colony numbers 1-3, 5, 7, 9-11, and 13 are colony-forming units — granulocyte-macrophage (CFU-GM)-derived colonies, whereas colonies 4, 6, 8, and 12 represent burst-forming units — erythrocyte (BFU-E) colonies. M, 100 bp ladder; -C, 100 ng nontransduced human genomic DNA.
[0037] Figure 21 shows LAM-PCR analysis of bone-marrow derived colonies from patient P2 at day +245 after transplantation. Colony numbers 1-3 and 5 are CFU-GM- derived colonies, whereas colonies 4 and 6 represent BFU-E colonies. M, 100 bp ladder; -C, 100 ng nontransduced human genomic DNA.
[0038] Figure 22 illustrates transcriptional activation of CIS genes by retroviral insertion. RT-PCR analysis of MDS1/EVI-1 (a), PRDM16 (b) and SETBP1 (c) was performed on bone marrow from patient P1 at day +381 and on peripheral blood leukocytes from patient P2 at days +287 and +343. Panel (a) shows analysis of MDS1/EVI-1 plus EVI-1 transcripts in the upper panel (PR+/PR-) and analysis of MDS1/EVI-1 only transcripts in the lower panel (PR+). The primer pairs used to detected EVI-1 transcripts are located within EVI-1 (exon 5 to exon 6) and therefore also detect MDS1/EVI-1 transcripts. In contrast, MDS/EVI-1 transcripts were detected with primer pairs located in the second exon of MDS1 and EVI-1 (Example 6). Panel (b) shows analysis of PR+/PR- in the upper panel and analysis of PR+ in the lower panel for PRDMl 6 transcripts. Panel (c) illustrates analysis of SETBP1 expression level. Panel (d) shows results from the β-actin RT-PCR. -C, H2O control; PR, PR-domain; BM, bone marrow cells; PB, peripheral blood leukocytes; ND, healthy donor.
[0039] Figure 23 illustrates expression of gp91phox protein on transduced cells in the days after transplantation of the gene-modified cells. Granulocytes (CD 15+) and T cells (CD3+) of patients P1 (a) and P2 (b) were labeled with the monoclonal antibody 7D5 and a lineage specific marker.
[0040] Figure 24 show results that demonstrate continued expression of gp91phox protein and functional reconstitution of NADPH oxidase activity in transduced cells. The top panel illustrates gp91phox expression in CD34+ bone marrow cells of patient P1 at day +381. The bottom panel exhibits dithionite reduced minus oxidized differential spectra of flavocytochrome in protein extracts obtained from granulocytes. The granulocytes were isolated from the peripheral blood of a healthy donor ("control"), patient P1 at day +242 ("P1") and patient P2 at day +120 ("P2") after reinfusion of gene transduced cells. Granulocytes were also obtained from an X-CGD patient ("X-CGD") for comparison. The two major absorption peaks at 426 nm (γ-peak) and 559 nm (α-peak) correspond to the reduced heme groups within gp91phox and are visible in granulocyte extracts from a healthy
donor and P1, while these bands are completely absent in extracts obtained from cells of an untreated X-CGD patient.
[0041] Figure 25 illustrates functional reconstitution of NADPH oxidase activity in peripheral blood leukocytes (PBLs) and isolated granulocytes of patient P1 as revealed by oxidation of dihydrorhodamine (DHR) 123 and NBT reduction. Superoxide production in PBLs was measured by DHR 123 oxidation in opsonised E. coli, as indicated by black dots. Superoxide production in isolated granulocytes was measured by stimulation with PMA (open dots) or by reduction of NBT to formazan (open squares).
[0042] Figure 26 shows an example of DHR 123 oxidation by neutrophils of patient P1 at day +473 after gene therapy both before (left panel) and after (right panel) PMA stimulation.
[0043] Figure 27 shows NBT reduction in single granulocytes obtained from patient P1 at day +381 after gene therapy both before (left panel) and after (right panel) stimulation with opsonised zymosan (OPZ).
[0044] Figure 28 illustrates functional reconstitution of NADPH oxidase activity in peripheral blood leukocytes (PBLs) and isolated granulocytes of patient P2 as revealed by oxidation of dihydrorhodamine (DHR) 123 and NBT reduction. Superoxide production in PBLs was measured by DHR 123 oxidation in opsonised E. coli, as indicated by black dots. Superoxide production in isolated granulocytes was measured by stimulation with PMA (open dots) or by reduction of NBT to formazan (open squares).
[0045] Figure 29 shows an example of DHR 123 oxidation by neutrophils of patient P2 at day +344 after gene therapy both before (left panel) and after (right panel) PMA stimulation.
[0046] Figure 30 shows NBT reduction in single granulocytes obtained from patient P2 at day +245 after gene therapy both before (left panel) and after (right panel) stimulation with opsonised zymosan (OPZ).
[0047] Figure 31 illustrates superoxide anion production by granulocytes obtained from a healthy control (a), patient P1 at day +193 (b) and patient P2 at day +50 (c) as revealed by cytochrome c reduction after stimulation with 0.1 μg/ml PMA plus 1 μM fMLP. The reaction was inhibited by superoxide dismutase (SOD) or specific inhibitors of
the phagocytic NADPH oxidase activity, such as 4-2- Aminoethylbenzene sulfonylfluoride (AEBSF) or diphenylene iodonium (DPI). In panel (a), IxIO6 cells/ml were used in the reaction, while in panels (b) and (c) 5*106 cells/ml were used.
[0048] Figure 32 shows the kinetics of E. coli killing by neutrophils obtained from a healthy donor ("pos. control"), patient P1 ("P1"), patient P2 ("P2") and an individual with X-CGD ("X-CGD") compared to incubation of E. coli in the absence of granulocytes as a negative control ("E. coli control").
[0049] Figure 33 illustrates transmission electron microscopy images of opsonised E. coli strain ML-35 at 2.5 hours after phagocytosis by granulocytes from the healthy donor (d, h), the X-CGD patient (b, e), and patient P1 at day +242 (c, f, g) at a ratio of 10:1 (E. cø/z:granulocytes). Black arrows in (e) and (f) denote undigested E. coli inside the phagocytic vacuole. White arrows in (g) and (h) indicate E. coli degradation. Inserts on the upper right hand corner show magnifications of undigested (e, f) and digested (g, h) bacteria. Encircled areas in panels (b-d) indicate enlarged cells shown in panels (e-h). Scale bars in panels (b-d) represent 5 μm; in panels (e-h), 2 μm.
[0050] Figure 34 illustrates killing of A. fumigatus hyphae by gene-modified granulocytes as revealed by mitochondrial MTT reduction (a) and transmission electron microscopy (b - d). In panel (a), the time course of fungus killing is shown at a ratio of 1 seeded Aspergillus spore to 20 granulocytes obtained from either a healthy donor or patient P1 at day +381 after reinfusion of gene transduced cells. MTT reduction of Aspergillus hyphae alone was normalized to 100%. In panels (b-d), the fate of A. fumigatus hyphae after engulfment by healthy (b), non-corrected X-CGD (c) and functionally corrected (d) granulocytes is illustrated. Intact hyphae engulfed by phagocytes are marked with a black arrows (c, d), while hyphae with cytoplasmic disintegration entangled by phagocytes are marked with a white arrows (b, d). Bars in (b-d) represent 5 μm.
[0051] Figure 35 shows fused PET scans of patient P1 (b) and fused PET-CT scans of patient P2 (c,d) both before (a,c) and either 50 (b) or 53 (d) daus after gene therapy. The circle in (a) denotes two active abscesses due to Staphylococcus aureus infection in the liver of patient P1, and the circle in (c) shows 18F-FDG uptake in the wall of a lung cavity of patient P2 due to A. fumigatus infection.
[0052] Figure 36 shows that immortalized bone marrow cells (SF-I cells) containing a Setbpl integration can engraft and induce myeloid leukemia with minimal to mild maturation in irradiated transplanted mice. Immortalized clones usually appeared after 1 month of culturing. The figure shows gates for Ly5.1+ cells from bone marrow (a, left), spleen (b, left), and thymus (c, left) from a mouse (Ly5.2) 2 months after transplantation with the immortalized clone SF-I. Staining was done with Gr-I (RB6-8C5)(a, right), CD 19 (lD3)(b, right), and Thy-1.2 (53-2. l)(c, right) antibodies and corresponding isotype control antibodies (a-c, middle lane) in combination with Ly5.2 antibody. Numbers represent the percent of gated events. Details of this protocol are described in Du et al., Blood 106:3932- 3939 (2005), herein incorporated by reference in its entirety.
Brief Description of the TABLES
[0053] Table 1 provides a list of proviral integration site sequences detected by LAM-PCR. LAM-PCR amplicons derived from patient P1 are shown in Table l(a) while those from patient P2 are listed in Table l(b). The RefSeq gene nearest to an identified integration site within a 100kb window is listed. The two integrations in the most productive clone in patient P1 are defined by the "Sequence Identity" 77110 A09 (MDS1) and 75916 A08 (OSBPL6 and PRKRA). "Genomic Length" denotes the size of the LAM-PCR amplicon without linker- and LTR-sequences. "Sequence Orientation" denotes vector integration within the human genome. TSS, transcription start site; PB, peripheral blood; BM, bone marrow; CD15, purified granulocytes; CD14-15, monocytes; In, intron; Ex, exon.
[0054] Table 2 provides a list of vector integrants detected in the CIS genes MDS1/EVI-1, PRDM16 and SETBPL Data for patient P1 is listed in Table 2(a) while data for patient P2 is listed in Table 2(b). Vector integration was detected by LAM-PCR (L), tracking PCR (T), and/or quantitative competitive PCR (Q). CIS clones chosen for a specific tracking over time are marked (T and/or Q) in the column "Track." The most productive clone in P1 which was tracked using the sequence information obtained from 75916 A08 is annotated in this table by the second integration 77110 A09 (MDS 1), which is also present in this particular clone. Empty spaces define no detection. CIS clones without "Integration Number" were additionally detected by tracking PCR due to their close location to other
clones for which tracking PCR was performed. "Vector integration" indicates whether vector integration took place in the same orientation or in the reverse orientation of CIS gene expression. *, no LAM-PCR performed; §, no tracking PCR performed; #, no QC-PCR performed.
[00S5] Table 3 provides a list of primers used for specific tracking of individual CIS clones and generation of clone specific internal standard. F1anking primers 1 and 2 (FP1 and FP2), in combination with vector specific primers, were used to track an individual CIS clone in patients P1 (Table 3a) and P2 (Table 3b) over time and to generate a clone specific internal standard. For quantitative competitive PCR vector specific primers and flanking primers 3 and 4 (FP3 and FP4) were used to coamplify a particular integration site and the appropriate internal standard (as described in Example 4).
[0056] Table 4 provides the accompanying SEQ ID NO for each primer listed in Table 3.
[0057] Table 5 is a summary of clinical data showing the colony formation of bone marrow total BM mononuclear cells obtained from bone marrow aspirates of patient P1.
[0058] Table 6 is a summary of clinical data showing the incorporation of 3H- Thymidine into mitogen- or antigen-stimulated mononuclear cells vs. non-stimulated mononuclear cells obtained from patients P1 and P2 at different time points.
[0059] Table 7 is a summary of clinical data showing examples of plasma protein levels at days +546 for patient P1 and day +489 for patient P2.
DETAILED DESCRIPTION OF THE INVENTION
[0060] LAM-PCR analysis, described in U.S. Patent No. 6,514,706, hereby incorporated by reference in its entirety, is a highly sensitive method for identifying an unknown nucleic acid sequence that flanks a known sequence present in a sample. The method is a powerful way to determine the insertion position of a transferred nucleic acid, such as a retroviral vector sequence, after an integration event. In addition to the use of LAM-PCR to determine target site selection of an integrated nucleic acid species, the method can also be used to determine how the integration sites change over time in a dividing cell
culture. Thus, the method is particularly useful for clonal analysis of transfected hematopoietic cells or other transfected cells.
CGD patient analysis using LAM-PCR
[0061] LAM-PCR analysis was used to examine blood samples from two patients that were successfully receiving gene therapy by retroviral-based gene correction to treat chronic granulomatous disease (CGD) in an ongoing trial as described in Example 1. In the CGD gene therapy trial, high efficiency transduction of autologous CD34+ bone marrow cells and busulfan conditioning were used to successfully correct the cytochrome b gρ91p ox gene defect in two patients for more than a year. A main goal of the analysis was to examine whether the retrovirus vector integration insertion site is less inert with respect to its genomic context than previously thought (Wu, et al. (2003) Science 300:1749-1751; Laufs, et al. (2003) Blood 101:2191-2198; Hematti, et al. (2004) PLoS Biol. 2:e423, each of which is hereby incorporated by reference in its entirety).
[0062] To determine whether an in vivo selective advantage of gene-modified myeloid cells capable of long term engraftment, proliferation and in vivo expansion, may be related to vector integration into particular genome regions, blood samples were taken from the two patients that achieved successful gene-corrected myelopoiesis in the CGD trial. A large-scale mapping analysis of retrovirus integration sites in the patient cells was then undertaken, using LAM-PCR as described in Example 3.
[0063] It was found that there is a significant influence of genomic vector integration on engraftment and proliferation of transduced hematopoietic cells. As shown herein, LAM-PCR based large-scale mapping of retrovirus integration sites (RIS) derived from the two successfully treated CGD patients shows that distribution of RIS became non- random starting about 3 months after reinfusion of gene corrected CD34+cells.
[0064] The repopulating cell clones contained activating insertions in three genes. These three genes are the "positive regulatory (PR) domain" zinc finger genes MDS1/EVI-1 and PRDM 16 and a SET binding protein SETBP1. The activating insertions were found to drive a 3 to 5 fold expansion of gene corrected cells, and selectively proliferated and dominated (>80%) gene-corrected long term myelopoiesis in both patients. These surprising
results are in contrast to other research suggesting that retrovirus-based gene therapy would result in random monoallelic integration without relevant biological consequences (Coffin, et al. (1997), supra, which is hereby incorporated by reference in its entirety).
EVI-I. PRDM16. and SETBPl
[0065] Two of the three genes that were found to contain the activating insertions encode zinc finger proteins that are related PR domain proteins. Several types of proteins, including certain transcriptional regulatory proteins, have regions that fold around a central zinc ion, producing a compact domain termed a "zinc finger." Several classes of zinc-finger motifs have been identified. One group of zinc finger proteins is the "PR domain family" of transcription factor proteins, which includes, for example, the related genes EVI-1, PRDM16, and others. These PR domain family genes have been implicated, in some cases, to play a role in the development of cancer.
[0066] The EVI-1 protein ("ecotropic viral integration site 1") is a zinc finger DNA-binding protein that is characterized by two domains of seven and three repeats of the Cys2-His2-type zinc finger motif (Morishita et al. (1988) Cell 54: 831-840; for a review, see Chi et al. (2003) J Biol Chem. 278:49806-49811, each of the foregoing which is hereby incorporated by reference in its entirety). Although EVI-1 is not generally detected in normal hematopoietic organs including bone marrow, the inappropriate expression of EVI-1 is often triggered by chromosomal rearrangements that disrupt the 3q26 chromosomal region where the EVI-1 gene is located (Fichelson, et al. (1992) Leukemia 6:93-99, which is hereby incorporated by reference in its entirety). Further, EVI-1 up-regulation can occur in chronic myelogenous leukemia patients, even though chromosomes appear normal by conventional cytogenetics, indicating that the inappropriate activation of EVI-1 can occur. High EVI-1 expression has been shown to predict poor survival in acute myeloid leukemia (Barjesteh van Waalwijk van Doom-Khosrovani, et al. (2003) Blood 101: 837-845, which is hereby incorporated by reference in its entirety). The related zinc finger protein PRDM16 ("positive regulatory domain containing 16") has also been found to be a DNA binding protein.
[0067] The PR domain is characteristic for a sub-class of zinc finger genes that function as negative regulators of tumorigenesis [Fears, S. et al., 1996, Proc. Natl. Acad. ScL
93:1642-1647, herein incorporated by reference in its entirety]. The PR domain of MDS1/EVI-1 (alias PRDM3) is a common target for wild-type retrovirus and vector insertion induced tumorigenesis, where the disruption of the PR domain activates PR domain negative oncogene EVI-1. Constitutive expression of the PR negative oncogene EVI-1 induces self- limiting myeloproliferation followed by a myelodysplastic syndrome in mice. The biology of PRDM16 (alias MDS1 -EVI-1 -like gene 1) is very similar to MDS1/EVI-1. In patients with myeloid malignancies, translocation of MDS1/EVI-1 or PRDM16 next to Ribophorin 1 gene on chromosome 3q21 leads to overexpression of the alternatively spliced PR domain negative transcript.
[0068] SET is a translocation breakpoint-encoded protein in acute undifferentiated leukaemia and SET binding protein 1 (SETBP1) is assumed to play a key role in SET associated leukemogenesis.
[0069] In experimental results, the LAM-PCR analysis showed a stable highly polyclonal hematopoietic repopulation of gene-corrected cells up to 381 days in patient 1 (P1) and up to 343 days in patient 2 (P2), although the band pattern indicated the appearance of individual pre-dominant clones 5 months after therapy (Figures 9, 10). A total of 948 unique RIS (patient P1: 551; patient P2: 397) were retrieved by shotgun cloning and sequencing of LAM products, of which 765 (P1: 435; P2: 330) could be mapped unequivocally to the human genome using the UCSC BLAT alignment tools. Integration preferentially occurred in gene coding regions (P1: 47%; P2: 52%) and was highly skewed to the ± 5kb transcriptional start site region (P1: 20%; P2: 21%) (Figures 7, 8).
[0070] RIS distribution in both patients was not stable over time and became increasingly non-random but still polyclonal in both patients. The distribution also clustered to a much higher degree around particular common insertion sites (CIS) than shown by previous in vitro and in vivo integration site studies (Wu, et al. (2003) Science 300:1749- 1751; Laufs, et al. (2003) Blood 101:2191-2198; and Hematti, et al. (2004) PLoS Biol. 2:e423, each of which is hereby incorporated by reference in its entirety). This clustering around common insertion sites allowed the prediction of the distribution and location of P2 insertions from the results in P1, whose gene modification procedure had been conducted 4 months earlier. The clonal contribution pattern turned into a less diverse pattern with distinct
bands starting 5 months after therapy (Figures 9, 10), indicating the appearance of multiple predominant progenitor cell clones which subsequently contributed substantially to the proportion of gene-corrected granulocytes. Sequencing of insertion loci revealed that these pattern changes were due to the emergence of clones containing an insertion in one of 3 genetic loci, or CISs [Suzuki, T. et al. New genes involved in cancer identified by retroviral tagging. Nature Genet 32, 166-174 (2004), herein incorporated by reference in its entirety]. (Tables 1-3). AU 134 detectable integrations at these three CISs occurred either in or near PR domain-containing zinc finger genes MDS1/EVI-1 or PRDM16 or in or near the SETBP1 gene. AU insertions were located in or near the upstream region of these genes, preferentially close to the transcriptional start site or internal ATG sites (Figures 7, 8, and 11-13), exhibiting an unprecedented degree of non-random clustering.
[0071] Multiple clones with insertion sites in or near 2 particular positive regulatory (PR) domain zinc finger genes and SETBP1 began to emerge almost 3 months (patient P1: day 84; patient P2: day 80) after treatment, continuously developing to sustained clonal domination within the next 2 months after treatment (P1: day 157, P2: day 149) in both patients. Of 134 PR domain and SETBP1 CIS that have been detected, 91 distinct integrants were found in or near MDS1/EVI-1 (patient P1: 42; patient P2: 49), 36 in PRDM16 (P1: 18; P2:18) and 7 in SETBP1 (P1: 7; P2: 0).
Selective advantage of EVI-L PRDM 16. and SETBPl integrants
[0072] Granulocytes have a life-span of 2-3 days. Therefore, the repeated detection over time of individual cell clones by retrovirus insertional marking is indicative of a repopulating progenitor cell or stem cell with long-term activity. The expansion of repopulating clones with these insertions occurred in both patients P1 and P2 with significant intensity. PR domain and SETBP1 related insertions comprised > 90% of all clones detected at more than three time points after treatment. The in vivo selection advantage of these clones was further underlined by the observation that of 134 hits into gene loci affected by insertions more than three times, all of these CIS were related to these 3 genes. Within these gene loci, insertion events were highly non-randomly distributed and clustered near the transcriptional start site and internal ATG sites, strongly suggesting that a vector induced
change of gene expression conferred a selective advantage to these clones (Figures 7,8, and 11-13).
[0073] In addition to the three genes discussed above, other gene insertion locations were found to be present. A summary list of the other LAM-PCR retrieved RIS and CIS is provided in Table 1.
Table 1a
Table 1a
Table 1b
Table 1b
Analysis of insertion location changes over time using LAM-PCR
[0074] To assess the overall contribution of PR domain (PR+) clones and SETBP1 clones to myelopoiesis over time, the retrieval frequency of unique insertions in shot-gun cloned and sequenced LAM-PCR amplicons was determined from the two patients. After the first appearance of PR+ and SETBP1 RIS on day 84 (patient P1) and day 80 (patient P2), their proportional contribution successively increased to more than 80% of insertions retrieved from circulating transduced cells within the next 100-150 days. The levels of contribution from the 3 CIS then stabilized, matching the 3- to 4-fold expansion of gene- modified myelopoiesis, and plateaued without abnormal elevation of total leukocyte or neutrophil numbers (Figures 16,17). Individual clones showed substantial differences in their quantitative myeloid contribution over time. PCR tracking (as described in Example 4) of the 3 CIS clones confirmed the presence of some insertions that were only detectable in one sample as well as other more dominant clones that persistently accounted for substantial percentages of peripheral blood myeloid cells without evidence of exhaustion (Figures 14, 15 and Table 2). Dominant clones were further analyzed by quantitative-competitive (QC) PCR (as described in Example 5), which confirmed their stability for a period of between 5 to 14 months after the initial expansion (Figures 18, 19).
Table 2b
[0075] Quantitative-competitive PCR was then used to further analyze the dominant clones (as described in Example 5). A spiked internal standard was used to test for clinically relevant continued proliferation. Stable activity was observed for a period of between 5 to 14 months (Figures 14, 15, 18, and 19). The most productive clone in patient P1 contained two insertions, one in intron 2 of the MDS1 gene locus and the other one in an intergenic DNA region. This clone's quantitative contribution to the transduced cell pool was first detected by LAM-PCR at +122 days post transplant. From day +122 on, it then increased until it peaked at about 80% of gene-modified cells present in the peripheral blood at day +381. So far, it has remained at this level until the last time point analyzed (day +542). Detection of this clone was also conducted by QC-PCR in sorted granulocytes, B and T cells at day +542 indicating the multilineage potential of the initial transduced cells (Table 2). The increasing dominance of this clone was also documented by integration site analysis and locus specific PCR of bone marrow progenitors (CFU-GM and BFU-E). Although at day +192 only 3 out of 6 (3 out of 11 by locus specific PCR) vector-containing colonies contained the same two insertion bands, the dominant clone contributed to 6 out of 7 (28 out of 36 by locus specific PCR) colonies at day +381 (Figure 20). Analysis of five additional clones revealed shared integration sites between CD3+ cells, CD 19+ cells and CD 15+ cells obtained from P1 at days +381 and +542, again suggesting effective gene transduction of hematopoietic stem cells (HSC) (Figures 9, 18, and Table 2). In P2, no single clone had a strong dominance, up to day +343 (Figure 21). Approximately 1.5 to 2.6 insertions are thought to be present in the gene modified cell transplants based on the average copy number per CD34 cell transplanted and its relation to the percentage of gp91phox protein expression in CD34 cells infused. In line with this average, LAM-PCR analysis of colonies sampled from long-term repopulating cells demonstrated that the CFU colonies contained between 1 and 4 integrants per cell (Figures 20, 21).
[0076] The highest frequency of PRDM 16 related integration sites retrieved from patient P1 by LAM-PCR was obtained at day +157 (30% of the transduced cell pool) and then continuously decreased until day +542 (1.1%). In patient P2, the frequency of PRDM16 inserted clones decreased from day +175 (23.7%) to day +343 (12.8%). Conversely, during the same time period, the frequency of MDS1/EVI-1 integrants increased in P1 from 12% to
90.1% and in P2 from 20.6% to 64.9%. On day +304, SETBP1 insertions accounted for 8.4% of all integrants in P1, but from day +339 no further SETBP1 insertions were detected by LAM-PCR. Residual activity of individual SETBP1 clones could be detected by tracking PCR on days +381, +416, +472 and +542 (Table 2).
[0077] The mechanistic relevance of these insertions can be demonstrated by the detection of specific mRNA transcripts in bone marrow (BM) from P1. Elevated levels (>1 log) of PR domain positive MDS1/EVI-1, PRDM 16 and of SETBP1 mRNA transcripts were found by RT-PCR.
[0078] As demonstrated herein, retrovirus gene activation can occur as a consequence of any retrovirus vector insertion event, and may be of influence on the biological fate of the target cell. The location of an insertion defines the likelihood of whether such events lead to side effects, ultimately depending on the biological relevance of a gene for the affected cell type, in this case hematopoiesis. This data is of very significant influence for the efficacy and biosafety assessment of gene therapy vectors in ongoing and future clinical trials. Depending on the clinical outcome, this insertional side effect, very likely favored by reinfusion of high numbers of gene corrected CD34+ BM cells containing insertion events, may have facilitated the therapeutic success observed.
[0079] The above described analysis demonstrates a previously unknown role of PR domain genes and SETBP1 in the proliferation of morphologically normal long-term repopulating progenitor cells. This finding can be used to treat a number of mammalian diseases, as described below.
Functional properties of MDSl/EVI-1. PRDM 16. and SETBPl clones
[0080] To confirm the functional influence of these insertions via gene activation, specific mRNA transcripts were analyzed by RT-PCR (as described in Example 6). At day +381 bone marrow cells from patient P1 contained substantially elevated levels of both MDS1/EVI-1 and of SETBP1 mRNA transcripts, whereas PRDM 16 transcripts were present at levels comparable to control bone marrow (Figure 22). RNA microarray analysis of the same sample using the Affymetrix HG U133_Plus_2.0 Array confirmed overexpression of MDS1/EVI-1 or EVI-1 (36-fold) and SETBP1 (32-fold). Abnormal expression of PRDM16
was not found. RT-PCR performed on RNA samples obtained from peripheral blood leukocytes from patient P2 at days +287 and +343 showed overexpression of MDS1/EVI-1 and PRDM 16, while SETBP1 transcripts were not detected. A microarray analysis of the same samples revealed a 74-fold overexpression of MDS1/EVI-1.
[0081] Transduced cells were strictly dependent on growth factors for proliferation and differentiation. No colony formation was observed when bone marrow mononuclear cells (patient P1: days +122, +192 and +241) were plated on methylcellulose and cultured for 14 days in the absence of cytokines (as described in Example 7). Colony forming cells (CFCs) derived from CD34+ cells of patient P1 at day +381 were replated in the presence of cytokines into secondary and tertiary methylcellulose cultures. Few cell clusters were visible after the second replating, while no growth was observed in further replatings, indicating the absence of self-renewal capacity. Similar results were obtained with cells from patient P2 at day +245. Furthermore, 1000 human CD34+ cells derived from patient P1 at day +381 were injected into each of two nude nonobese diabetic-severe combined immunodefϊcient (NOD-SCID) B2m~/~ mice. No engraftment of CD45+ cells in these mice were observed.
Functional reconstitution of phagocytic killing activity
[0082] Expression of gp91phox was detected by FACS using the monoclonal antibody 7D5 (as described in Example 8 and Yamauchi, A. et al. Location of the epitope for 7D5, a monoclonal antibody raised against human flavocytochrome b558, to the extracellular peptide portion of primate gp91phox. Microbiol Immunol 45, 249-257 (2001), herein incorporated by reference in its entirety). Gρ91phox was present mainly in CD 15+ cells with as many as 60% (patient P1, day +304) and 14% (patient P2, day +287) of the cells expressing the transgene. Correctly assembled flavocytochrome_b558 heterodimers were found by spectroscopy in cell membrane extracts from granulocytes obtained from P1 and P2. Gp91phox expression was also detected in bone marrow derived CD34+ cells from P1 +381 days posttransplantation (Figures 23,24).
[0083] Functional reconstitution of respiratory burst activity in peripheral blood leukocytes (PBLs) was assayed after stimulation with opsonized E. coli by the
dihydrorhodamine (DHR) 123 assay (Figures 25,28) (as described in Example 12). NADPH oxidase activity was detected in 10% to 20% of P1 leukocytes until day +122. Thereafter, a strong increase in the number of oxidase positive cells was observed. As many as 57% of patient Pi's leukocytes tested positive for superoxide production at day +304, followed by a decrease to 34.4% at day +542 (Figure 25). Similar results were obtained with purified granulocytes after stimulation with phorbol 12-myristate 13 -acetate (Figure 26) or by monitoring the reduction of nitroblue tetrazolium (NBT) to formazan in gene corrected neutrophils (Figure 27).
[0084] The time course of superoxide production was very similar in patient P2. The number of oxidase positive cells was high (>35%) shortly after infusion of gene- transduced cells, but decreased to 9.6% at day +149 post-transplantation. Subsequently, an increase in the number of oxidase positive cells of up to 24% (day +245) was observed (Figures 28, 29). This value decreased to 15.3% at day +287 and fluctuated thereafter between 19.8% (day +413) and 15% (day +491). These results were confirmed by the NBT assay on individual neutrophils (Figure 30).
[0085] Superoxide production was quantified in patient neutrophils by the cytochrome C reduction assay [Mayo, L.A. & Curnutte, J.T. Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. Methods Enzymol 186, 567- 575 (1990), herein incorporated by reference in its entirety]. Total neutrophils obtained from patient P1 at day +193 produced 1.23 nmol superoxide/ 106 cells/min, which corresponds to 4.13 nmol/106 cells/min after correction for the number of oxidase positive cells at this time point (33%). Similarly, total neutrophils from patient P2 at day +50 produced 2.12 nmol superoxide/ 106 gene-corrected cells/min. In comparison, the amount of superoxide produced by wild type neutrophils was 14.35 ±6.28 nmol superoxide/106 cells/min (n=10; Figure 31).
[0086] Since the level of superoxide production in gene-corrected cells was at most one-third to one-seventh of the level measured in wild type cells, these cells were tested to determine whether they could kill ingested microorganisms. Bacterial killing was measured by monitoring β-galactosidase activity released by engulfed and perforated E. coli (as described in Example 9 and by Hamers, M.N., Bot, A.A., Weening, R.S., Sips, HJ. & Roos, D. Kinetics and mechanism of the bactericidal action of human neutrophils against
Escherichia coli. Blood 64, 635-641 (1984), herein incorporated by reference in its entirety). In this assay, X-CGD cells showed minimal β-Gal activity due to impaired perforation capacity in the absence of superoxide production (Figure 32). In contrast, gene corrected granulocytes obtained from patients P1 (day +473) and P2 (day +344) showed a substantial increase in β-Gal activity, illustrating improvement in antibacterial activity in neutrophils of both patients after gene therapy.
[0087] These results were confirmed by electron microscopy visualization of bacterial killing by healthy, X-CGD or gene corrected neutrophils from patient P1 (as described in Example 10 and illustrated in Figure 33). Phagocytosis of E. coli was observed in all samples. However, the morphology of E. coli inside of the phagocytic vacuole differed drastically between specimens. While the vast majority of E. coli ingested by X-CGD granulocytes were not degraded (Figures 33b,e), E. coli ingested by wild type granulocytes showed clear signs of degradation as revealed by necrotic microorganisms with irregular morphology (Figures 33 d,h). Neutrophils from patient P1 consisted of a mixture of cells with clear bacterial degradation (lower circle, Figures 33c,g), and others without signs of bacterial degradation that were indistinguishable from non-corrected controls (upper circle, Figures 33c,f). Similarly, gene corrected granulocytes obtained from P1 at day + 381 were able to degrade Aspergillus fumigatus hyphae as demonstrated by an enzymatic assay [Rex, J.H., Bennett, J.E., Gallin, J.I., Malech, H.L. & Melnick, D.A. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 162, 523-528 (1990), herein incorporated by reference in its entirety] and transmission electron microscopy (Figure 34).
Clinical resolution of infection
[0088] Prior to gene therapy, the combination of whole body positron emission tomography (PET) and computed tomography (CT) scanning (as described in Example 13) revealed an active bacterial or fungal infection in each of the two patients. For patient P1, a high focal uptake of fluorine-18-fluoro-2-deoxy-D-glucose (18F-FDG) was observed in two hypodense lesions in liver segments VD/VIII and VTfI, representing Staphylococcus aureus abscesses (Fig. 35a, circle). Similarly, patient P2 had suffered from severe invasive
pulmonary aspergillosis due to A. fumigatus, visualized by 18F-FDG uptake in PET/CT scanning as a cavernous cavity extending from the apical to the posterior segment of the superior lobe on the right side (Fig. 35c, circle). Repeat scans performed 50 days after administration of gene-transduced cells showed no evidence of lesions in the liver of patient P1 (Figure 35b), while only minimal 18F-FDG activity was evident at day +53 post therapy in the cavity wall of patient P2 (Figure 35d). Follow-up analysis of the patients has not revealed any reappearance of these lesions. These and other clinical parameters (as described in Examples 14-20) demonstrate that gene therapy provided a therapeutic benefit to both patients.
Treatment to increase cell proliferation by administering a retroviral vector
[0089] In some embodiments of the invention, a patient in need of hematopoietic cell proliferation can be treated by retroviral insertion methods. For example, a patient cell sample can be transfected with a retroviral or other type of gene vector carrying these genes, or activating their cellular alleles, using methods known to those of skill in the art. The cells can then be reinfused into the patient. Cell counts can be performed periodically to determine the effectiveness of the blood cell proliferation treatment. The amount of cells to be transfected, the ratio of viral vector to cells, cell growth methods, and readministration methods can be varied as needed to treat the particular disorder. The progress can be followed, for example, by LAM-PCR to confirm the activation of EVI-related genes. (Figures 9-10, 14-15)
[0090] If desired, the retroviral vector or other gene vector can be administered to the patient directly, rather than to cells that have been isolated from the patient.
[0091] The method can be used to expand any type of mammalian cell. Examples of the types of cell that may be expanded include but are not limited to a stem cell, an embryonic stem cell, an adult stem cell, a multipotent stem cell, a pluripotent stem cell, a hematopoietic cell, a hematopoietic stem cell, a progenitor cell, a myelopoietic stem cell, a peripheral blood cell, non-hematopoietic stem cells or progenitor cells, and the like. The cells to be treated can be present in a cell culture, or can be present in the body.
[0092] The retroviral vector insertion or other vector transfer can be used to treat many cell-based diseases, in addition to the CGD shown herein. Any disease where an increase in cell proliferation is helpful can be treated by the method of the invention. Examples of such diseases include but are not limited to inherited diseases (severe combined immunodeficiencies, anemias like Fanconi anemia), cancer, AIDS, and the like.
[0093] The invention can, in some embodiments, be used to predict the insertion location of a retroviral vector insertion in one patient, by following previous insertion results of another patient or similar animal and in vivo models. For example, in the current CGD analysis, the earlier studied successfully treated patient had activating DNA insertions in similar positions as those of the later studied successful patient. This can be especially useful for early prediction of the likelihood of successful treatment. Further, a knowledge of where a successful insertion is likely to be located can make more simple assays, such as dipstick assays for EVI-1 (or related gene) gene or protein expression useful for a quick test to see if a patient is responding to treatment.
[0094] In some embodiments of the invention, a patient in need of gene- correction can be treated. The gene correction can be performed in an in vitro culture of cells isolated from the patient. To increase the proliferation of the gene-corrected cells, activation of the EVI-related genes can be performed. This can be done, for example, by administering a retroviral vector to the culture of gene corrected cells, allowing the cells to proliferate in vitro, then reinfusing or readministering said cells to the patient. These retroviral treated cells are then both gene corrected and fast growing, allowing the patient to receive the gene therapy more rapidly. Many types of gene corrections can be performed using this method. Examples of suitable genes for correction include but are not limited to single gene or multiple gene inherited disorders of the blood forming and immune system or other body tissues that can be complemented, treated or stabilized by gene transfer, and the like. Examples include but are not limited to X-SCID, ADA-SCID, CGD, alpha 1 antitrypsin deficiency, and the like.
Methods of treatment involving transfection of cells with EVI-related genes and SETBPl
[0095] Because of the surprising finding that the repopulated cells of the successfully treated CGD patients had activating insertions in the EVI-related genes and SETBP1, it is likely that other methods of increasing levels of EVI-related and SETBP1- related gene products can increase proliferation rates. Accordingly, in some embodiments of the invention, a nucleic acid encoding EVI-1, PRDM 16, or SETBP1 is operably linked to a transcriptional regulatory sequence, and transfected to a cell. The exogenous nucleic acid can be, for example, integrated into the genome, or can be present in the cell, for example, in the cytoplasm on a cytoplasmic vector. Thus, the nucleic acid can be stably or transiently expressed, transferred in synthetic form, including nucleic acid equivalents or mRNAs. The transcriptional regulator sequence, such as a promoter, can be chosen, for example, so as to allow for constitutive expression, conditional expression, or inducible expression.
[0096] Further, EVI-1, PRDM 16, or SETBP1 polypeptides, or fragments thereof, can be administered to a cell, hi some embodiments, active synthetic peptide analogs derived from EVI-1, PRDM 16, or SETBP1 polypeptide sequences can be administered to a cell, either in culture or in a patient, to allow increased cell proliferation.
[0097] It may be desirable to grow cells that express the EVI-related and / or SETBP1 genes for a short period of time only, in order to increase the rate of cell proliferation. This can be achieved, for example, using specific inducible promoters or transient expression methods as known in the art. In such situations, when the high rate of cell proliferation is achieved, the expression of the EVI-related and SETBP1 genes can be turned off by, for example, removing the inducing agent from the cell environment.
[0098] The method can be suitable for increasing the proliferation of cells that are gene-corrected, or non-corrected. The method can be used for increasing the proliferation of any type of mammalian cell.
[0099] Depending on the desired effect, EVI-related and SETBP1 -related gene expressing cells can be allowed to proliferate for several cycles before being reinfused into the patient. For example, the cells can proliferate for about 1, 3, 5, 8, 10, 13, 17, or 20 or division cycles, prior to reinfusion into the patient, if desired.
Agents that upregulate EVI-related and SETBPl genes
[0100] In additional embodiments of the invention, cell proliferation can be increased, either in vitro or in vivo, by contacting the cells to be proliferated with agents that can upregulate or modulate endogenous EVI-related and SETBP1 genes. Cell culture assays can be performed to determine candidate agents from a library of potential compounds, if desired. Test compounds that modulate EVI-related and SETBP1 gene expression are then chosen for further testing. This method can be used to find pharmaceutically valuable agents that can increase cell proliferation in vitro or in vivo.
Expansion of gene-corrected cells
[0101] Many gene therapy methods involve obtaining a cell from a patient in need of gene correction, then transforming the cell to add a corrected copy of a gene. The cell is then proliferated and eventually the patient is readministered with a large amount of corrected cells. One common problem with such a gene-corrected cells may grow slowly, and may not be able to repopulate the patient adequately for a noticeable improvement to occur.
[0102] In such situations, the addition of an EVI-related gene as described herein, such as EVI-1, PRDMl 6, or SETBP1, and the like, either constitutively or transiently, can increase the proliferation of the gene-corrected cells so that successful readministration and treatment is more likely to occur. This modulation of EVI-related gene expression can be done by several means, such as simply administering the retroviral vector to gene-corrected cells, or, for example, by traditional molecular cloning methods.
[0103] In some embodiments of the invention, a method of forming a bodily tissue is provided, by obtaining a desired cell type from a patient, if desired, treating the cell with a nucleic acid to accomplish a gene-correction, treating the cell to allow for increased expression of an EVI-related and/or SETBP1 gene to cause increased cell proliferation, and treating the cell so as to form a desired tissue. The tissue can then be readministered into the patient as a form of gene therapy.
Use of LAM-PCR to identify genes that increase cell proliferation using LAM-PCR
[0104] Additional embodiments of the invention provide for a method of identifying genes whose modulation (such as upregulation or downregulation) can increase
the proliferation rate, selective advantage, or persistence of a stem or progenitor cell. The method can involve obtaining a transfected cell, allowing it to proliferate for several cycles, then testing using LAM-PCR to determine where the successfully repopulated cells have the nucleic acid insertions. The testing can be performed, if desired, over a period of time to determine how the insertion sites change over time. Candidate genes can then be chosen for further analysis. As an example of this method, Table 1 shows a list of exemplary genes found to contain retroviral insertions in at least one of the two successfully treated CGD patients.
Insertion sites for nucleic acid insertion that allow for increasing cell proliferation
[0105] As shown herein, integration of an exogenous sequence into specific regions of the genome resulted in an increase in cell proliferation, selective advantage, or persistence. A representative example of such integration site sequences (50bp genomic DNA in bold and 50bp vector DNA underlined) is shown below:
5 ' CTTCTCTGGAAAATTCCTCATAAGAAAACTGiVAATTCAAGCTCCTGCTCGTGAAAGACCC CACCTGTAGGTTTGGCAAGCTAGCTGCAGTAACGCCATTT 3 '
[0106] Many other insertion sites, as well as genes, identified to be downstream of these insertion sites, are shown in Table 1. These genes include but are not limited to MGC10731, PADI4, CDA, CDW52, ZBTB8, AK2, FLJ32112, TACSTD2, FLJ13150, MGC24133, NOTCH2, NOHMA, EST1B, PBXl, PLA2G4A, HRPT2, ATP6V1G3, PTPRC, NUCKS, CABC1, LOC339789, PRKCE, AFTffHHIN, NAGK, MARCH7, DHRS9, PRKRA, SESTD1, MGC42174, CMKOR1, TBC1D5, THRB, MAP4, IFRD2, ARHGEF3, FOXP1, ZBTB20, EAF2, MGLL, PLXND1, SLC9A9, SELT, CCNLl, MDS1, BCL6, MIST, STM2, TEC, OCIAD1, FLJ10808, SEPTIl, PRKG2, MLLT2, PGDS, MANBA, SRYl, SET7, MAML3, DCTD, CARF, IRF2, AHRR, POLS, ROPN1L, FLJ10246, POl 1, C2GNT3, SSBP2, EDIL3, SIAT8D, FLJ20125, GNB2L1, C6orfl05, JARID2, C6orf32, HCG9, MGC57858, TBCC, SENP6, BACH2, REPS1, HDAC9, OSBPL3, H0XA7, CALN1, FKBP6, NCF1, HIP1, GNAI7, ZKSCAN1, MGC50844, LOC346673, CHRM2, ZH3HAV1, REPIN1, SMARCD3, CTSB, ADAM28, LYN, YTHDF3, SMARCA2, C9orf93, NPR2, BTEBl, ALDHlAl, AUH, C9orf3, WDR31, CEP1, GSN, RABGAP1, ZNF79, CUGBP2, C10orf7, PTPLA, PLXD2, ACBD5, PRKGl, MYST4, IFIT1, C10orfl29, CUEDC2,
FAM45A, GRK5, OR52NI, OR2AG2, ZNF143, C1lorfB, LM02, NGL-I, DGKZ, NR1H3, KBTBD4, C1QTNF4, MGC5395, ARRBl, FLJ23441, FGIF, MAML2, LOC196264, HSPC063, ELKS, CACNA2D4, CHD4, EPS8, LRMP, NEUR0D4, RNF41, FAM19A2, RASSF3, PAMC1, PLXNC1, DAP13, MGC4170, FLJ40142, JIK, CDK2AP1, GPR133, PCDH9, C13orf25, ABHD4, AP4S1, MIA2, RPS29, PSMC6, RTN1, MED6, C14orf43, C14orfll8, RPS6KA5, GNG2, PAK6, B2M, ATP8B4, TRIP4, CSK, MESDC1, RKHD3, AKAP13, DET1, DKFZp547K1113, SV2B, LRRKl, CHSYl, TRAF7, ZNF205, ABCC1, THUMPD1, IL21R, MGC2474, N4BP1, SLIC1, CDH9, GPR56, ATBF1, ZNRF1 , CMIP, MGC22001, C17orβl, SAT2, AD0RA2B, TRPV2, NF1, LOCI 17584, MLLT6, STAT5A, STAT3, HOXB3, HLF, MAP3K3, SCN4A, ABCA10, EPB41L3, ZNF521, RNF125, SETBP1, FLJ20071, CDH7, MBP, MBP, NFATC1, GAMT, MOBKL2A, NFIC, CALR, GPSN2, ZNF382, EGLN2, PNKP, LAIR1, ZNF579, SOX12, C20orG0, PLCBl, SNX5, LOC200261, ZNF336, BAKl, SPAG4L, EPB411L1, NCOA3, KIAA1404, STMN3, CBR3, DYRKlA, CSTB, C22orfl4, UPBl, MN1, XBP1, C22orfl9, RBM9, MYH9, TXN2, PSCD4, UNC84B, FLJ2544, ZCCHC5, MST4, EDS, UTY, SKI, PRDM16, PARK7, CHC1, ZMYMl, INPP5B, GLIS1, SLC27A3, ASHlL, SLAMF1, PBXl, CGI-49, ELYS, RNF144, FAM49A, FLJ21069, SFRS7, SPTBN1, TMEM17, ARHGAP25, FLJ20558, CAPG, PTPN18, RBMS1, LOC91526, KLF7, FLJ23861, CMKOR1, CRBN, ITPR1, RAFTLIN, TNA, CCDC12, FHIT, VGL-3, PPMlL, EVI-1, MDS1, HDSH3TC1, DHX15, TMEM33, CXCL3, EPGN, LRBA, FLJ25371, CPE, POLS, PTGER4, LHFPL2, C5orfl2, CETN3, PHF15, PFDN1, KIAA0555, GNB2L1, HLA-E, SLC17A5, UBE2J1, BACH2, HIVEP2, SNX8, TRIAD3, RAC1, ARL4A, ELMOl, BLVRA, SUNC1, ABCA13, GTF2IRD1, RSBN1L, ADAM22, MLL5, IMMP2L, SEC8L1, FLJ12571, CULl, ANGPT1, DEPDC6, EPPKl, MLANA, MLLT3, SMUl, TLE4, C9orf3, ABCAl, STOM, RABGAP1, NEK6, NR5A1, MGC20262, FLJ20433, MAP3K8, ARHGAP22, C10orf72, TACR2, NKX2, OBFC1, VTIlA, ABLMl, FLJ14213, MS4A3, B3GNT6, NADSYN1, CENTD2, MAML2, ATP5L, FLIl, CACNAlC, HEBP1, MLSTD1, IPO8, ARID2, SLC38A1, KRT7, USP15, KIAA1040, WIF1, CGI-119, DUSP6, FLJl 1259, CMKLR1, SSHl, TPCN1, FLJ42957, JIK, FLT3, TPT1, FNDC3, ARHGAP5, ARF6, GPHN, C14orf4, STN2, PPP2R5C, CDC42BPB, CEP152, OAZ2, AKAP13, CHSYl, CRAMP1L, MHC2TA, NPIP, SPN, MMP2,
DKFZp434I099, SIAT4B, PLCG2, MYOlC, C17orf31, MGC51025, WSBl, TRAF4, SSH2, HCA66, RPFL, DUSP14, TCF2, ZNF652, STXBP4, HLF, MSI2, VMP1, HELZ, TREM5, RAB37, SEC14L1, SEPT9, BIRC5, PSCD1, MGC4368, NDUFV2, C18orf25, ATP8B1, CDH7, FLJ44881, NFATC1, C19orf35, GNG7, MATK, C3, ZNF358, LYLl, F2RL3, ZNF253, ZNF429, KIAA1533, U2AF1L3, GMFG, BC-2, C20orf30, PLCBl, LOC200261, C20orfll2, ADA, PREXl, C21orf34, C21orf42, ERG, ABCGl, MN1, HORMAD2, LOCI 13826, C22orfl, EFHC2, SYLT4, MGC27005, FHLl, GAB3, and CSF2RA.
EXAMPLES
[0107] The following examples are offered to illustrate, but not to limit, the claimed invention.
Background: Clinical history of Patient Pl and Patient P2 Before and After Gene Therapy
[0108] First diagnosis of X-linked chronic granulomatous disease (X-CGD) in patient P1 was done in 1981. He suffered from severe bacterial and fungal infections as well as granuloma of the ureter with stenosis, pyeloplastic operation (1978), liver abscesses (1980), pseudomonassepticemia (1985), candida-oesophagitis(1992), salmonellasepticemia (1993), severe osteomyelitis, spondylitis with epidural and paravertebral abscess and corporectomy (June 2002). Since 2003 severe therapy-resistant liver abscesses {Staph, aureus) were diagnosed. On admission to the hospital in Frankfurt, the patient was treated with clindamycin, cefalexin, cotrimoxazol and itraconazol, the later two as standard long- term prophylaxis. Treatment was changed from clindamycin to rifanipicin orally. After gene therapy and resolution of the liver abscesses, rifampicin was removed (day +65) and the patient was kept under standard prophylactic care with itraconazol. During the follow-up and concomitant increase in gene marked cells with effective killing of Aspergillus fumigatus, itraconazol was also removed (day +381). No reappearance of liver abscesses and no positive bacterial culture were observed until the last monitoring time point. The patient had a net weight gain of 10 kg since transplantation and a marked decrease of lung granulomas in the CT scan. Lung function was stable.
[0109] First diagnosis of X-CGD for patient P2 was in 1979. He suffered from cervical lymph node abscesses (1983), meningitis (1985), parotis abscesses (1990), two liver
abscesses, cervical lymph node abscesses (1991 and 1992), sinusitis maxillaris (1995), bilateral hidradenitis axillaris and pneumonia (2000). Since 2002 he was suffering from bilateral lung aspergillosis with cerebral emboli and formation of a lung cavity. The patient was admitted to the hospital treated by voriconazol and cotrimoxazol. After gene therapy a complete resolution of the aspergillosis was observed, but no improvement in lung function was observed due to excess abuse of nicotine. The patient developed a mycoplasma pneumonia (positive serological IgM titers, no antigen positivity in serum and sputum, negative culture after bronchoalveolar lavage) and sinusitis maxillaris on day +149. He was treated with oral clindamycin for 3 weeks. During gene therapy and busulfan treatment, the voriconazol treatment was changed to liposomal amphotericin B until day +23. Voriconazol treatment was restarted on day +24. No hospital admissions after gene therapy and no positive bacterial cultures were observed. P2 is currently still under cotrimoxazole/voriconazole prophylaxis because the number of oxidase positive cells and the amount of superoxide production per cell were less than 20%. Furthermore, killing of A. fumigatus could not be demonstrated in vitro.
EXAMPLE l Description of the Vector and Gene Transfer Protocol for Treatment of the
2 Successfully-Treated CGD Patients Receiving Gene Therapy [0110] For the construction of the retroviral vector SF71gp91phox the pSF71 backbone [Hildinger, M. et al. FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells. Gene Ther 5, 1575-1579 (1998), herein incorporated by reference in its entirety] was used, in which the coding region of gρ91phox was inserted by standard molecular cloning. In this vector, gp91phox expression is driven by the Friend mink cell Spleen focus-forming virus (SFFV) LTR, which has been shown to be highly active in stem and myeloid progenitor cells [Baum, C. et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 69, 7541-7547 (1995), herein incorporated by reference in its entirety]. Vector containing supernatants were obtained from a stable PG 13 packaging cell line in X-VIVO10 at a titer of 1 x 106 TU/ml. CD34+ cells were prestimulated for 36 hours at
a density of 1 x 106 cells/ml in X-VIVO 10 medium + 2 mM L-glutamine, supplemented with EL-3 (60 ng/ml), SCF (300 ng/ml), Flt3-L (300 ng/ml), and TPO (100 ng/ml) (Strahtman Biotech, Dengelsberg, Germany) in Lifecell Bags (Baxter). Following prestimulation, cells were adjusted to a density of 1 x 106 cells/ml in cytokine containing medium as described above. Transduction was performed in tissue culture flasks coated with 5 μg/cm2 of CH-296 (Retronectin, Takara, Otsu, Japan) and preloaded with retroviral vector containing supernatant as described previously [Kuhlcke, K. et al. Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels. MoI Ther 5, 473-478 (2002), herein incorporated by reference in its entirety]. After 24 hours cells were pelleted and cell density was again adjusted to 1 x 106 cells/ml in cytokine containing medium. Cells were incubated on freshly coated/preloaded flasks for another round of transduction. This procedure was repeated once more for a total of three transduction rounds. 24 hours after the final transduction, cells were harvested and analyzed for phenotype and gene transfer efficiency, transported to the transplantation unit and reinfused into the patients.
[0111] End of production materials were also tested for the presence of replication competent retroviruses by the extended XC plaque assay [Cham, J.C. et al. Alteration of the syncytium-forming property of XC cells by productive Moloney leukemia virus infection. Cancer Res 35, 1854-1857 (1975), herein incorporated by reference in its entirety] and by a gag-specific PCR as follows: Primers 5'- AGAGGAGAACGGCCAGTATTG-S1 (SEQ ID NO: 136) and 5r- ACTCCACTACCTCGCAGGCATT-3' (SEQ ID NO: 137) were used to amplify a 69-bp fragment of the retroviral gag cDNA. Amplification was detected with a FAM-labelled gag- probe (5I-TGTCCGTTTCCTCCTGCGCGG-3I) (SEQ ID NO: 138). The human EPO receptor gene was used as an internal amplification control. PCR reactions were carried out for 40 cycles in a single tube. Each reaction cycle consisted of 15 seconds at 94°C followed by 1 minute at 60°C.
[0112] The pretreatment preparation, treatment, and clinical examination of the 2 successfully treated CGD patients is described further in Ott, M. G. et al. Correction of X- linked chronic granulomatous disease by gene therapy, augmented by insertional activation of
MDS1-EVl, PRDM16 or SETBP1. Nat Med 12(4):401-409, (2006), hereby incorporated by reference in its entirety.
EXAMPLE 2
Description of the Gp91phox PCR Method
[0113] The ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Weiterstadt, Germany) was used to determine the presence of proviral sequences in genomic DNA isolated from the blood and bone marrow cells of patients P1 and P2. The exon 8 primer gp91-f (5'-GGTTTTGGCGATCTC AACAGAA-3') (SEQ ID NO: 1) and exon 9 primer gp91-r (5I-TGTATTGTCCCACTTCCATTTTGAA-3I) (SEQ ID NO: 2) were used to amplify a 114-bρ fragment of the gp91phox cDNA. Amplification was detected with the FAM-labelled probe gp91-p (5'-TCATCACCAAGGTGGTC ACTCACCCTTTC-S1) (SEQ ID NO: 3). The human EPO receptor gene was used as an internal control to quantify the gp91phox reaction. Primers hepo-f (5'-CTGCTGCCAGC TTTGAGTACACTA-S1) (SEQ ID NO: 4) and hepo-r (5'-GAGATGCCAGAGTCAGATACCACAA-S') (SEQ ID NO: 5) amplified a 138-bp fragment from exon 8 of the 2£P0-receptor-gene. Amplification was determined by the VIC-labelled probe hepo-p (5'-ACCCCAGCT CCCAGCTCTTGCGT-S') (SEQ ID NO: 6). Both reactions were carried out in a single tube. The amplification cycle was 15 s at 94 °C followed by 1 min at 60 °C. hi each experiment, the amplification of DNA generated from HT 1080 cells containing a single copy of a gp91phox vector mixed with wild type HT1080 cells in defined ratios was used to quantify the percentage of SF71 gp91phox integrations per human genome. The percentage of transduced cells was estimated from the values obtained from the quantitative PCR (Q-PCR), which represent vector copies per diploid genome, after dividing by two to account for the mean of two proviral copies per transduced cell. Similarly, genomic DNA was isolated from individual bone marrow colonies and analyzed for the presence of vector derived sequences by nested PCR using gp91phox specific primers. The primers used for first PCR (95 °C, for 5 min, 95 °C for 1 min, 56 °C for 1 min, 72 °C for 1 min, for 30 cycles) were gpforOl: (5'-TTGTACGTGGG C AGACCGC AG AGA-3') (SEQ ID NO: 7) and gprevO2: (5'- CCAAAGGGCCCATCAACCGCTATC-3') (SEQ ID NO: 8). Nested PCR was done under
similar conditions using the primer combination P8: (5'- GGATAGTGGGTCCCATGTTTCTG-3') (SEQ ID NO: 9) and RI l: (5'- CCGCTATCTTAGGTAG TTTCCACG-3') (SEQ ID NO: 10). As an internal control the EPO-R gene was amplified in parallel with the primer combination hEpo-F1: (5'- GAGCCGGGGACAGATGATGAGG-S') (SEQ ID NO: 11) and hEpo-R1: (5'- GCGGCTGGGATAAGGCTGTTC-3') (SEQ ID NO: 12) for the first PCR reaction and primers hepo-f (SEQ ID NO: 4) and hepo-r (SEQ ID NO: 5) for the nested PCR primers.
EXAMPLE 3 Integration Site Analysis by the Linear Amplification Mediated (LAMVPCR Method
[0114] 100 ng of DNA from peripheral blood leukocytes was used for integration site analysis that was performed by LAM PCR as previously described (Schmidt, et al. (2002) Blood 100:2737-2743; Schmidt, et al. (2003) Nature Med. 9:463-468, each of the foregoing which is hereby incorporated by reference in its entirety) but biotinylated primer LTR I (5'XϊTT TGG CCC AAC GTT AGC TAT T<3') (SEQ ID NO: 13) was used for the initial linear amplification of the vector genome junctions. Following magnetic capture, hexa- nucleotide primed double strand synthesis with Klenow polymerase, restriction digest using Msel, HinP1I, or Tsp5091 and ligation of a restriction site complementary linker cassette allowed amplification of the vector genome junctions. For the 1st and 2nd exponential PCR amplification, vector specific primers LTR II (5'>GCC CTT GAT CTG AAC TTC TC<3') (SEQ ID NO: 14) and LTR IH (5'>TTC CAT GCC TTG CAA AAT GGC<3 ') (SEQ ID NO: 15) were used in combination with linker cassette specific primers LC I (5'>GAC CCG GGA GAT CTG AAT TC3') (SEQ ID NO: 16) and LC II (5>GAT CTG AAT TCA GTG GCA CAG<3') (SEQ ID NO: 17), respectively. LAM-PCR amplicons were purified, shotgun cloned into the TOPO TA vector (Invitrogen, Carlsbad, CA) and sequenced (GATC, Konstanz, Germany). Sequences were aligned to the human genome (hgl7, release 35, May 2004) using the UCSC BLAT genome browser (available on the world wide web at ucsc.genome.edu). (See also Table 1.) Relation to annotated genome features were studied with the same tool. Sequences that could not be mapped were either too short (< 20 bps, 136
sequences, 15.5% of all obtained sequences), or showed no definitive hit or multiple hits on the human genome (40 sequences, 4.5% of all obtained sequences).
EXAMPLE 4
Qualitative Tracking of Individual Common Insertion Site CCIS) Clones [0115] Individual MDS1/EVI-1, PRDMl 6, and SETBP1 related insertions were followed over time using clone specific nested primer sets (Perkins, A. S. et al. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. MoI Cell Biol 11, 2665-2674 (1991), hereby incorporated by reference in its entirety). To identify clones with possible predominance, PCR tracking was performed on 10 ng of GenomiPhi™ DNA Amplification Kit (Amersham) pre-amplified DNA from patient peripheral blood leukocytes. 0.5% of the pre-amplified DNA served as template for an initial amplification by PCR with the genomic flanking primer FP1 (SEQ ID NOs: See Table 4) and the vector specific primer LTR I (SEQ ID NO: 13). 2% of this product was applied to a nested PCR with FP2 (SEQ ID NOs: See Table 4) and LTR II (SEQ ID NO: 14) using the same conditions. The products were separated on a 2% agarose gel. Individual ones were purified and sequenced (GATC) (Table 2). Clone specific genomic flanking primers are listed in Tables 3 and 4 (SEQ ID NO: 18 through SEQ ID NO: 135, Table 4). PCR cycling conditions were performed for 35 cycles of denaturation at 95°C for 45 s, annealing at 56-58°C for 45 s and extension at 72°C for 60 s, after initial denaturation for 2 min and before final extension for 5 min.
Table 3a
Table 3b
TABLE 4
EXAMPLE 5
Quantitative Competitive (QC) PCR Analysis
[0116] To calculate the proportional contribution of individual predominant clones to gene corrected myelopoiesis, an internal standard (IS) PCR template revealing a 26- bp deletion within the 5'LTR vector sequence was generated for each vector genome junction of interest [Hoyt, P.R. et al. The Evil proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 65, 55-70 (1997), hereby incorporated by reference in its entirety]. The coamplification of a certain amount of 'wild- type' (WT) patient DNA with a defined copy number of IS allowed estimation of the abundance of the specific integrant in the patient DNA. QC-PCR was performed with defined dilutions of IS (50 copies and 500 copies) added to 50ng of patient DNA. Using vector primer LTR I (SEQ ID NO: 13) and genomic flanking primer FP2 (SEQ ID NOs: See Table 4), the templates were coamplifϊed with 35 PCR cycles (denaturation at 95°C for 45 s, annealing at 54-60°C for 45 s, extension at 72°C for 60 s) after initial denaturation for 2 min and before final extension for 5 min. 0.1-2% of the reaction product was used as template for a second nested PCR, which was performed for 35 cycles with the same parameters as for the first PCR with primers LTR H (SEQ ID NO: 14) and FP3 (SEQ DD NOs: See Table 4). QC- PCR products were separated on a 2% agarose gel (Figures 18, 19 and Table 2). Primers used for the generation of IS and further QC-PCR are listed in Tables 3 and 4 (SEQ ID NO: 18 through SEQ ID NO: 135, Table 4).
EXAMPLE 6
Methods of RNA Extraction and Analysis
[0117] Total RNA was extracted from bone marrow derived from patient 1 and a healthy donor with the RNeasy Mini Kit (Qiagen). cDNA was synthesized using the First Strand cDNA Synthesis Kit (Amersham) with whole RNA extracted and 0.2 μg of Not I d(T)18 primer (5'>AAC TGG AAG AAT TCG CGG CCG CAG GAA<3') (SEQ ID NO: 139). A 35 cycle actin PCR was carried out as a loading control using primers actin-1 (5'- TCCTGTGGCATCCACGAAACT-3') (SEQ ID NO: 140) and actin-2 (5'-
GAAGCATTTGCGGTGGAC GAT-3') (SEQ ID NO: 141) for 5 min at 95 °C, 1 min at 95 °C, 1 min at 58 °C, 1 min at 72 °C, and 10 min at 72 °C.
[0118] EVI-1 and MDS1-EVI-1 transcripts were detected, by ICR with primers EVT1-ex5-F2 (5'-TGGAGAAACACATGCTGTCA-3') (SEQ ID NO: 142) and EVl1-ex6-R2 (5'-ATAAAGGGCTTCACA CTGCT-3') (SEQ ID NO: 143). To amplify only PR domain positive MDS1-EVI-1 transcripts, cDNA was subjected to a 36 cycle PCR using primers MDS1-ex2-F1 (5'-GCCACATCCAGT GAAGCATT-3') (SEQ ID NO: 144) and EVl1-ex2- R1 (5 '-TGAGCCAGCTTCCAACATCT-3') (SEQ ID NO: 145). 2% of the PCR product was introduced into a second PCR using nested primers MDS1-ex2-F2 (5'- AGGAGGGTTCTCCTTACAAA-3') (SEQ ID NO: 146) and EVl1-ex2-R2 (5'- TGACTGGCATCTATG CAGAA-3') (SEQ ID NO: 147).
[0119] To define the expression of PRDM16, a fragment of this PR domain was amplified using primer MEL1PR-F1 (5'-CTGACGGACGTGGAAGTGTCG-3') (SEQ ID NO: 148) with MEL1PR-F1 (5'-CAGGQGGTAGACGCCTTCCTT-3') (SEQ ID NO: 149), which hybridised in exon 3 and exon 5, respectively. 2% of the PCR product was amplified to a second PCR with primers MEL1PR-F2 (5'-TCTCCGAAGACCTGGGCAGT-3') (SEQ ID NO: 150) and MEL1PR-R2 (5'-CACCTG GCTCAATGTCCTTA-3') (SEQ ID NO: 151). Fragments of both the PR-containing and the non PR-domain containing form of PRDM16 were amplified using primer MEL1N-F1 (5'-CCCCAGATCAGCCAACTCACCA-3') (SEQ ID NO: 152) and MEL1N-R1 (5'-GGTGCCGGTCCAGGT TGGTC-3') (SEQ ID NO: 153). Nested PCR was performed with 2% of the product and primer MEL1N-F2 (5'- ACACCTGAGGACGCACACTG-3') (SEQ ID NO: 154) and MEL1N-R2 (5'- GGTTGCACAGGT GGCACTTG-3') (SEQ ID NO: 155). Expression level of SETBP1 was analyzed using primers SETBP-F1 (5'-TAAAAGTGGACCAGACAGCA-3') (SEQ ID NO: 156) and SETBP-R1 (5'-TCACGAAGTTG TTGCCTGTT-3') (SEQ ID NO: 157).
[0120] To assign whether there are fusion transcripts between the vector LTR and MDS1, EVI-1, or PRDM16, the primer U5 IV (5'>TCC GAT AGA CTG CGT CGC<3') (SEQ ID NO: 158) together with primer EVI-ex2-R1, MDS1-ex2-F1, or MEL1N-R1. Nested PCR was performed, with 2% PCR product and primer U5 VI (5 '>TCT TGC TGT TTG CAT CCG AA<3') (SEQ ID NO: 159) was used together with primer EVI1-ex2-R2 (SEQ ID NO;
147), MDS1-ex2-F2 (SEQ ID NO: 146), or MEL1N-R2 (SEQ ID NO: 155). Additionally, nested PCR was carried out with LTR I (SEQ ID NO: 13) and MELl-PR-F1 (SEQ ID NO: 148). 2% of the product was amplified with primer LTR II (SEQ ID NO: 14) and MELlPR- F2 (SEQ ID NO: 150). 36 cycle PCRs were accomplished with 3.33% of whole cDNA from patient 1 and 0.33% of whole cDNA from the normal donor for 2 minutes at 95°C, 45 seconds at 95°C, 45 seconds at 54°C, 1 minute at 72°C, and 5 minutes at 72°C. A 35 cycle actin PCR was carried out as a loading control with 0.0002-0.008% of cDNA and primers actin-1 (5'TCC TGT GGC ATC CAC GAA ACT 3') (SEQ ID NO: 140) and actin-2 (5' GAA GCA TTT GCG GTG GAC GAT 3') (SEQ ID NO: 141) for 5 minutes at 95°C, 1 minute at 95°C, 1 minute at 58°C, 1 minute at 72°C, and 10 minutes at 72°C.
EXAMPLE 7 Colony Assay Methods
[0121] Bone marrow mononuclear cells (l-5xlθ4) or CD34+ purified cells (1- 5x103) were plated on methylcellulose in the presence or absence of cytokines (50 ng/ml hSCF, 10 ng/ml GM-CSF, 10 ng/m hIL3 and 3 U/ml hEpo) (MethoCult, Stem Cell Technologies, Vancouver, Canada). Colony growth was evaluated after 14 days.
EXAMPLE 8
Method to Detect gp91phox Cell Surface Expression
[0122] Heparinized whole blood (100 μl) was incubated with the murine monoclonal antibody 7D5 [Nakamura, M. et al. Monoclonal antibody 7D5 raised to cytochrome b558 of human neutrophils: immunocytochemical detection of the antigen in peripheral phagocytes of normal subjects, patients with chronic granulomatous disease, and their carrier mothers. Blood 69, 1404-1408 (1987), herein incorporated by reference in its entirety] or an IgGl isotype control (Becton Dickinson, San Jose, CA) for 20 minutes. After washing, samples were stained with FITC-goat (Jackson ImmunoResearch, West Grove, PA,) or APC-goat (Caltag Laboratories, Burlingame, CA) anti-mouse antibodies. Lineage markers were determined using monoclonal antibodies against CD3 (HIT3a), CD 15 (HI98) and CD 19 (4G7). After erythrocyte lysis, stained cells were washed, fixed, and analyzed on a FACSCalibur (Becton Dickinson, San Jose, CA).
EXAMPLE 9 Killing Assay Methods
[0123] Neutrophils obtained either from an untreated CGD patient, or healthy donors were incubated with the E. coli strain ML-35, which lacks the membrane transport protein lactose permease and constitutively expresses β-galactosidase (β-Gal). Engulfment of E. coli ML-35 by wild type neutrophils is followed by perforation of the bacterial cell wall and accessibility to β-Gal, which is subsequently inactivated by reactive oxygen species [Hamers, M.N. et al. Kinetics and mechanism of the bactericidal action of human neutrophils against Escherichia coli. Blood 64, 635-641 (1984), herein incorporated by reference in its entirety]. 2x109 E. coli/ml were opsonized with 20% (v/v) Octaplas® (Octapharma AG, Lachen, Switzerland) for 5 min at 37°C. Opsonized E. coli (final concentration 0.9x108/ml) were added to granulocytes (0.9x107/ml) obtained from healthy donors or X-CGD patients after gene therapy. At defined time points granulocytes were lysed with 0.05% saponin (Calbiochem, Darmstadt, Germany) and samples were incubated with ImM ortho- nitrophenyl- βD-galactopyranoside (Sigma-Aldrich, Seelze, Germany) at 37 °C for 30 min. β-galactosidase activity was followed by standard procedures at 420 nm.
[0124] The Aspergillus fumigatus killing assay was conducted as described by Rex et al. [Rex, J.H. et al. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 162, 523-528 (1990), herein incorporated by reference in its entirety] with minor modifications. Briefly, Aspergillus spores were seeded in 12 well plates at a density of 5x104 spores per well in Yeast nitrogen with amino acids (Sigma-Aldrich, Seelze, Germany). Hyphae were opsonized with 8% Octaplas® (Octapharma AG, Lachen, Switzerland) for 5 min at room temperature. Subsequently, 1x 106 healthy granulocytes or 4x106 neutrophils from patient P1 were added. Following incubation at 37 °C, granulocytes were lysed at defined time points in 0.5% aqueous sodium deoxycholate solution for 5 min at room temperature. The mitochondrial activity of the remaining adherent hyphae was monitored by an MTT assay as described [Rex et al. 1990, supra, herein incorporated by reference in its entirety].
EXAMPLE 10
Transmission Electron Microscopy Methods
[0125] For evaluation of E. coli killing 5x107 opsonized E. coli were incubated with 5x106 granulocytes in HBSS+Ca/Mg containing 2% human albumin in a water bath shaker at 37 °C for 2.5 h. The cells were harvested by centrifugation and fixed in 2.5% glutaraldehyde in PBS at room temperature for 30 min. For the evaluation of Aspergillus fumigatus killing, 3x105 Aspergillus spores were seeded in a 4 cm petri dish in Yeast Nitrogen Base with amino acids (Sigma). Germination was induced by 6 h incubation at 37 °C followed by decelerated growth at room temperature over night. Hyphae were washed in HBSS+Ca/Mg and opsonized with 8% Octaplas® (Octapharma AG, Lachen, Switzerland) in HBSS+Ca/Mg containing 0.5% human albumin for 5 min at room temperature. The opsonized hyphae were incubated with 3×106 granulocytes in HBSS+Ca/Mg containing 0.5% human albumin for 2 h at 37 °C. Fixation was carried out by direct addition of glutaraldehyde to a final concentration of 2.5%. Glutaraldehyde fixed samples were washed three times in PBS, fixed in 2% osmium tetroxide in PBS for 30 minutes, and dehydrated in ethanol followed by embedding in Epon and polymerization at 60 °C for 2 days. Ultrathin sections of 60 nm were prepared using an Ultramicrotome (Ultracut E, Reichert). The sections were then post-stained with 5% aqueous uranyl acetate for 30 min and lead citrate for 4 min, and examined on a Philips CM 12 transmission electron microscope.
EXAMPLE Il
Immune Reconstitution Assay Methods
[0126] Immune reconstitution was monitored by four-color-flow cytometric assessment of T cell subsets, NK cells and B cells in peripheral blood (PB) samples on a Coulter Epics XL. Samples were labelled with the 45/4/8/3 or 45/56/19/3 tetraChrome reagents from Coulter (Krefeld, Germany). All antibodies were obtained from Coulter Immunotech (Marseilles, France). The percentages of cell subtypes determined in these analyses were used to calculate the absolute cell counts in a dual-platform approach.
EXAMPLE 12
Assay Methods for Granulocyte Function
[0127] Reconstitution of NADPH oxidase activity in neutrophils after gene therapy was assessed by oxidation of dihydrorhodamine 123 [Vowells, S.J., Sekhsaria, S., Malech, H.L., Shalit, M, & Fleisher, T.A. F1ow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 178, 89-97 (1995), herein incorporated by reference in its entirety], reduction of nitrobluetetrazolium13, reduction of cytochrome C [Mayo, L.A. & Curnutte, J.T. Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. Methods Enzymol 186, 567-575 (1990), herein incorporated by reference in its entirety] and flavocytochrome b spectral analysis [Bohler, M.C. et al. A study of 25 patients with chronic granulomatous disease: a new classification by correlating respiratory burst, cytochrome b, and flavoprotein. J Clin Immunol 6, 136-145 (1986), herein incorporated by reference in its entirety] according to standard protocols.
EXAMPLE 13 PET/CT-Scanning Methods
[0128] Whole body positron emission tomography (PET) using fluorine-18- fluoro-2-deoxy-D-glucose (FDG) was performed simultaneously and fused with computed tomography (CT) scans. Transmission scanning began immediately after the administration of at least 350 MBq of FDG, emission scanning followed 40 min later.
EXAMPLE 14
Clinical Parameters After Gene Therapy: BM Cellularity
[0129] Bone marrow aspirates of both patients were routinely examined at several time points (P1: days +122, +192, +241, +381; P2: days +84, +119, +245). The following analyses were done: morphology (Pappenheim staining) was normal at all time points and showed a completely normal hematopoiesis, normal cellularity, normal megakaryo-, erythro- and granulopoiesis and no signs of leukemia. One example each is described as such: P1 day +381: megakaropoiesis normal, X-cell 1%, promyelocytes 8%, myelocytes 16%, metamyelocytes and bands 14%, segmented 15%, eosinophils 6%, basophils 1%, monocyte
3%, erythroblasts 21%, plasma cells 2%, lymphoids 12%. P2 day +245: megakaryopoiesis normal, promyelocytes 10%, myelocytes 19%, metamyelocytes and bands 12%, segmented 11%, eosinophils 4%, basophils 1%, monocytes 3%, erythroblast 26%, plasma cells 4%, lymphoids 10%.
EXAMPLE 15
Clinical Parameters After Gene Therapy: CFU-C Content
[0130] Bone marrow aspirates were taken at days +122, +192, +241 and +381 for P1 and at days +84, +119 and +245 for P2. On each occasion a bone marrow total BM mononuclear cells were plated on methylcellulose (Methocult, Stem Cells Technologies) and colony formation was assessed 14 days later. Table 5 shows a summary of these data.
Table 5.
[0131] Immunophenotyping of bone marrow cells performed by FACS analysis with antibodies against CD19, CD10, CD10/CD19, CD34, CD33 and CD34/CD33 showed no abnormal expression profile or cell counts in either patient at any time.
EXAMPLE 17
Clinical Parameters After Gene Therapy: Immuno staining Methods [0132] Immunohistostaining of bone marrow biopsies for CD10, CD34, CD117,
CD3, and CD20 was performed at day +381 (P1) and day +491 (P2). No infiltration of blast
(' cells, no myelo- or lymphoproliferative disease and no myelodyplastic syndrome were seen in these preparations.
EXAMPLE 18
Clinical Parameters After Gene Therapy: BM Cytogenetics Analysis [0133] Cytogenetic analysis were performed at the Department of Molecular Pathology, University Medical School, Hannover, Germany under the direction of Prof. Dr. med. B. Schlegelberger. The following samples were analyzed: P1: day +241 (16 metaphases), day +381 (18 metaphases); P2 day +119 (15 metaphases), day +245 (21 metaphases). In all cases a normal karyotype was observed.
EXAMPLE 19
Clinical Parameters After Gene Therapy: T-CeIl Function Analysis [0134] Mononuclear cells obtained at different time points from P1 and P2 were stimulated with diverse mitogens and antigens. Proliferative responses were assayed by 3H- Thymidine incorporation. The ratio of 3H-Thymidine incorporation in mitogen- or antigen stimulated vs. non-stimulated cells is given in Table 6 as a quotient, hi all cases, robust incorporation of 3H-Thymidine were observed, indicating that the mitogen and antigen responses of patient lymphocytes are within the range of age-matched healthy individuals. Also, immunoscope analysis of Vβ T lymphocytes at day +245 (P1) and day +491 (P2) showed normal T cell receptor repertoires in both patients.
Table 6.
EXAMPLE 20
Clinical Parameters After Gene Therapy: Antibody Production Analysis [0135] Among others normal levels of IgG, IgA, IgM, IgG1, IgG2, IgG3 and IgG4 were found. Examples of plasma protein levels are shown below at days +546 (P1) and day +489 (P2) in Table 7.
Table 7.
[0136] Similarly, IgG antibodies against Tetanus Toxoid (610 U/l), Diphteria Toxoid (270 U/l) and Hemophilus influenzae Type B (3.10 μg/ml) were detected at day 597 in serum samples of P1.
EXAMPLE 21 Mouse Integration and Transplantation Data Related to the Clinical Study
[0137] To create immortal mouse cell clones, bone marrow cells obtained from C57EL/6-Ly5.1+ mice were expanded for 2 days in the presence of DMEM plus 15% heat- inactivated FBS, 10ng/ml IL-6, 6ng/ml IL-3, and 100ng/ml SCF. Expanded cells were subsequently transduced by co-culture on top of GP+E86 cells stably expressing MSCVneo. After transduction, cells were cultured in IMDM with 20% heat-inactivated horse serum plus 100 ng/ml SCF and 10 ng/ml IL-3, or 100 ng/ml SCF and 30 ng/ml FLT3L. More than 80 immortal cell clones were generated after retroviral transduction of murine bone marrow cells in the presence of SCF and IL3, of which some have been maintained in culture for more than 1.5 years. The majority of these clones had a phenotype similar to committed immature myeloid progenitors and were still IL-3 dependent. All karyotypes were found to be normal. Spontaneous differentiation of the cultures yielded neutrophils (10-40%) and macrophages (1-5%). 95% of cells could be differentiated into neutrophils in response to G-CSF, whereas GM-CSF treatment induced differentiation into macrophages (30%) and neutrophils (70%). Addition of PMA induced 50-70% of cells to differentiate into macrophages. Integration sites were analyzed in 37 clones, demonstrating between 1 to 7 integrants per cell. 7 cell clones showed integrants in the Evil gene locus, 13 in the Prdmlό gene region and 1 in Setbpl. Northern analysis showed that expression of Evil and Prdmlό was mutually exclusive [Du, Y., Jenkins, N.A. & Copeland, N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106, 3932-3939 (2005), herein incorporated by reference in its entirety].
[0138] The engraftment potential of these immortalized cell lines was also tested. 2-8xl06 Ly5.1+ cells from Evil (two clones), Prdmlό (one) and Setbpl (one) immortalized cell lines, together with 5x105 unirradiated C57BL/6-Ly5.2+ supporting bone marrow cells, failed to engraft lethally irradiated C57BL/6-Ly5.2+ mice.
[0139] Further, 10 immortalized early hematopoietic progenitor cell clones were produced by retroviral transduction in the presence of SCF and FLT3 ligand. Of these, one (SF-I) revealed a very immature phenotype (Sca-1-, 50% c-kit+) with lymphomyeloid differentiation capacity and an integration in Setbpl. In contrast to the immortalized clones with the committed myeloid progenitor phenotype, transplantation of 2.5-5.6x106 Ly5.1+ SF- 1 cells resulted in a leukemic phenotype. All eleven hosts died of leukemia 56-118 days post transplant. Secondary recipients of IxIO6 leukemic cells developed leukemias 30 days after transplantation. This SF-I cell line revealed two integrants, one located at an unknown gene locus (without abnormal gene expression) and one in intron 1 of Setbpl. The leukemic potential of SF-I cells is very likely related to the immature phenotype of the clone (engraftment and self-renewal capacity). This knowledge can be used to develop assays that evaluate the therapeutic value of gene-modified cells against its potential risks in clinical use. For example, such assays can be used to screen gene-modified cells in order to eliminate those clones that exceed a specified risk threshold for clinical therapies. In summary, immortalized early hematopoietic progenitor cells induced leukemias in transplanted hosts whereas immortalized immature myeloid cells did not.
[0140] In the clinical study, no SETBP1 integrant was detected in patient P2 (and no SETBP1 overexpression). In contrast, seven integrants in SETBP1, six located about 20kb upstream and one in intron 1 of the gene, were detected in patient P1. The position of the integrant in intron 1 was similar to the two integrants found in the mouse study. This particular clone (77509D02) was detected only once by LAM-PCR in peripheral blood of P1 at day +241, but was not detected at any other time point by tracking PCR (Tables 1 and 2).
EXAMPLE 22
Transduction and Busulfan Conditioning of Patients
[0141] G-CSF mobilized peripheral blood CD34+ cells were collected from two X-CGD patients aged 26 (patient P1) and 25 years (patient P2), transduced with a monocistronic gammaretroviral vector expressing gp91phox (SF71gp91phox) and reinfused 5 days later (Example 1). Transduction efficiency was 45% for P1 and 39.5% for P2 as estimated by gp91phox expression (Example 2). The proviral copy number was 2.6 (P1) and
1.5 (P2) per transduced cell. The number of reinfused CD34+/gp91+ cells per kg was 5.IxIO6 for P1 and 3.6 x106 for P2. Prior to reinfusion, liposomal busulfan (L-Bu) was administered intravenously on days -3 and -2 every 12 hours at a dose of 4 mg/kg/day. Liposomal busulfan conditioning was well tolerated by both patients P1 and P2. With the exception of a grade I mucositis from day +11 to day +17 observed in P1, no other non-hematological toxicities were observed.
[0142] Both patients experienced a period of myelosuppression (neutrophil nadir for P1: day +14 and for P2: day +15) with absolute neutrophil counts (ANC) below 500 cells per μl between days +12 and +21 (P1) and days +13 and +18 (P2) (Figures 1,2). Severe lymphopenia (CD4+ counts <200/μl) was observed in P1 between days +21 and +32, while lymphopenia in P2 was observed only at day +17 (Figures 1,2). Cell counts recovered gradually to the normal values observed prior to busulfan conditioning (P1: 476 CD4+ cells/μl, age 19; P2: 313 CD4+ cells/μl, day -28). Similar results were observed for CD8+ and CD19+ cells (Figures 1,2) (Example 11).
EXAMPLE 23 Engraftment of Gene-modified Cells
[0143] Gene-modified cells were detected in peripheral blood leukocytes (PBL) from patient P1 at levels between 21% (day +21) and 13% (day +80) (Example 2). From day 157, a continuous increase in gene-marked cells was observed until day +241. At this point, 46% of total leukocytes were positive for vector encoded gp91phox. The percentage of gene- marked cells remained at this level until day +381 and decreased thereafter to 27% at day 542 (Figure 3). A similar result was observed in patient P2. The level of gene marked leukocytes fluctuated between 31% (day +35) and 12% (day +149). Thereafter, an increase in gene- marked cells was observed with 53% of the patient leukocytes containing vector-derived sequences at day +413, which decreased again to 30% at day +491 (Figure 4).
[0144] Vector-containing cells were found predominantly in the myeloid fraction. The level of gene marking in the granulocytes of P1 increased from 15% (day +65) to 55% (day +241) and fluctuated thereafter between 60% (day +269) and 54% (day +542) (Figure 3). Similar results were observed for P2. While 15% of the granulocytes were marked at day
+84, 48% of the granulocytes contained vector-derived sequences at day +245 and fluctuated thereafter between 36% (day +343) and 42% (day +491) (Figure 4). In both patients the level of gene marking in CD3+ cells remained low (range, 2%-7% (P1) and 0.4%-5% (P2)). in contrast, gene marking levels in isolated CD19+ cells of P1 (purity >98%) were 18% (day +472) and 17% (day +542) (Figure 3), while in B-cells of P2 (purity >94%) these values fluctuated between 11% (day +343) and 10% (day +491) (Figure 4).
[0145] Gene marking in bone marrow hematopoietic progenitor cells was estimated from the number of vector-positive colony-forming cells (CFC). Gene-marked CFCs were detected at a frequency of 68.8% (day +122) and 58.8% (day +381) for patient P1 (Figure 5), while these values were 33.3% (day +119) and 42.8% (day +245) for patient P2 (Figure 6). Vector-derived sequences were detected both in colony-forming units- granulocyte-macrophage (CFU-GM; range, 63.2%-76.9% (P1) and 25.0%- 6.6% (P2)) and burst-forming units-erythrocyte (BFU-E; range, 50.0%-75% (P1) and 20%-40.0% (P2)) colonies, indicating effective gene marking in common myeloid progenitors with long-term engraftment capacities or in hematopoietic stem cells (HSCs).
EXAMPLE 24 Expansion of Hematopoietic Cells in a Patient by Reinfusing Cells
Transfected with a Retroviral Vector
[0146] Cells are isolated from a cell sample taken from a patient in need of blood cells. A retroviral vector is prepared. A cell culture is prepared in the presence of permissive cytokines. The cells are allowed to proliferate. When ex vivo expansion is required, cells are kept in culture in the presence of the same or a different set of cytokines or growth factors, e.g. to induce proliferation only at the stem cell stage, or only at a lineage differentiated stage, e.g. myelopoiesis or thrombopoiesis. The cells are prepared for reinfusion to the patient by washing in PBS to remove cell culture components, followed by sorting of cells according to phenotype. The cells are reinfused to the patient. The patient's cell count is taken weekly. By this method, the patient's blood cell count improves.
EXAMPLE 25 Expansion of Hematopoietic Cells in vitro by Upregulating
EVI-I or PRDM 16 Expression
[0147] The human EVI-1 nucleic acid sequence, operably linked to a tetracycline- inducible promoter, is inserted into a plasmid vector sequence using known molecular techniques, and is then transfected to a hematopoietic cell culture. The cell culture is allowed to proliferate as described in Example 24 for a 2 week period in the presence of the inducer agent. The cells are then counted and characterized using cell-type specific markers.
EXAMPLE 26 Administration of EVI-I Expanded Hematopoietic Cells to
Patient in Need of Treatment
[0148] Cells are reinfused intravenously, directly into the bone marrow or delivered to specific target tissues by direct application or injection in appropriate media, e.g. PBS.
EXAMPLE 27 Administration of EVI-I to Hematopoietic Cells in vivo using Nucleic Acid Vector
[0149] A patient in need of expansion of hematopoietic cells is treated with an injection of purified nucleic acid vector containing a nucleic acid sequence encoding EVI-1, operably linked to an inducible promoter. Once in a suitable hematopoietic cell, the nucleic acid integrates into the chromosomal DNA of the patient and/or is transcribed after the inducing agent is provided to the patient orally for 1 year. The hematopoietic cells are capable of in vivo expansion by this method, and the patient health improves.
EXAMPLE 28 Administration of an Agent that Upregulates EVI-related Genes in a Cell Culture
[0150] Cells are isolated from a patient in need of treatment. An agent that upregulates endogenous EVI-1 expression is added to a cell culture, such as an upstream regulator of EVI-1 expression. Cell count is measured daily. After several days, the agent is removed from the culture, the expanded cells are washed and reinfused into the patient.
EXAMPLE 29
Expansion of Hematopoietic Cells in vitro by Upregulating SETBPl Expression [0151] The human SETBP1 nucleic acid sequence, operably linked to a steroid hormone inducible promoter, is inserted into an integrating vector sequence using known molecular techniques, and is then transfected to a hematopoietic cell culture. The cell culture is allowed to proliferate as described in Example 6 for one week in the presence of a steroid inducer agent. The cells are then counted and characterized using cell-type specific markers.
EXAMPLE 30 Administration of SETBPl Expanded Hematopoietic Cells to Patient in Need of Treatment
[0152] The desired cells are isolated from the culture described in Example 11, and are washed in PBS. The cells are then reinfused directly into the bone marrow of the patient. By use of this method, the patient hematopoietic cell count improves, and the patient health improves.
EXAMPLE 31 Administration of PRDM 16 to Hematopoietic Cells in vivo using Nucleic Acid Vector
[0153] A patient in need of expansion of hematopoietic cells is treated with an injection of purified nucleic acid vector containing a nucleic acid sequence encoding PRDM 16, operably linked to an inducible promoter. Once in a suitable hematopoietic cell, the nucleic acid integrates into the chromosomal DNA of the patient and/or gets transcribed after the inducing agent is provided to the patient orally for 1 year. The hematopoietic cells are capable of in vivo expansion by this method, and the patient health improves.
EXAMPLE 32
Administration of an Agent that Upregulates PRDMl 6 Genes in a Cell Culture [0154] Cells are isolated from a patient in need of treatment. An agent that upregulates endogenous PRDM 16 expression is added to a cell culture, and the cells are allowed to proliferate for 9 days. Cell count is measured daily. After 9 days, the agent is
removed from the culture, the expanded cells are washed and reinfused into the patient. By use of this method, the patient health improves.
[0155] One skilled in the art will appreciate that these methods and devices are and may be adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods, procedures, and devices described herein are presently representative of preferred embodiments and are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the disclosure.
[0156] It will be apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.
[0157] Those skilled in the art recognize that the aspects and embodiments of the invention set forth herein may be practiced separate from each other or in conjunction with each other. Therefore, combinations of separate embodiments are within the scope of the invention as disclosed herein.
[0158] All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
[0159] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of and "consisting of may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions indicates the exclusion of equivalents of the features shown and described or portions thereof. It is recognized that various modifications are possible within the scope of the invention disclosed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification
and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the disclosure.
[0160] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
Claims
1. A method of expanding cells, comprising: obtaining at least one cell from a patient; transfecting, infecting or transducing said cell with a retroviral or nonintegrating vector, such that cell entry and/ or integration of the vector promotes proliferation, persistence, or selective advantage of the cell; allowing the transfected cell to proliferate; reinfusing a plurality of proliferated transfected cells into said patient; and allowing said proliferated cells to expand further in the patient.
2. The method of Claim 1, wherein said transfected cell is or has characteristics of a cell selected from the group consisting of a hematopoietic progenitor cell, a hematopoietic stem cell, and a stem cell.
3. The method of Claim 2, wherein said method is used to treat a patient with a hematopoietic or other treatable disease.
4. The method of Claim 1, wherein the vector further comprises a sequence for correction or modification of a defective or deleterious gene.
5. A method of increasing cell proliferation in a mammalian cell, comprising: obtaining a cell; contacting said cell with a nucleic acid sequence encoding a protein selected from the group consisting of EVI-1, PRDM16, SETBP1, and a fragment thereof; allowing said nucleic acid to enter the cell; and allowing said cell to proliferate; wherein said cell containing said nucleic acid proliferates at an increased rate compared to a cell that has not been contacted with said nucleic acid sequence.
6. The method of C1aim 5, wherein said proliferation occurs in a cell culture.
7. The method of Claim 5, wherein said proliferation occurs in vivo.
8. The method of Claim 5, wherein said nucleic acid integrates into the chromosomal DNA.
9. The method of C1aim 5, wherein said nucleic acid is present in the cytoplasm of the cell.
10. The method of Claim 5, wherein said nucleic acid is operably linked to a promoter.
11. The method of Claim 5, wherein said nucleic acid' is constitutively expressed.
12. The method of Claim 5, wherein expression of said nucleic acid is inducible by an exogenously added agent.
13. The method of Claim 5, wherein said nucleic acid is conditionally expressed.
14. The method of Claim 5, wherein said nucleic acid is present in a vector.
15. The method of C1aim 14, wherein said vector is a viral vector.
16. The method of Claim 5, wherein said nucleic acid is expressed for a number of division cycles selected from the group consisting of: about 1, 3, 5, 8, 10, 13, 17, or 20 division cycles, then expression decreases or stops thereafter.
17. The method of C1aim 5, wherein said cell is or has characteristics of a cell selected from the group consisting of a hematopoietic stem cell, hematopoietic progenitor cell, a stem cell, an embryonic stem cell, an adult stem cell, a multipotent stem cell, and a myelopoietic stem cell.
18. The method of Claim 17, wherein said cell is a hematopoietic stem cell.
19. A method of expansion of a gene-corrected cell, comprising: obtaining a cell in need of gene correction; transfecting said cell with a functional copy of a said gene in need of correction; transfecting said cell with a copy of a nucleic acid encoding a polypeptide sequence selected from the group consisting of EVI-1, PRDM 16, SETBP1, and a fragment thereof; and allowing said cell to proliferate in culture; thereby obtaining an expanded culture of gene corrected cells.
20. A method of forming a bodily tissue having gene corrected cells, comprising: obtaining a cell in need of gene correction; transfecting said cell with a functional copy of a said gene in need of correction; transfecting said cell with a copy of a nucleic acid encoding a polypeptide sequence selected from the group consisting of EVI-1, PRDM16, SETBP1, and a fragment thereof; allowing said cell to proliferate in culture; and treating said cell culture to allow formation of a bodily tissue; thereby obtaining an expanded culture of gene corrected cells.
21. A method of identifying a gene, the modulation of which increases the proliferation rate of a cell, comprising: obtaining a sample of cells from a patient having previously received a therapeutic transfection with a nucleic acid sequence; identifying positions of nucleic acid insertion in the cells from the sample; identifying a favorable insertion site based upon disproportional representation of said site in the population of transfected cells; and identifying a gene associated with the insertion site.
22. A nucleic acid integration region that, when insertionally modulated, results in increased hematopoietic cell proliferation, comprising a sequence selected from the group consisting of: the EVI-1 gene, the PRDM16 gene, and the SETBP1 gene.
23. A nucleic acid sequence whose modulation of expression is associated with the increased proliferation of hematopoietic cells, selected from the group consisting of: MGC10731, PADI4, CDA, CDW52, ZBTB8, AK2, FLJ32112, TACSTD2, FLJ13150, MGC24133, NOTCH2, NOHMA, EST1B, PBX1, PLA2G4A, HRPT2, ATP6V1G3, PTPRC, NUCKS, CABC1, LOC339789, PRKCE, AFTPHILIN, NAGK, MARCH7, DHRS9, PRKRA, SESTD1, MGC42174, CMKOR1, TBC1D5, THRB, MAP4, IFRD2, ARHGEF3, FOXP1, ZBTB20, EAF2, MGLL, PLXND1, SLC9A9, SELT, CCNL1, MDS1, BCL6, MIST, STIM2, TEC, OCIAD1, FLJ10808, SEPTIl, PRKG2, MLLT2, PGDS, MANBA, SRY1, SET7, MAML3, DCTD, CARF, IRF2, AHRR, POLS, ROPN1L, FLJ10246, IPO11, C2GNT3, SSBP2, EDIL3, SIAT8D, FLJ20125, GNB2L1, C6orf105, JARID2, C6orf32, HCG9, MGC57858, TBCC, SENP6, BACH2, REPS1, HDAC9, 0SBPL3, HOXA7, CALN1, FKBP6, NCF1, HIP1, GNAI7, ZKSCAN1, MGC50844, LOC346673, CHRM2, ZH3HAV1, REPlN1, SMARCD3, CTSB, ADAM28, LYN, YTHDF3, SMARCA2, C9orf93, NPR2, BTEB1, ALDH1A1, AUH, C9orf3, WDR31, CEP1, GSN, RABGAP1, ZNF79, CUGBP2, C10orf7, PTPLA, PLXD2, ACBD5, PRKG1, MYST4, IFIT1, C10orf129, CUEDC2, FAM45A, GRK5, OR52N1, OR2AG2, ZNF143, C11orf8, LM02, NGL-1, DGKZ, NR1H3, KBTBD4, C1QTNF4, MGC5395, ARRB1, FLJ23441, FGIF, MAML2, LOC196264, HSPC063, ELKS, CACNA2D4, CHD4, EPS8, LRMP, NEUROD4, RNF41, FAM19A2, RASSF3, PAMC1, PLXNC1, DAP13, MGC4170, FLJ40142, JIK, CDK2AP1, GPR133, PCDH9, C13orf25, ABHD4, AP4S1, MIA2, RPS29, PSMC6, RTN1, MED6, C14orf43, C14orf118, RPS6KA5, GNG2, PAK6, B2M, ATP8B4, TRIP4, CSK, MESDC1, RKHD3, AKAP13, DET1, DKFZp547K1113, SV2B, LRRK1, CHSY1, TRAF7, ZNF205, ABCC1, THUMPD1, IL21R, MGC2474, N4BP1, SLIC1, CDH9, GPR56, ATBF1, ZNRF1, CMIP, MGC22001, C17orf31, SAT2, ADORA2B, TRPV2, NF1, LOC117584, MLLT6, STAT5A, STAT3, HOXB3, HLF, MAP3K3, SCN4A, ABCA10, EPB41L3, ZNF521, RNF125, SETB P1, FLJ20071, CDH7, MBP, MBP, NFATC1, GAMT, MOBKL2A, NFIC, CALR, GPSN2, ZNF382, EGLN2, PNKP, LAIR1, ZNF579, SOX12, C20orf30, PLCB1, SNX5, LOC200261, ZNF336, BAK1, SPAG4L, EPB411L1, NC0A3, KIAA1404, STMN3, CBR3, DYRKlA, CSTB, C22orf14, UPB1, MN1, XBP1, C22orf19, RBM9, MYH9, TXN2, PSCD4, UNC84B, FLJ2544, ZCCHC5, MST4, IDS, UTY, SKI, PRDM16, PARK7, CHC1, ZMYM1, TNPP5B, GLIS1, SLC27A3, ASHlL, SLAMF1, PBX1, CGI-49, ELYS, RNF144, FAM49A, FLJ21069, SFRS7, SPTBN1, TMEM17, ARHGAP25, FLJ20558, CAPG, PTPN18, RBMS1, LOC91526, KLF7, FLJ23861, CMKOR1, CRBN, ITPR1, RAFTLIN, TNA, CCDC12, FHIT, VGL-3, PPMlL, EVI-1, MDS1, HDSH3TC1, DHX15, TMEM33, CXCL3, EPGN, LRBA, FLJ25371, CPE, POLS, PTGER4, LHFPL2, C5orf12, CETN3, PHF15, PFDN1, KIAA0555, GNB2L1, HLA-E, SLC17A5, UBE2J1, BACH2, HIVEP2, SNX8, TRIAD3, RAC1, ARL4A, ELMO1, BLVRA, SUNC1, ABCA13, GTF2IRD1, RSBN1L, ADAM22, MLL5, IMMP2L, SEC8L1, FLJ12571, CUL1, ANGPT1, DEPDC6, EPPK1, MLANA, MLLT3, SMUl, TLE4, C9orf3, ABCAl, STOM, RABGAP1, NEK6, NR5A1, MGC20262, FLJ20433, MAP3K8, ARHGAP22, C10orf72, TACR2, NKX2, OBFC1, VTI1A, ABLIM1, FLJ14213, MS4A3, B3GNT6, NADSYN1, CENTD2, MAML2, ATP5L, FLI1, CACNA1C, HEBP1, MLSTD1, IPO8, ARID2, SLC38A1, KRT7, USP15, KIAA1040, WIF1, CGI-119, DUSP6, FLJ11259, CMKLR1, SSH1, TPCN1, FLJ42957, JIK, FLT3, TPT1, FNDC3, ARHGAP5, ARF6, GPHN, C14orf4, STN2, PPP2R5C, CDC42BPB, CEP152, OAZ2, AKAP13, CHSY1, CRAMP1L, MHC2TA, NPIP, SPN, MMP2, DKFZp434I099, SIAT4B, PLCG2, MYO1C, C17orf31, MGC51025, WSB1, TRAF4, SSH2, HCA66, RFFL, DUSP14, TCF2, ZNF652, STXBP4, HLF, MSI2, VMP1, HELZ, TREM5, RAB37, SEC14L1, SEPT9, BIRC5, PSCD1, MGC4368, NDUFV2, C18orf25, ATP8B1, CDH7, FLJ44881, NFATC1, C19orf35, GNG7, MATK, C3, ZNF358, LYL1, F2RL3, ZNF253, ZNF429, KIAA1533, U2AF1L3, GMFG, BC-2, C20orf30, PLCB1, LOC200261, C20orf112, ADA, PREX1, C21orf34, C21orf42, ERG, ABCG1, MN1, HORMAD2, LOC113826, C22orf1, EFHC2, SYLT4, MGC27005, FHL1, GAB3, and CSF2RA.
24. A method of identifying a favorable insertion site of a nucleic acid sequence in a proliferating cell culture, comprising: transfecting a cell sample with a nucleic acid sequence; allowing cell proliferation to occur; determining at least one main insertion site of the nucleic acid using LAM- PCR over time; using said at least one main insertion site to predict the location of at least one main insertion site of another cell sample transfected with a substantially similar nucleic acid sequence over a similar time period; obtaining a sample of cells from a patient having previously received a therapeutic transfection with a nucleic acid sequence; identifying positions of nucleic acid insertion in the cells from the sample; and identifying a favorable insertion site based upon disproportional representation of said site in the population of transfected cells.
25. A method of expansion of a cell, comprising contacting said cell with a polypeptide selected from the group consisting of: an EVI-1 polypeptide, a PRDM 16 polypeptide, a SETBP1 polypeptide, a fragment thereof, or a synthetic peptide derivative thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/948,920 US20090028836A1 (en) | 2005-06-01 | 2007-11-30 | Stem and progenitor cell expansion by evi, evi-like genes and setbp1 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68696305P | 2005-06-01 | 2005-06-01 | |
US60/686,963 | 2005-06-01 | ||
US78844606P | 2006-03-31 | 2006-03-31 | |
US60/788,446 | 2006-03-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/948,920 Continuation US20090028836A1 (en) | 2005-06-01 | 2007-11-30 | Stem and progenitor cell expansion by evi, evi-like genes and setbp1 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007008309A2 true WO2007008309A2 (en) | 2007-01-18 |
WO2007008309A3 WO2007008309A3 (en) | 2007-07-26 |
Family
ID=37137578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/021413 WO2007008309A2 (en) | 2005-06-01 | 2006-06-01 | Stem and progenitor cell expansion by evi, evi-like genes and setbp1 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007008309A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102155A1 (en) * | 2011-12-29 | 2013-07-04 | Cell Machines, Inc. | Cells for virus and protein production |
US11421287B2 (en) * | 2016-07-29 | 2022-08-23 | Juno Therapeutics, Inc. | Methods for assessing the presence or absence of replication competent virus |
US11535903B2 (en) | 2018-01-31 | 2022-12-27 | Juno Therapeutics, Inc. | Methods and reagents for assessing the presence or absence of replication competent virus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005083097A1 (en) * | 2004-02-25 | 2005-09-09 | Children's Hospital Medical Center | A method for creating myeloid cell lines |
-
2006
- 2006-06-01 WO PCT/US2006/021413 patent/WO2007008309A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005083097A1 (en) * | 2004-02-25 | 2005-09-09 | Children's Hospital Medical Center | A method for creating myeloid cell lines |
Non-Patent Citations (10)
Title |
---|
BJORGVINSDOTTIR HELGA ET AL: "Retroviral-mediated gene transfer of gp91-phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease" BLOOD, vol. 89, no. 1, 1997, pages 41-48, XP002427458 ISSN: 0006-4971 * |
CHI YIQING ET AL: "EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 50, 12 December 2003 (2003-12-12), pages 49806-49811, XP002406183 ISSN: 0021-9258 * |
HACEIN-BEY-ABINA S ET AL: "LMO2-Associated Clonal T Cell in Two Patients after Gene Therapy for SCID-X1" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 302, 17 October 2003 (2003-10-17), pages 415-419, XP002987515 ISSN: 0036-8075 * |
LI Z ET AL: "Murine Leukemia Induced by Retroviral Gene Marking" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 296, 19 April 2002 (2002-04-19), page 497, XP002987516 ISSN: 0036-8075 * |
MINAKUCHI MASAYOSHI ET AL: "Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET" EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 268, no. 5, March 2001 (2001-03), pages 1340-1351, XP002427456 ISSN: 0014-2956 * |
MOCHIZUKI N ET AL: "A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 96, no. 9, 1 November 2000 (2000-11-01), pages 3209-3214, XP002366033 ISSN: 0006-4971 * |
OTT MARION G ET AL: "Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1" NATURE MEDICINE, vol. 12, no. 4, April 2006 (2006-04), pages 401-409, XP002406184 ISSN: 1078-8956 * |
OTT MARION G ET AL: "Gene therapy for x-linked chronic granulomatous disease" BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11), page 120A, XP002406182 & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004 ISSN: 0006-4971 * |
PODSAKOFF G M ET AL: "Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34<+> cells" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 1, July 2005 (2005-07), pages 77-86, XP004974951 ISSN: 1525-0016 * |
YUASA HIROMI ET AL: "Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 24, no. 11, June 2005 (2005-06), pages 1976-1987, XP002427457 ISSN: 0261-4189 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102155A1 (en) * | 2011-12-29 | 2013-07-04 | Cell Machines, Inc. | Cells for virus and protein production |
US11421287B2 (en) * | 2016-07-29 | 2022-08-23 | Juno Therapeutics, Inc. | Methods for assessing the presence or absence of replication competent virus |
US11535903B2 (en) | 2018-01-31 | 2022-12-27 | Juno Therapeutics, Inc. | Methods and reagents for assessing the presence or absence of replication competent virus |
Also Published As
Publication number | Publication date |
---|---|
WO2007008309A3 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6586192B1 (en) | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals | |
Schuringa et al. | Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation | |
US10653123B2 (en) | Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo | |
Stier et al. | Ex vivo targeting of p21Cip1/Waf1 permits relative expansion of human hematopoietic stem cells | |
KR20090015976A (en) | Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates | |
EP3060670B1 (en) | Method | |
Gori et al. | Endothelial cells promote expansion of long-term engrafting marrow hematopoietic stem and progenitor cells in primates | |
JP2022523052A (en) | Compositions and Methods for Targeting Mutant RAS | |
EP1129175A2 (en) | Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors | |
CN112601812A (en) | Gene therapy | |
JP2022103424A (en) | Suicide gene therapeutic agent for brain tumors using pluripotent stem cell | |
Broxmeyer | Cord blood as an alternative source for stem and progenitor cell transplantation | |
US5837507A (en) | Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods | |
JP2002502599A (en) | Expanded and genetically modified human hematopoietic stem cell population | |
US20090028836A1 (en) | Stem and progenitor cell expansion by evi, evi-like genes and setbp1 | |
WO2007008309A2 (en) | Stem and progenitor cell expansion by evi, evi-like genes and setbp1 | |
Suzuki et al. | Homeostasis of hematopoietic stem cells regulated by the myeloproliferative disease associated-gene product Lnk/Sh2b3 via Bcl-xL | |
Andrews et al. | Differential engraftment of genetically modified CD34+ and CD34− hematopoietic cell subsets in lethally irradiated baboons | |
Otsu et al. | Reconstitution of lymphoid development and function in ZAP-70–deficient mice following gene transfer into bone marrow cells | |
Watts et al. | Differential effects of HOXB4 and NUP98-HOXA10hd on hematopoietic repopulating cells in a nonhuman primate model | |
AU4419396A (en) | System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells | |
WO1996017627A9 (en) | System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells | |
EP3893898B1 (en) | Method of treating autoimmune and inflammatory diseases using b cells | |
US20040029271A1 (en) | Pax5-deficient pro-B cells, methods of producing them and the use of such cells in human therapy | |
EP1361268A1 (en) | Pax-5-deficient pro-B cells, methods of producing them and the use of such cells in human therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06771918 Country of ref document: EP Kind code of ref document: A2 |